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ABSTRACT 
 The risk of cardiovascular disease increases with elevated plasma levels of very-
low density lipoproteins (VLDL) and chylomicrons.  The human apolipoprotein Cs (apo 
C1, C2, C3) are small secretory proteins that circulate in plasma and play unique roles in 
the metabolism of VLDL and chylomicrons.  ApoC2 is the required cofactor for 
lipoprotein lipase (LPL) which hydrolyzes plasma triacylglycerol.  ApoC3 promotes 
VLDL synthesis in hepatocytes and both apoC1 and apoC3 inhibit LPL.  The molecular 
details of these processes are largely unknown, but we hypothesized that apoC functions 
depend on protein structure, protein:lipid interactions, and surface pressure.  Each apoC 
contains amphipathic N- and C-terminal helices that bind to and remodel lipid surfaces.  
Surface pressure—or the density of amphipathic molecules—increases significantly as 
LPL hydrolyzes triacylglycerol in VLDL. 
 To probe the effects of protein structure and surface pressure on protein:lipid 
interactions, we used wild-type and point mutant variants of the apoCs, which differed in 
helical content and hydrophobicity.  We used Oil-Drop Tensiometry to characterize the 
adsorption, conformational rearrangement, and desorption of each protein at lipid/water 
 vii 
 
interfaces that mimic the core and surface of VLDL.  This technique measured the effect 
of protein adsorption on surface pressure, and the surface area and pressure response of 
protein/lipid/water interfaces to volume changes that mimic lipogenic and lipolytic 
processes.  We showed that the degree of protein amphipathic α-helical structure 
correlated with lipid affinity and provide a model for phenotypes in subjects with point 
mutations in apoC2 and apoC3.  Each apoC exhibited multiple, pressure-dependent 
conformations at lipid surfaces, which indicates that the C-terminus of apoC2 likely 
desorbs from lipid at higher pressures to interact with LPL.  ApoC3 exhibited a marked 
preference for lipid in the VLDL core, which provides novel insight into its role in VLDL 
assembly and secretion.    
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1. Chapter 1: Lipoproteins and Cardiovascular Disease 
The work outlined in this thesis uses Oil-Drop Tensiometry, a technique 
pioneered in the laboratory of Dr. Donald Small, to probe the protein-lipid interactions 
between variants of the apolipoprotein Cs and lipid surfaces.  The results provide novel 
insights into the roles of the apolipoprotein Cs in regulating metabolism of 
triacylglycerol-rich lipoproteins.  Chapter 1 will provide an introduction to lipoproteins, 
lipoprotein metabolism, and the role of lipoproteins in cardiovascular disease.  
Cardiovasuclar disease has been the leading cause of death in the United States since the 
beginning of the 20
th
 century (Bentzon et al., 2014; Hoyert & Xu, 2012).  Chapter 2 will 
describe the hypotheses and goals of this thesis work and focus on the structures and 
functions of the apolipoprotein Cs.  Chapter 3 will describe Oil-Drop Tensiometry, the 
primary technique used in this thesis work.  Chapter 4-6 will present results for wild type 
(WT) and variants of apoC1, apoC2, and apoC3, respectively.  Chapter 7 will conclude 
the thesis with a comparison among the results for the apoCs and their implications for 
lipoprotein metabolism and cardiovascular diseases. 
1.1 Major Lipoprotein Classes and their Composition 
Lipoproteins are protein-lipid emulsion particles that solubilize hydrophobic 
molecules, such as triacylglycerol (TG) and cholesterol ester (CE), for transport through 
the circulatory system  (Wältermann & Steinbüchel, 2005).  This transport provides 
various regions of the body with the cholesterol and other lipids necessary for cell 
growth, hormone production, axon myelination, or formation of the skin barrier (van 
Meer, Voelker, & Feigenson, 2008; Wymann & Schneiter, 2008; Zuo et al., 2008).   
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Lipoproteins have core and surface phases.  Hydrophobic lipids fill the core 
(Figure 1.1A); the most common of which are TG and CE (Brown, Levy, & Fredrickson, 
1969; Small, 1986).  Amphipathic lipids and apolipoproteins form a monolayer at the 
surface to shield the core from water.  The major surfactant lipids are phospholipids and 
cholesterol (Figure 1.1A).  Lecithin is the most common phospholipid in plasma and has 
a phosphatidylcholine (PC) head group (Brown et al., 1969).  The major apolipoproteins 
are designated as apoA1, apoA2, apoA4, apoB48, apoB100, apoC1, apoC2, apoC3, and 
apoE.  Their properties are described in Tables 1.1, 1.2. 
Lipoproteins are grouped into five classes based on density and composition.  In 
order of increasing density, these classes are: chylomicrons (CM), very-low density 
lipoproteins (VLDL), intermediate density lipoproteins (IDL), low density lipoproteins 
(LDL), and high density (HDL) lipoproteins (Figure 1.1B, Table 1.1).  The two major 
classes, HDL and LDL, are known as “good” and “bad” cholesterol, because they have 
opposite effects on the progression of atherosclerosis (see Section 1.3).  HDL transport 
excess cholesterol from extrahepatic tissues to the liver for secretion into the bile and is a 
source of CE for LDL precursors (see Section 1.2.1).  The other lipoproteins—notably, 
LDL—deliver cholesterol and CE from the liver to peripheral tissues (see Section 1.2.2). 
Lipoprotein particles are heterogenous in size and composition.  Nascent HDL are 
small (5-8 nm), dense (1.09-1.21 g/mL) particles comprised mostly of phospholipid, free 
cholesterol, and apoA1 (Table 1.1).   Mature HDL are up to twofold larger and contain a 
large amount of CE and variety of exchangeable apolipoproteins.  As compared to mature 
HDL, VLDL and CM are larger particles (>> 30 nm) of lower density (<1.006 g/mL). 
 3 
 
 
Figure 1.1: The protein and lipid constituents of lipoproteins (A) and the variation 
in density and diameter between lipoprotein subclasses (B).   
(A) Lipoproteins are macromolecular assemblies of proteins (red, green, purple) and 
lipids.  Hydrophobic lipids, such as cholesterol ester and triacylglycerol partition to the 
core, while amphipathic lipids, such as cholesterol and phospholipid, and apolipoproteins 
form a monolayer at the lipid/water interface.  While cholesterol esters and TG are 
depicted as core molecules, a small amount also partitions to the lipoprotein surface.  
Free cholesterol primarily localizes to the lipoprotein surface, but also partitions to the 
oily core (Miller & Small, 1983).   
(B)  Subclasses of lipoproteins differ in density and size (Table 1.1).  The size of the 
lipoprotein core correlates with the total cholesterol and TG in the core.  Figure adopted 
from (Ridker, 2014; Weiford, 2005). 
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Properties Chylomicrons VLDL IDL LDL n-HDL m-HDL 
Source Intestine Liver VLDL IDL Liver & 
Intestine 
n-HDL 
Density [g/mL] <0.95 0.95-1.006 1.006-1.02 1.02-1.06 1.09-1.21 1.06-1.12 
Size [nm] 75-1200 30-80 25-35 18-25 5-8 7-12 
Lipid [%wt] 98 90-92 82-87 78-82 61-65 60-67 
TG [%wt] 80-95 45-65 31 4-9 0 8 
Phospholipid 
[%wt] 
3-7 15-20 15-25 18-24 50 26-30 
Cholesterol 
[%wt] 
1-3 4-8 4-8 6-8 8 5-8 
CE [%wt] 2-4 16-22 22-26 45-50 3 21-24 
Protein [%wt] 2 8-10 13-18 18-22 35-39 33-40 
Major 
Apolipoproteins 
ApoB48, A1, 
A4, C1, C3, E 
apoB100, 
E, the Cs 
apoB-100 apoB100 apoA1 apoA1, A2 
Minor 
Apolipoproteins 
apoA2, C2 apoA1, A2, 
A4, A5, C4 
apoE   the apoCs, 
D, E, J, A5 
Table 1.1. Properties of the human plasma lipoproteins 
The density, size, and composition vary among lipoprotein classes.  Chylomicrons and 
VLDL have a high percentage of triacylglycerol (TG).  LDL and HDL have low amounts 
of TG, but high amounts of CE.  The surface of every lipoprotein is coated with 
amphipathic phospholipids, cholesterol, and apolipoproteins.  Values are from (Cohen & 
Fisher, 2013; Zannis et al., 2004).  n-HDL, nascent HDL; m-HDL, mature HDL 
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Apoprotein Amino 
Acids 
Lipoproteins Blood Conc. 
[mg/dL]* 
Function Association 
with Disease 
Exchangeable 
ApoA1 243 HDL, VLDL, 
CM 
110-150 Promotes HDL assembly 
via ABCA1, maturation 
via LCAT, and uptake 
via SRB1 
Deletion of the 
ApoA1, C3, and 
A4 loci and 
inversion of the 
apoA1 and C3 
loci are 
associated with 
atherosclerosis 
ApoA2 77 HDL, VLDL, 
CM 
60-70 Inhibits HL; Atherogenic 
in mice models 
ApoA4 376 HDL, VLDL, 
CM 
15-17 Mimics apoA1 functions 
to a moderate extent 
ApoC1 57 HDL, VLDL, 
CM 
6-10 Inhibits VLDL & CM 
catabolism, inhibits 
CETP 
 
ApoC2 79 HDL, VLDL, 
CM 
3-4 LPL Cofactor; Promotes 
catabolism of VLDL & 
CM 
Hyper-
triglyceridemia 
due to genetic 
polymorphisms ApoC3 79 HDL, VLDL, 
CM 
7-10 Promotes VLDL 
assembly; Impairs 
VLDL & CM uptake 
ApoE 299 HDL, VLDL, 
IDL, CM 
4-10 Interacts with LRPs to 
promote VLDL uptake; 
Essential for cholesterol 
transport in brain 
Hyper-
lipoprotenemia
Alzheimer’s 
Non-Exchangeable 
ApoB100 4529 VLDL, IDL, 
LDL 
120-130 Essential for assembly & 
stability of VLDL; 
Interacts with LDLR to 
promote LDL uptake 
Abeta-
lipoproteinemia, 
Hypobeta-
lipoproteinemia, 
Familial 
apoB100 
deficiency 
ApoB48 2152 CM  Essential for assembly, 
stability, & secretion of 
CM 
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Table 1.2. Properties of the major human apolipoproteins.  
Data and facts are from (Ginsberg, 1998; Zannis et al., 2004).  *Plasma concentrations 
are estimated for normolipidemic subjects; values are from (Curry, McConathy, Fesmire, 
& Alaupovic, 1981; Wang, McConathy, Kloer, & Alaupovic, 1985). ABCA1, ATP-
binding cassette transporter 1; LCAT, lecithin-cholesterol acyltransferase; SRB1, 
scavenger receptor class B member 1; CETP, cholesterol ester transfer protein; HL, 
hepatic lipase; LPL, lipoprotein lipase;  LRP, LDL receptor-related protein; LDLR, LDL 
receptor 
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CM and VLDL contain large amounts of TG, one molecule of apoB48 or 
apoB100, and several exchangeable apolipoproteins (Figure 1.1B, Table 1.1).  IDL and 
LDL are smaller than VLDL and contain less TG but more CE.  IDL contain some apoE 
molecules, while LDL contain virtually no exchangeable apolipoproteins (Figure 1.1B, 
Table 1.1). 
 
1.2 Lipoprotein Function and Metabolism 
1.2.1 HDL Function and Metabolism 
HDL mediate reverse cholesterol transport—a process in which HDL remove 
excess cholesterol from peripheral tissues for transfer to TG-rich lipoproteins and 
excretion by the liver (Cohen & Fisher, 2013; Rader & Hovingh, 2014).  Most cells 
synthesize the cholesterol they require, but the liver contains the enzymes and cellular 
machinery to degrade and eliminate cholesterol via conversion to bile salts and secretion 
into the bile (Cohen & Fisher, 2013).  Nascent, or pre-β, HDL are synthesized by 
hepatocytes, enterocytes, and macrophages. (Table 1.1).  The ATP-binding cassette 
(ABC) transporter ABCA1 in the plasma membrane of these cells exports free cholesterol 
and phospholipid to lipid-poor apoA1 to form nascent HDL (Figure 1.2) (Cohen & 
Fisher, 2013; Kielar et al., 2001).  The structure of nascent HDL is dictated by apoA1, 
which forms an anti-parallel, α-helical dimer that surrounds a ~90 Å disk of cholesterol 
and phospholipid in a belt-like fashion (Borhani, Rogers, Engler, & Brouillette, 1997; 
Brouillette, Anantharamaiah, Engler, & Borhani, 2001; Mei & Atkinson, 2011).   
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Figure 1.2. Overview of HDL metabolism. 
Nascent, or pre-β, HDL are produced by ABCA1 and contain apoA1, phospholipid (PL), 
and FC.  To produce spherical, mature HDL several processes occur.   LCAT esterifies 
HDL-cholesterol to produce CE, which partitions to the core.  PLTP transfers PL to HDL 
from VLDL and CM.   Mature HDL can accept cholesterol desorbed from the plasma 
membrane or effluxed by ABCA1 or ABCG1 in peripheral cells.  CETP transfers 
cholesterol ester from HDL to lipoproteins with apoB100 in exchange for TG.  This 
decreases the cholesterol ester content of HDL, while increasing their TG content.  On 
return to the liver, HDL can interact with SR-B1 on the plasma membrane of hepatocytes.  
Hydrophobic core lipids of HDL are taken up by hepatocytes, while apoA1 and 
phospholipid molecules are recycled to plasma.  In HDL catabolism, hepatic lipase (HL) 
and endothelial lipase (EL) hydrolyze TG and PL in HDL.  Figure adopted from (Rader 
& Hovingh, 2014).    
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Maturation of nascent HDL occurs through several processes (Figure 1.2).  Free 
cholesterol in nascent HDL is converted to CE in plasma by lecithin-cholesterol 
acyltransferase (LCAT), a 416 amino acid-long enzyme that is synthesized and secreted 
by the liver.  LCAT cleaves fatty acids at the sn-2 position of PC phospholipids and 
trans-esterifies the released fatty acids to the 3-β-hydoxyl group on the A-ring of 
cholesterol molecules (Rousset, Vaisman, Amar, Sethi, & Remaley, 2009).  This 
produces CE and lyso-PC.  75% of LCAT activity in plasma is associated with HDL, 
while the other 25% is associated with CE formation in LDL and other apoB-containing 
lipoproteins (Rousset et al., 2009). As free cholesterol, at the surface of HDL, is 
converted to CE, which partitions mainly to the core (Tall & Small, 1980), nascent HDL 
are converted to mature, spherical HDL (Chetty et al., 2013). 
Phospholipid transfer protein (PLTP)—a glycoprotein synthesized primarily by 
the liver and adipose tissue—transfers phospholipid to HDL from TG-rich, apoB100 
lipoproteins (Cohen & Fisher, 2013).   As lipolytic enzymes hydrolyze TG in VLDL (see 
Section 1.2.2), the lipoproteins’ core shrinks.  PLTP transfers excess phospholipids to 
HDL. Other exchangeable apolipoproteins, such as the apoCs (C1, C2, C3) and apoE, 
transfer from plasma or IDL to HDL.  The functions of these proteins are briefly 
described in Table 1.2, and the apoCs are discussed extensively in Chapter 2.   
Mature HDL contain apoA1 and other apolipoproteins, CE, and small amounts of 
TG (Table 1.1).  These particles remove excess cholesterol from cells for transport to the 
liver.  HDL accept cholesterol effluxed by ABCA1 from peripheral cells, or promote 
cholesterol efflux through ABCG1 and ABCA1 from macrophages to alleviate 
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cholesterol build-up in the arterial wall (Figure 1.2) (Cohen & Fisher, 2013).  HDL 
undergo extensive modifications before returning to the liver.  Cholesterol ester transfer 
protein (CETP)—a glycoprotein synthesized by the liver and other tissues—transfers CE 
from HDL to apoB100-containing lipoproteins (Barter et al., 2003; Charles & Kane, 
2012).  Net transfer of CE depends on the availablity of TG-rich lipoproteins and results 
in the reciprocal transport of TG to HDL.  This process allows for cholesterol, originating 
from nonhepatic cells, to be transferred from HDL to apoB100-containing remnant 
particles and cleared by the liver (Cohen & Fisher, 2013).  Hepatic lipase (HL) 
hydrolyzes TG acquired by HDL and endothelial lipase (EL) hydrolyzes phospholipids in 
HDL to accelerate particle clearance (Rader & Hovingh, 2014; Young & Zechner, 2013). 
On return to the liver, HDL are taken up by the scavenger receptor class B, 
member 1 (SR-B1) (Cohen & Fisher, 2013).  SR-B1 is an 82 kDa membrane glycoprotein 
that is expressed primarily in the liver (Zannis, Kan, Kritis, Zanni, & Kardassis, 2001a).  
SR-B1 mediates the selective uptake of CE, but not apolipoproteins, into hepatocytes by 
a mechanism that is largely unknown (Figures 1.2, 1.3) (Cohen & Fisher, 2013).   
HDL have several additional cardioprotective functions.  HDL are associated with 
vasodilation effects to promote blood flow in humans due to increased eNOS protein 
levels (Rämet et al., 2003).  HDL inhibit oxidation of LDL (Navab, Hama, 
Anantharamaiah, et al., 2000; Navab, Hama, Cooke, et al., 2000), inhibit expression of 
proinflammatory cytokines by macrophages (Okura et al., 2010), promote expression of 
adhesion molecules in endothelial cells (Murphy et al., 2008), inhibit cell apoptosis 
(Nofer et al., 2001), and inhibit platelet aggregation and thrombosis (Dole et al., 2008).  
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Figure 1.3. Schematic of lipoprotein metabolism in the liver.  
VLDL are secreted by the liver to transport TG through plasma to muscle and adipose 
tissue.  ApoB100 translation in hepatocytes initiates VLDL assembly.  MTP lipidates 
ApoB100 co-translationally.  Mature VLDL are secreted into plasma.  ApoC2 on VLDL 
binds to LPL, which is tethered to the surface of endothelial cells by GPIHBP1.  As LPL 
hydrolyzes TG, released fatty acids are taken up by muscle or fat; or transported in 
plasma to other tissues including the liver by albumin.  VLDL detach from LPL enriched 
in apoE as VLDL remnants.  IDL and chylomicron remnants can be endocytosed by 
interactions between apoE and various receptors (VLDLR, LDLR, LRP) on peripheral 
tissues and on hepatocytes.  Hydrolysis of additional TG by HL produces LDL and any 
remaining apoE desorbs.  LDL are cleared from circulation through interactions between 
apoB100 and the LDL receptor (LDLR).  Figure adopted from (Cohen & Fisher, 2013). 
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1.2.2 Chylomicron and VLDL Function and Metabolism 
Chylomicrons (CM) and VLDL mediate the delivery of TG and cholesterol from 
the liver and intestine to peripheral tissues, notably muscle and adipose.  CM package 
dietary TG with phospholipids and apolipoproteins (most essentially, apoB48) and are 
secreted from the small intestine (Rader, Cohen, & Hobbs, 2003).  VLDL package 
endogenous TG in hepatocytes with phospholipids and apolipoproteins (most essentially, 
apoB100) (Rader & Hovingh, 2014).  ApoB100 and apoB48 are non-exchangeable, 
water-insoluble proteins that travel with VLDL and CM from synthesis and secretion, 
through plasma, to cellular uptake (Segrest et al., 1992).  The apoBs are transcribed from 
the same gene, but apoB48 contains the first 48% of apoB100 (4536 amino acids).  In the 
small intestine, the apoB gene is edited by the deaminase apobec1 at base 6666 and the 
codon for Gly-2153 becomes a stop codon (Brown et al., 1969).  
Endogenous TG is packaged into VLDL in the liver, which are secreted directly 
into the plasma (Figure 1.3) (Cohen & Fisher, 2013).  VLDL assembly primarily depends 
on the supply of TGs, which are synthesized within the liver, and the activity of 
microsomal triacylglycerol transfer protein (MTP) (Cohen & Fisher, 2013).  ApoB100 
co-translationally translocates to the lumen of the endoplasmic reticulum (ER) (Cohen & 
Fisher, 2013).  MTP incorporates TGs into apoB100 co-translationally and promotes 
proper folding of the protein (Figure 1.3) (Hussain, 2002).  Chaperones, including BiP, 
HSP70, and calreticulin also associate with apoB100 during translation to assist in 
folding and lipid recruitment (Rutledge, Su, & Adeli, 2010; Zhang & Herscovitz, 2003).  
If apoB100 is not lipidated, the protein is directed to the proteasome-mediated ER-
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associated degradation (ERAD) pathway (Cohen & Fisher, 2013).   The majority of 
nascent VLDL secreted from hepatocytes (VLDL1) have one apoB100 molecule and a 
sedimentation factor of Sf = 20-100 (Yao & Wang, 2012).   
In insulin-resistant states, nascent VLDL translocate between the Golgi and ER 
and are lipidated to produce VLDL2 (Sf > 100) with a twofold larger diameter than 
VLDL1 (Sundaram, Zhong, Bou Khalil, Links, et al., 2010; Yao & Wang, 2012).  ApoC3 
is essential for production of VLDL2 and is up-regulated in insulin-resistant states, but its 
role in VLDL assembly is unclear (Section 2.5.4). VLDL2 contain one apoB100 and other 
exchangeable apolipoproteins, notably apoC3 and apoE (Yao & Wang, 2012). 
VLDL1 are secreted from hepatocytes and acquire exchangeable proteins—
including multiple molecules of apoE and the apoCs—in plasma and, to a smaller extent, 
from golgi during assembly (Table 1.1) (Cohen & Fisher, 2013).  ApoB100 constitutes 
30%, by weight, of the protein in VLDL (Brown et al., 1969).  Acquisition of apoC2 is 
essential for VLDL catabolism.  The large sizes of VLDL prevent movement across 
capillaries such that TG hydrolysis is essential for delivery of lipids to parenchymal cells 
in target tissues (Young & Zechner, 2013).  ApoC2 on VLDL activates lipoprotein lipase 
(LPL), which hydrolyzes core TG (LaRosa, Levy, Herbert, Lux, & Fredrickson, 1970).   
LPL is expressed in muscle, heart, and adipose tissues.  LPL is anchored to the 
luminal surface of endothelial cells via non-covalent interactions with glycosyl-
phosphatidylinositol-anchored HDL-binding protein 1 (GPIHBP1) (Figures 1.4, 1.5).  
LPL removes ~50% of the TG from the VLDL core before particles dissociate from the 
extracellular matrix of endothelial cells (Cohen & Fisher, 2013).   
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Figure 1.4. VLDL remodeling to IDL and LDL in plasma.  
TG-rich VLDL are secreted by hepatocytes directly to plasma.  LPL, which is tethered to 
the capillary endothelium by GPIHBP1, hydrolyzes core TG to produce free fatty acids 
and monoacylglycerols.  These amphipathic lipids partition from the particle core to its 
surface.  This generates excess surface material, which can fission from the VLDL 
particle in the form of small, HDL-like protein:lipid complexes that contain exchangeable 
apolipoproteins, such as apoE.  VLDL remnants (i.e., IDL) are cleared from circulation 
by LRP or VLDLR.  Alternatively, IDL are remodeled by HL and CETP.  This results in 
hydrolysis of core TG and exchange of core TG for CE (from HDL) to produce CE-rich 
LDL.  LDL, which contain one apoB100 as their sole protein, are taken up by LDLR in 
the liver and peripheral tissues.  Figure adopted from (Guha & Gursky, 2010). 
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Figure 1.5. Intravascular and intracellular lipolysis.   
In the process of intravascular lipolysis, LPL hydrolyzes TG in CM and VLDL on the 
luminal face of capillaries.  LPL is anchored to the surface of capillaries by GPIHBP1.  
The products of hydrolysis by LPL are fatty acids (FA) and monoacylglycerols (MG).  
FAs and MGs transverse the endothelium and are taken up by underlying parenchymal 
cells—principally adipocytes and myocytes.  Monoacylglycerol lipase (MGL) in 
parenchymal cells hydrolyzes MGs to FAs and glycerol.  Glycerol is re-secreted and 
transported to the liver.  Fatty acids and glycerol can be used to synthesize TGs for 
storage in the lipid droplets of adipocytes.  These TGs can be hydrolyzed by the 
intracellular lipases adipose triacylglycerol lipase (ATGL) and hormone sensitive lipase 
(HSL).  Released FAs can enter oxidative pathways to produce energy.  Figure adopted 
from (Young & Zechner, 2013). 
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The products of lipolysis, free fatty acids and monoacylglycerols, translocate 
across the endothelium and are taken up by parenchymal cells of peripherial tissues 
(Figure 1.5).  To give myocytes “priority access” to TG in fasting states, expression of 
the LPL inhibitor angiopoietin 4 (angptl4)  is up-regulated in adipocytes (Wang & Eckel, 
2009).  In fed states, insulin upregulates LPL expression in adipose tissue.  
Depletion of TG results in conversion of VLDL to VLDL remnants, i.e. IDL 
(Figure 1.4). Dissociation of apoC2 from these particles is linked to cessation of LPL 
activity (Cooper, 1997).  Other exchangeable apolipoprotein dissociate from IDL and 
apoC2, apoC3, and apoE may transfer to HDL (Cooper, 1997; Murdoch & Breckenridge, 
1996).  IDL have two fates.  Whole particles can be endocytosed by hepatocytes via 
interactions between apoE and receptors—the VLDL receptor (VLDLR), LDL receptor 
(LDLR), and the LDL-receptor-related protein (LRP) (Figures 1.3, 1.4).  ApoE interacts 
with negatively-charged ligand-binding regions on these receptors via a lysine-rich region 
(amino acids 140-150) in helix 4 (Mahley & Rall, 2000).  Approximately 50% of IDL are 
removed from plasma via interaction with LDLR or LRP (Rader et al., 2003).  
The remaining IDL are catabolized to LDL by hepatic lipase (HL) (Young & 
Zechner, 2013).  HL is largely expressed at the surface of hepatocytes and hydrolyzes TG 
in chylomicron remnants, IDL, and HDL (Young & Zechner, 2013).  As HL hydrolyzes 
TG, apoE molecules dissociate from the particles.  After hydrolysis of IDL-TG, the 
particles become smaller and more dense; and are reclassified as LDL (Table 1.1).  The 
actions of LPL and HL remove 90% of TG from VLDL and CM (Bergman et al., 1971).  
LDL have little TG, a core rich in CE, and one molecule of apoB100 (Table 1.1).   
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LDL interact with LDLR via specific sites on apoB100, but this is a weak 
interaction such that LDL have a lifespan on the order of days in circulation (Cohen & 
Fisher, 2013).  70% of LDLR receptors are in the liver, with the other 30% in 
macrophages, lymphocytes, and gonadal, adrenocortical, smooth muscle, and intestinal 
cells (Cohen & Fisher, 2013).  On binding to LDLR, whole LDL are removed from 
plasma by receptor-mediated endocytosis (Brown & Goldstein, 1986).  Since it lowers 
the rate of cell cholestesterol biosynthesis, this process is non-atherogenic (Brown & 
Goldstein, 1986; Yokoyama et al., 1993).  Within hepatocytes, apoB100 is degraded, CE 
is hydrolyzed to free cholesterol, and LDLR are recycled back to the plasma membrane 
(Davis et al., 1985; Goldstein & Brown, 2009).   
Defects in the hepatic uptake and degradation of LDL via LDLR-mediated 
endocytosis are commonly caused by loss-of-function mutations in the LDLR or apoB 
genes (Soutar & Naoumova, 2007).  The result is Familial Hypercholesterolemia (FH), 
which is characterized by elevated serum levels of LDL-cholesterol, excess cholesterol 
deposition in tissues, and accelerated atherosclerosis (Soutar & Naoumova, 2007).  The 
rate of cholesterol synthesis remains the same in peripheral cells, and a greater amount of 
LDL is oxidized and accumulates in atherosclerotic plaques, as described in Section 1.3.   
CM package dietary TG with apoB48 in the intestinal epithelium.  These particles 
are secreted into the lymphatic system, quickly reach the bloodstream, and are 
catabolized similar to VLDL (Cohen & Fisher, 2013; Young & Zechner, 2013).  During 
passage from lymph to plasma, CM acquire free cholesterol, the apoCs, and apoE.  After 
TG hydrolysis by LPL and HL, CM remnants rely on interactions between apoE and 
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LDLR or LRP for uptake by the liver (Cohen & Fisher, 2013).  CM remnants and IDL 
spend less time (hours) in circulation than LDL, due to a higher affinity between apoE 
and LDLR or LRP (Cohen & Fisher, 2013).  In the liver, dietary cholesterol has several 
possible fates. These include esterification and storage, packaging into VLDL, and 
secretion into the bile (Matsuo, 2010; Rader et al., 2003). 
 
1.3 The Role of Lipoproteins in Cardiovascular Disease 
Cardiovascular disease is the leading cause of death in the United States (Hoyert 
& Xu, 2012).  In 2011, cardiovascular disease accounted for ~24% of all deaths in the 
United States (Hoyert & Xu, 2012).  Chronic diseases, of which cardiovascular disease is 
the most prevalent, accounted for seven of the top ten leading causes of death in 
2011(Bauer, Briss, Goodman, & Bowman, 2014).  The net cost for provision of care for 
people with chronic illnesses is extremely high: in 2010 the total spending for the 
Medicare populate (mostly adults over 65) exceeded US $300 billion (Bauer et al., 2014).  
Understanding the mechanisms behind cardiovascular disease will facilitate production of 
therapeutics to reduce morbidity from cardiovascular disease, which will reduce the cost 
for care of people with this prevalent chronic illness. 
 The major cause of cardiovascular disease is the development and rupture of 
atherosclerotic plaques in vascular walls.  These plaques restrict blood flow to down-
stream tissues, thereby starving them of essential nutrients and leading to high blood 
pressure.  Elevated plasma concentrations of apoB-containing lipoproteins can cause 
atherosclerosis, such as in FH and other genetic hyperlipidemias (Bentzon et al., 2014; 
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Moore & Tabas, 2011; Zannis et al., 2004).  Cardiovascular disease often develops at 
lower plasma concentrations of LDL in combination with other risk factors that promote 
atherosclerosis.  These factors include smoking, hypertension, diabetes mellitus, male 
sex, aging, and a complex genetic susceptibility to the disease (Bentzon et al., 2014).   
 Elevated levels of apoB100-containing lipoproteins, often marked as increased 
levels of plasma TG and LDL-cholesterol, occur in patients with genetic defects in genes 
that regulate lipoprotein metabolism (Table 1.3).  For example, FH, which is the most 
common and severe form of monogenic hypercholesterolemia, is caused by mutations in 
the LDLR gene (Rader et al., 2003).  Mutations in the LDLR gene can result in a lack of 
LDLR synthesis, defective intracellular trafficking of LDLR, or defective LDLR binding 
to LDL (Zannis et al., 2004).  This results in elevated plasma levels of LDL and reduced 
LDLR activity (Rader et al., 2003).  If untreated, receptor-negative patients with 
homozygous FH die in the second decade of life, while receptor-defective patients with 
heterozygous FH develop cardiovascular disease by age 30 (Rader et al., 2003).  
Heterozygous FH has a prevalence of 1 in 500. 
The point mutation Arg3500Gln in apoB results in production of defective 
apoB100 that cannot interact with LDLR.  This results in familial defective apoB-100 
(FDB), which presents a phenotype similar to LDLR deficiency: elevated plasma LDL-
cholesterol levels and premature atherosclerosis (Rader et al., 2003).  A variety of 
nonsense, missense, and frameshift mutations have been identified in the apoC2 gene.  
Heterozygous apoC2 deficiency has little effect on lipid levels, but homozygous loss of 
apoC2 leads to greatly elevated plasma levels of TG (Young & Zechner, 2013).   
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Defective Gene Inheritance Disease Common Phenotypes 
LDLR Autosomal 
Dominant 
Familial 
Hypercholesterolemia 
(FH) 
Elevated plasma levels of LDL-
cholesterol (C), decreased LDLR activity, 
xanthomas, premature atherosclerosis 
ApoB Autosomal 
Dominant 
Familial Defective 
ApoB-100 (FDB) 
Elevated plasma levels of LDL-C, tendon 
xanthomas, premature atherosclerosis 
ABCA1 Autosomal 
Recessive 
Tangier’s Disease Low plasma levels of HDL-C & apoA-I, 
early chronic kidney disease, no sign of 
premature atherosclerosis 
ABCG5/G8 Autosomal 
Recessive 
Sitosterolemia >50-fold increase in plasma levels of 
sitosterol, elevated LDL-C, decreased 
cholesterol excretion, xanthomas, 
premature atherosclerosis 
LPL Autosomal 
Dominant 
Familial 
Hypertriglyceridemia, 
LPL Deficiency 
Elevated plasma levels of triacylglycerol 
(TG), deficiencies of essential fatty acids 
(FA) in adipose and breast milk, 
pancreatitis, xanthomas, lipemia retinalis, 
hepatosplenomegaly 
ApoC2 Autosomal 
Recessive 
Familial 
Hypertriglyceridemia, 
apoC-II deficiency 
Elevated plasma TG levels, pancreatitis, 
xanthomas, lipemia retinalis; less severe 
and presents later than LPL deficiency 
ApoC3 Autosomal 
Dominant 
ApoC-III deficiency Heterozygous deficiency results in low 
plasma TG levels, protection from 
atherosclerosis 
GPIHBP1 Autosomal 
Recessive 
Familial 
Chylomicronemia, 
GPIHBP1 deficiency 
Elevated plasma TG levels, pancreatitis, 
xanthomas, lipemia retinalis 
Table 1.3. Monogenic diseases that influence atherosclerosis.   
Apo, apolipoprotein; LDLR, LDL receptor; GPIHBP1, glycosylphosphatidylinositol-
anchored high density lipoprotein binding protein 1; ABC, ATP-binding cassette; LPL, 
lipoprotein lipase.  Facts from (Rader, Cohen & Hobbs, 2003; Young & Zechner, 2013). 
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Loss of LPL activity through genetic mutations has an even more severe effect.  
Patients develop familial chylomicronemia, which is characterized by creamy plasma and 
markedly elevated plasma TG levels, xanthomas, and are at risk for acute pancreatitis 
(Young & Zechner, 2013).   
Most of the genetic mutations that influence genes regulating the metabolism of 
VLDL and chylomicrons increase the risk of premature atherosclerosis (Table 1.3).  In 
contrast, the effect of mutations in genes regulating HDL metabolism on the progression 
of atherosclerosis is unclear.  For example, patients with homozygous mutations in the 
ABCA1 gene develop Tangier’s disease, which is characterized by undetectable or very 
low plasma levels of HDL-cholesterol and accumulation of CE in various tissues (Frikke-
Schmidt, 2010; Rader & Hovingh, 2014).  The risk for premature atherosclerosis for 
carriers of ABCA1 mutations has not been clearly defined. In one study (Schaefer, Zech, 
Schwartz, & Brewer, 1980), 50% of homozygotes, but only 25% of heterozygotes, 
between the age of 35 and 65 exhibited premature atherosclerosis.  In an MRI imaging 
study (Bochem et al., 2013), increased atherosclerosis was evident in Tangier 
heterozygotes, but a larger epidemiological study (Frikke-Schmidt, 2010) showed that 
genetically low HDL-cholesterol does not increase the risk of cardiovascular events. 
The initial step in the formation of atherosclerotic plaques on arterial walls is the 
sub-endothelial accumulation of apoB-containing lipoproteins (Figure 1.6).  In the arterial 
intima, LDL are modified by oxidation and aggregation (Steinberg & Witztum, 2010).  
LDL oxidation triggers innate and adaptive immune responses, inducing the expression 
of chemokines and growth factors by endothelial cells.  These molecules interact with   
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Figure 1.6. Progression of atherosclerosis.  
In early fatty streak lesions, apolipoprotein B-containing lipoproteins (apoB-LP) 
accumulate in the subendothelial space.  This promotes recruitment of dentritic cells and 
macrophages.  Smooth muscle cells and T cells infiltrate the intima, which promotes 
amplification of apoB-LP retention.  Accumulation of apoptotic cells and defective 
efferocytosis results in a lipid-filled necrotic core and characterizes vulnerable plaques.  
As the fibrous cap thins, lesion stability decreases and plaques become susceptible to 
rupture and the formation of a thrombus.  Figure adopted from (Moore & Tabas, 2011). 
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monocyte receptors and promote directional monocyte migration into the intima and 
differentiation into macrophages and dendritic cells (Figure 1.6) (Bentzon et al., 2014; 
Moore & Tabas, 2011).   
Some recruited macrophages attain proinflammatory M1-like phenotypes and 
secrete cytokines, enzymes and reactive oxygen species (Leitinger & Schulman, 2013).  
This promotes further retention and oxidation of LDLs.  Other macrophages have M2-
like phenotypes and secrete factors to resolve inflammation. 
The initial lesion created by the accumulation of LDL and macrophage is called a 
fatty streak and is reversible.  Macrophages phagocytose oxidized LDL particles and 
become lipid-rich foam cells (Zannis et al., 2004).  Once ingested by macrophages, the 
cholesterol esters of LDL are hydrolyzed in late endosomes to free cholesterol and fatty 
acids (Maxfield & Tabas, 2005).  Free cholesterol is effluxed out of macrophages by 
ABCA1 and ABCG1 to cholesterol-poor HDL, which promotes resolution of 
atherogenesis (Tall, Yvan-Charvet, Terasaka, Pagler, & Wang, 2008). 
Smooth muscle cells migrate to the lesion, proliferate, and synthesize components 
of the extracellular matrix, such as collagen and proteoglycans (Ross, 1999).  Smooth 
muscle cells, collagen, and calcium deposits form a fibrous cap at the luminal face of the 
lesion (Figure 1.6).  As the lesion develops, the lipid load exceeds the efflux and storage 
capacity of macrophages and smooth muscle cells in the plaque, resulting in cell death.  
Apoptosis and secondary necrosis of these cells produce a necrotic core in advanced 
lesions (Bentzon et al., 2014).  A necrotic core develops as cell death exceeds the rate of 
efferocytosis and the lipid-rich cargo of the dead cells is deposited in tissue (Figure 1.6).   
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As smooth muscle cells die and collagen synthesis decreases, macrophage-derived 
metalloproteinases (MMPs) begin to degrade the collagen-rich cap matrix and the fibrous 
cap thins (Moore & Tabas, 2011).  Plaques with a fibrous cab thickness <65 µm are at 
risk for rupture (Bentzon et al., 2014).  A growing necrotic core and thinning fibrous cap 
in vulnerable plaques can lead to rupture of the plaque, which results in clot formations 
and bleeding into the arterial wall.   With plaque rupture, cap collagen and apoptotic 
microparticles that are enriched in tissue factor are released into the artery and promote 
blood clot formation (Bentzon et al., 2014).  This may result in a significant blockage of 
the artery, called a stenosis, which cuts off downstream tissues from oxygen and other 
essential nutrients.  When this occurs in arteries that feed vital organs, such as the heart, 
brain, gut, or kidney the results can be fatal (Zannis et al., 2004). 
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2. Chapter 2: The Roles of the Apolipoprotein Cs in Lipoprotein Metabolism 
The human apoCs (C1, C2, C3, and C4) were initially thought to be a single 
protein, because of their low molecular weights (6.6 to 8.8 kDa) and similar distribution 
among lipoprotein subclasses (Jong, Hofker, & Havekes, 1999).  Each protein received 
its name after its distinct properties were discovered (Brown et al., 1969; Brown, Levy, & 
Fredrickson, 1970).  ApoC4 is expressed at very low levels in the liver and is a minor 
component of VLDL, while the other human apoCs are major protein constituents of 
chylomicrons and VLDL, and minor protein constituents of HDL (Table 1.2).  The genes, 
structures, and functions of the three major human apoCs are reviewed in this chapter. 
2.1 Apolipoprotein C Genes 
The genes coding for human apoC1 and apoC2 are located within a 48-kb gene 
cluster on the long arm of chromosome 19 (T J Knott et al., 1984; Lusis et al., 1986).  
This cluster includes the apoE and apoC4 genes, and a non-expressed apoC1 pseudogene 
(Figure 2.1A).  The apoC3 gene is ~3.2 kb and is on the long arm of human chromosome 
11 between the apoA1 and apoA4 genes (Figure 2.1B) (Karathanasis, 1985).   
The gene for human apoC1 codes for 57 amino acids of the mature protein and a 
26 amino acid signal sequence.  In the pseudogene, the codon for the penultimate amino 
acid of the apoC1 signal sequence (Gln) has been converted to a stop codon (Andersson, 
Thelander, & Bengtsson-Olivecrona, 1991).  The apoC1 gene and pseudogene differ by 
22 additional nucleotides.  The gene encodes a basic protein, while the pseudogene 
encodes a negatively-charged virtual protein (Puppione & Whitelegge, 2013). 
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Figure 2.1.  The location and composition of the apoC genes.  
(A) The apoE/C1/C4/C2 gene cluster is on the long arm of chromosome 19 in humans.  
This gene cluster is ~48 kb in length. All genes in the cluster have the same 
transcriptional orientation, as indicated by arrows.  The apoC1 gene is 4.7 kb and is ~5 kb 
downstream of the apoE gene.  ApoC-IΨ is the apoC1 pseudogene; 7.5 kb downstream of 
the apoC1 gene.  The apoC2 gene is 3.3 kb and is ~16 kb downstream of the apoC1 
pseudogene.  Figure adopted from  (Puppione & Whitelegge, 2013).  
(B) The apoA1/C3/A4 gene cluster (~17 kb) is on the long arm of chromosome 11 in 
humans.  The apoC3 gene is 3.1 kb and is ~2.5 kb downstream of the apoA1 gene.  The 
apoC3 gene is transcribed in the opposite direction as the apoA genes. The most 
frequently occurring polymorphic sites in this cluster are shown, of which some are 
discussed in Appendix A.  The 4-exon, 3-intron composition (C) of each gene is shown.  
Figure adopted from (Groenendijk, Cantor, De Bruin, & Dallinga-Thie, 2001).  
(C) The human genes for many of the exchangeable apolipoproteins have a structural 
organization of four exons of varying length.  Transcription is from left to right.  The 
wide bars mark exons, while the thin line marks the 5’ flanking region, introns, and 3’ 
flanking region for each gene.  Open bars mark untranslated regions, hatched bars mark 
signal peptide regions, and solid bars mark mature protein regions.  Numbers above the 
exons indicate exon length. Figure adopted from (Chan, 1989).  
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The apoC2 gene is 3.3 kb in length and has introns of 2391, 167, and 298 bases 
(Figure 2.1C) (Wang, 1991).  The gene codes for 79 amino acids in the mature protein 
and a 22 residue signal sequence.  The apoC3 gene is ~3.2 kb and is on the long arm of 
human chromosome 11 between the apoA1 and apoA4 genes (Figure 2.1B) 
(Karathanasis, 1985).  The gene codes for 79 amino acids in the mature protein and a 20-
residue signal sequence (Bruns, Karathanasis, & Breslow, 1984; Karathanasis, 1985).  
Regulation of the expression of the apoC genes is discussed in Appendix A.   
The apoA1, apoA2, apoC3, apoC2, apoC1, apoC1’, and apoE genes have similar 
organization:  four exons are separated by three introns and the first exon is non-coding 
(Figure 2.1C) (Lauer et al., 1988).  Intron 1 interrupts the 5’ untranslated region of the 
gene, intron 2 interrupts a coding region of the gene close to the signal peptidase cleavage 
site, and intron 3 interrupts the part of the gene that encodes the mature protein (Chan, 
1989).  Exons 3 and 4 encode the amino acid sequence of the mature apolipoprotein and 
feature regular 11 or 22 codon repeats (Figure 2.1C) (Rozek, Sparrow, Weisgraber, & 
Cushley, 1999).  The apoC1 sequence contains four 11mer repeats, three of which are 
encoded by exon 3 and one by exon 4 (Rozek et al., 1999).  ApoA1, apoA4, and apoE 
contain 22-mer repeats, which is the result of a tandem duplication of an 11-mer repeat  
(Figure 2.2) (Mei & Atkinson, 2011; Segrest et al., 1992).  These repeats code for 
amphipathic α-helices with a periodicity of 3.6 residues per turn (Segrest et al., 1992).  
Based on their degree of homology and pattern of internal repeats, an evolutionary tree 
(Figure 2.2) was proposed for the exchangeable apolipoproteins (Chan, 1989).   
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Figure 2.2. Proposed scheme for the evolution of apolipoprotein genes.   
The primordial apolipoprotein gene, which was similar in structure and length to that of 
apoC1, was duplicated.  One of the genes led to apoC1, while the other became the 
common ancestor of all other human apolipoprotein genes.  In the latter lineage, the first 
11 codons of exon 4 were duplicated before the whole gene was duplicated.  One of the 
genes became apoC2, while the other became the common ancestor of the other human 
apolipoprotein genes.  In the latter lineage, the first 11 codons of exon 4 were duplicated 
before the whole gene was duplicated.  In one lineage, the first 11 codons of exon 4 were 
deleted and the gene was duplicated to produce apoA2 and apoC3.  In the other lineage, 
at least six duplications of 22 codons occurred and possibly a duplication of 11 codons.  
A duplication of the whole gene occurred and, after more modification, one gene became 
apoE while the other became apoA1 and apoA4.  Image adopted from (Chan, 1989). 
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2.2 Synthesis and Structure of the Apolipoprotein Cs 
 Each of the apoCs is primarily expressed in the liver and in the intestines (Jong, 
Hofker, et al., 1999).  ApoC1 is primarily expressed in the liver, but lower expression is 
found in the intestines, lung, skin, testes, and spleen.  ApoC2 is primarily expressed in the 
liver and intestine (Jong, Hofker, et al., 1999).  ApoC3 is synthesized in the liver and, to a 
lesser extent, in the intestine (Bruns et al., 1984; Karathanasis, 1985).  The properties of 
the mature proteins are shown in Table 2.1.   
The apoCs have similar secondary structures.  Far-UV circular dichroism (CD) 
and nuclear magnetic resonance (NMR) studies showed that monomers of the apoCs are 
largely unfolded in solution and lack tertiary structure (Gursky, 2001; Hatters, MacPhee, 
Lawrence, Sawyer, & Hewlett, 2000; Liu, Talmud, et al., 2000; Morrisett, David, 
Pownall, & Gotto, 1973; Rozek et al., 1999) but acquire 50-70% helical content on 
binding to lipid (Benjwal, Jayaraman, & Gursky, 2007; Gangabadage et al., 2008; 
Larsson, Vorrsjo, Talmud, Lookene, & Olivecrona, 2013; MacRaild, Hatters, Howlett, & 
Gooley, 2001; MacRaild, Howlett, & Gooley, 2004; Morrisett et al., 1973; Rozek et al., 
1999; Zdunek et al., 2003).  Each apoC has helical regions in the N- and C-terminus.  
Table 2.1 and Figure 2.3 summarize differences in the secondary structure of the three 
apoCs, each of which is discussed below. 
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Protein Plasma 
Conc. 
[mg/dL] 
Isoelectric 
Point (pI) 
Amino 
Acids 
Residues 
in α-
helices 
ΔGbi→w 
[kcal mol
-1
 
/ res] 
 
ΔGw→o 
[kcal mol
-1
 
/ res] 
<µH> 
[kcal mol
-1
 
/ res] 
ApoC1 6-10 7.9 57 8-29 
34-47 
 
0.43 
0.66 
-1.7 
-2.0 
0.29 
ApoC2 3-4 4.6 79 14-38 
63-76 
 
0.65 
0.38 
-1.7 
-1.5 
0.27 
ApoC3 7-10 4.7 79 8-29 
34-43 
47-65 
0.42 
0.47 
1.10 
-1.3 
-1.5 
-2.6 
 
0.28 
 
Table 2.1.  Properties of the apolipoprotein Cs.  
ApoC plasma concentration is the concentration in normolipidemic subjects.  Isoelectric 
points were determined from ExPasy analysis.  Residues in α-helices were determined 
from NMR structures of protein in complex with SDS or DPC.  ΔGbi→w is the average 
free energy change per residue for the apolar face of a helix on transition from a lipid 
bilayer to water, as calculated from the Wimley & White scale (Wimley & White, 1996).  
This scale was calculated from measuring the partition coefficients of short WL-X-LL 
peptides between water and large unilamellar vesicles (LUVs) of POPC.  Amino acids 
were individually inserted into these peptides at position X.  ΔGw→o is the average free 
energy change per residue for the apolar face of a helix on transition from water to oil, as 
calculated from the Goldman, Engelman, & Steitz scale (Engelman, Steitz, & Goldman, 
1986).  Positive ΔGbi→w marks an energetically unfavorable transition to the lipid-free 
state, while negative ΔGw→o marks a favorable transition to the lipid-bound state.  The 
mean hydrophobic moments (<μH>) for each peptide were  calculated as previously 
described (Bolanos-Garcia, Renault, & Beaufils, 2008; Eisenberg, Weiss, & Terwilliger, 
1982) using the hydrophobicity scale of (Janin, 1979).  
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Figure 2.3.  Secondary structure of each ApoC Protein  
The sequence of each apoC was drawn as a thin line.  Blue, open circles mark the N-
terminus and red, closed circles mark the C-terminus.  Gray rectangles show regions 
predicted to form α-helices (Segrest et al., 1992) or shown in NMR studies to form α-
helices in protein complexes with SDS or DPC.  Over three NMR studies (MacRaild et 
al., 2001, 2004; Zdunek et al., 2003), the helical content of the central region of apoC2 
decreased as the molar protein:lipid ratio decreased from 1:760 (SDS) to 1:120 (SDS) to 
1:60 (DPC).  NMR studies of apoC1 (Rozek et al., 1999) and apoC3 (Gangabadage et al., 
2008) were conducted at 1:40 and 1:360 apoC:SDS molar ratios, respectively.  A 
representative NMR structure is shown for apoC1, apoC2, and apoC3 in complex with 
SDS at the lowest protein:SDS ratio available.  Figure adapted from (Das & Gursky, 
2015). 
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2.2.1 ApoC1 Sequence and Structure 
The 26-residue signal peptide of apoC1 is cleaved co-translationally in the rough 
ER, as revealed by nucleotide analysis (T. J. Knott et al., 1984).  Mature apoC1 has 57 
amino acids, a molecular mass of 6.63 kDa, and an isoelectric point of 7.9 (Table 2.1) 
(Morrisett, Jackson, & Gotto, 1977).  Studies with far-UV CD (O. Gursky, 2001; Rozek 
et al., 1999) showed that aqueous apoC1 monomers, at concentrations ≤0.01 mg/mL, 
adopt a fluctuating helix-turn-helix conformation with an average helical content of 31%.  
On apoC1 aggregation (at concentrations >0.01 mg/mL) or binding to lipids (i.e., sodium 
dodecyl sulphate (SDS) micelles, DMPC, cholesterol: egg yolk PC complexes), this value 
increases to 50-65% (Gursky, 2001; Jonas et al., 1984; Rozek et al., 1999).     
The NMR spectra of native human apoC1 (isolated from blood plasma) and 
15
N-
labeled synthetic apoC1 were acquired in the presence of SDS at a molar protein:SDS 
ratio of 1:40, 50ºC, and pH 4.8 (Rozek et al., 1999).  From 685 NOE-derived distance 
restraints, 3D structures of apoC1 were calculated by distance geometry-simulated 
annealing and molecular dynamics.  50 calculated structures were categorized into two 
groups:  a “closed” conformation with helix-helix distances shorter than 5Å and an 
“open,” V-shaped conformation.  No long-range NOEs were observed to support the 
“closed” conformation.  18 structures had an “open” conformation with helix-helix 
distances larger than 5 Å and small residual NOE restraint violations (Figure 2.4).  Two 
well-defined helical regions in the N- and C-terminal halves of apoC1 are present in each 
of the structures (Figure 2.4), with RMS deviations <0.5 Å (Rozek et al., 1999).  
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Figure 2.4. NMR structure of apoC1 in complex with SDS micelles.  
(Top) Cartoon representation of the 18 structures of apoC1 (in an “open” conformation) 
determined in complex with SDS micelles by NMR (PDB ID: 1IOJ).  The N-terminal 
helix, from residues 7-29, is highlighted in blue.  The C-terminal helix, from residues 38-
52, is highlighted in orange.  The N- and C-termini are labeled.  
(Bottom) A representative apoC1 structure.  The N-terminus is on the left.  The apolar 
face (yellow), acidic (red), and basic (blue) residues are colored accordingly.  Leu11, 
Lys12, Phe46, and Gln47 are labeled.   
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Analysis of backbone torsion angles and the hydrogen bond pattern indicates 
helical geometry for residues 7-29 and 38-52 in the N- and C-terminal regions (Figure 
2.4).  The N-terminal helix is a class A-amphipathic helix (Figure 2.5).  Class-A helices 
are characterized by an apolar face that subtends <180°, acidic residues in a linear array 
along the polar face, and basic residues at the polar/apolar boundary (Segrest et al., 
1992).  Due to their methyl groups, the lysines at the edge of the apolar face are predicted 
to snorkel out of lipid/water interfaces (Mishra, Palgunachari, Segrest, & 
Anantharamaiah, 1994). The N-terminal helix contains two hydrophobic clusters (Leu8, 
Leu11, Phe14, Leu18 and Leu25, Ile26, Ile29) and two highly-charged regions (Asp9, 
Lys12, Glu13 and Glu19, Asp20, Lys21, Arg23, Glu24).  The position of residues 7-10 
vary between NMR structures due to a bend at Leu11/Lys12 (Figure 2.4).  This bend 
decreases the average distance between Leu8 and other residues in the first hydrophobic 
cluster (Phe14, Leu18) by 2-3 Å, thereby increasing the density of the hydrophobic 
cluster (Rozek et al., 1999). 
An unordered linker region connects the N-terminal helix to the C-terminal helix, 
which spans residues 38-52 (Rozek et al., 1999).  Mutagenesis studies favor a C-terminal 
helix that spans residues 34-47 (Benjwal et al., 2007; Mehta, Gantz, & Gursky, 2003).    
These studies showed that mutation of Met38 to Pro resulted in complete helical 
unfolding in apoC1 and reduced helical content on DMPC from 65% in WT to 45% in 
the mutant.  Mutation of Leu34 to Pro did not alter the DMPC-bound helical content of 
apoC1 (Mehta et al., 2003).  As Pro mutations in the middle, but not at the end, of helices 
reduce helical content (Ponsin, Hester, Gotto, Pownall, & Sparrow, 1986), these results   
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Figure 2.5.  ApoC1 sequence (bottom) and structure (top).  
(Bottom) The sequence of mature apoC1 reveals a greater number of basic than acidic 
amino acids, which gives apoC1 a net positive charge at neutral pH.  The lone tryptophan 
(W41) is shown in bold in the sequence. 
(Top) Helical wheel representations of the two predicted class-A amphipathic α-helices in 
apoC1 (Benjwal et al., 2007; O. Gursky, 2001; Rozek et al., 1999). Helices are modeled 
as canonical α-helices with 3.6 residues per turn.  Apolar residues are colored in yellow, 
polar in gray, basic in blue, acidic in red, and glycine in pink. The hydrophobic face of 
each helix is indicated by dotted lines. In previous studies (Benjwal et al., 2007; Gursky, 
2001; Gursky, 1999; Mehta et al., 2003), the secondary structure of apoC1 was altered by 
single Ala or Pro substitutions.  The residues mutated to Ala or Pro in apoC1 variants 
used in this study (Chapter 4) have a thick, black outline. 
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indicate that the C-terminal helix spans residues 34-47, as in Figure 2.5.  Consistent with 
this, the calculated NMR structures of the C-terminal helix are bent at various angles 
about residues Phe46/Gln47 (Rozek et al., 1999).   
The C-terminal helix is, approximately, an 11-mer class A-amphipathic α-helix, 
with one hydrophobic cluster rich in aromatic residues (Leu34, Ala36, Met38, Trp41, 
Phe42, Ph46) and one cluster of highly-charged residues (Lys37, Arg39, Glu40, Glu44) 
(Figure 2.5).  Extension of the C-terminal helix to include residues 48-52 provides a 
second cluster of charged residues rich in lysines. 
The C-terminal helix of apoC1 has a higher affinity for lipid than the N-terminal 
helix, as predicted by hydrophobicity (Table 2.1) and shown in several studies.  In the 
NMR structures of apoC1:SDS complexes, residues in the C-terminal helix had slower 
deuterium exchange rates and more uniform backbone amide line widths than residues in 
the N-terminal helix (Rozek et al., 1999).   This indicates that the C-terminal helix binds 
to lipid more tightly than the N-terminal helix.  LC-MS analysis of apoC1 bound to 
DMPC disks showed that residues 38-51 are more protected from proteolysis than other 
regions (James et al., 2009).  Clustering of Trp41, Phe42, and Phe46 produces a strong 
near-UV CD signal that was only completely disrupted by Pro mutations to those, or 
nearby, residues (Gursky, 2001).  This suggests that the aromatic cluster is the most 
stable helical element in apoC1.  
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2.2.2 ApoC2 Sequence and Structure 
ApoC2 is primarily expressed in the liver and intestine (Jong, Hofker, et al., 
1999).  As a percentage of the liver value, fetal apoC2 mRNA expression is 3% in 
intestine and <1% in pancrease RNA (Zannis et al., 1985).  ApoC2 is translated and 
secreted to plasma as follows.  The 22-residue signal sequence is cleaved during 
translation and the 79-residue peptide is post-translationally modified via glycosylation 
(Fojo et al., 1986).  After secretion, most apoC2 is de-glycosylated and ~15% of normal 
fasting apoC2 is glycosylated.  Neither the glycosylation site on apoC2, nor the enzyme 
responsible, have been identified.  80% of normal fasting apoC2 is the mature protein, 
while 5% is a short, 73-residue apoC2 variant missing N-terminal residues Thr-Gln-Gln-
Pro-Gln-Gln due to a post-translational cleavage at the Gln-Asp bond (Fojo et al., 1986).   
CD analysis showed that lipid-free apoC2 in solution contains little α-helical 
content (~20% at ≤0.15 mg/mL and solubilized for <<24 hr) (Hatters, et al., 2000).  
ApoC2 self-assembles at concentrations >0.1 mg/mL into homogeneous fibrils with 
increased levels of β-structure and hallmarks of amyloid (Hatters et al., 2000; Hatters, 
Minton, et al., 2002; Hatters, Wilson, et al., 2002), as reviewed in appendix B.   
In contrast, apoC2 adopts α-helical structure in the presence of lipid and lipid 
mimetics, as shown by NMR studies (MacRaild et al., 2001, 2004; Zdunek et al., 2003).  
2D- and 3D-NMR spectra were acquired for single (
15
N) labeled apoC2 in the presence of 
a 1:60 molar ratio of dodecyl-phosphocholine (DPC) at 30ºC and pH 5.0 (MacRaild et al., 
2004), single (
15
N) labeled apoC2 in the presence of a 1:120 molar ratio of SDS at 40ºC 
and pH 5.0 (Figure 2.6, top) (MacRaild et al., 2001), and double (
15
N/
13
C) labeled apoC2  
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Figure 2.6. NMR structures of apoC2 in complex with SDS.   
(Top) Cartoon representation of 4 of the 22 structures of apoC2 residues 13-79 
determined in complex with SDS (at a 1:120 apoC2:SDS molar ratio) by NMR (PDB ID: 
1I5J).  The N-terminal helix, from residues 14-38, is highlighted in blue.  The C-terminal 
helix, from residues 63-76, is highlighted in orange.  The C-terminus (colored black) and 
N-terminus are labeled for each representation.  
(Middle) A select cartoon of 1 of the 22 structures of apoC2 residues 13-79 determined in 
complex with SDS micelles by NMR (PDB ID: 1I5J).  Hydrophobic residues are colored 
yellow, basic residues blue, and acidic residues red.  Tyr25 and Trp26, which represent a 
30º-60º bend in the N-terminal helix are colored magenta and labeled.  Pro43, which 
splits the N- and C-terminal halves is labeled.  The C-terminal glutamates, which bend 
back, away from the apolar face of the C-terminal helix, are labeled.  The C- and N-
termini are labeled. 
(Bottom) Cartoon representation of 4 of the 96 structures of apoC2 determined in 
complex with SDS micelles (at a 1:760 apoC2:SDS molar ratio) by NMR (PDB ID: 
1O8T).  These structures are notable for a clearly defined central helix, from residues 45-
57, which is highlighted in purple.  The N-terminal helix, from residues 16-38, is 
highlighted in blue.  The C-terminal helix, from residues 64-74, is highlighted in orange.  
The N-terminus (colored black) and C-terminus are labeled for each representation. 
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in the presence of a 1:760 molar ratio of SDS at 40ºC and pH 5.0 (Figure 2.6, bottom)  
(Zdunek et al., 2003).  In these studies, SDS and DPC induced ~60% α-helical structure 
in apoC2 and prevented fibril formation.  
As summarized in Figure 2.3, NMR studies showed that lipid-bound apoC2 
contains N- and C-terminal helices.  Medium-range NOEs, secondary chemical shifts 
(Δδ) for Hα and HN resonances, backbone torsion angles, and order parameters from 
these NMR data were used to define helical regions.  At a protein:SDS molar ratio of 
1:120, residues 14-38 and 63-76 of apoC2 formed well-defined helices (MacRaild et al., 
2001), as shown in Figure 2.6 (top).   Residues 50-56 form a more poorly defined helix, 
as can be seen in Figure 2.6 (middle).   
From these helical assignments, the N- and C- terminal helices of apoC2 are 
modeled in Figure 2.7.  The residue assignments for these helices are almost identical in 
the other structures of apoC2 in complex with SDS (Zdunek et al., 2003) and DPC 
(MacRaild et al., 2004), (Figure 2.3).  The N-terminal helix is an imperfect class-A α-
helix (Figure 2.7), with serines, rather than basic residues defining one edge of its apolar 
face.  Three glutamates (E20, E27, E38) form a linear array along the polar face.  The 
apolar face has two clusters of residues—F14, L15, V18, L22 and A29, A32, A33, L36 
(Figure 2.7).  Y25 and W26 mark a bend of 30-60º in the helix (Figure 2.6, middle) 
(MacRaild et al., 2001; Zdunek et al., 2003).  This makes the apolar face convex and 
induces a binding preference for the less-curved surfaces of large, TG-rich lipoproteins.  
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Figure 2.7.  ApoC2 sequence (bottom) and structure (top).  
(Bottom) The sequence of mature apoC2 has more acidic (red) than basic (blue) residues, 
giving apoC2 a negative charge at neutral pH.  The lone tryptophan (W26) is in bold.   
(Top) Helical wheel representations of the N-terminal (left) and C-terminal (right) α-
helices in apoC2.  These helices were similarly defined in NMR structures of apoC2 in 
complex with SDS (MacRaild et al., 2001; Zdunek et al., 2003) or DPC (MacRaild et al., 
2004).  The N-terminal helix is a class-A helix, with an apolar face (marked by a dashed 
line) of nine residues (yellow), basic residues at the polar/apolar boundary, and acidic 
residues along the polar face. The C-terminal helix (right) is a class-G helix, 
characterized by a random radial distribution of basic and acidic residues.  The four 
residues that interact with LPL (Shen, Lookene, Nilsson, & Olivecrona, 2002) have a 
thick, black edge.  Polar residues are gray, glycine is pink. 
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The C-terminal helix is a class-G amphipathic α-helix (Figure 2.7).  Class-G 
helices are characterized by apolar and polar faces, but charged residues are randomly 
oriented (Segrest et al., 1992).  Two hydrophobic clusters (Y63, I66, F67, V74 and V71, 
L72, L75) are ~120º out of alignment about the helical axis.  In the NMR structures of 
apoC2:SDS at 1:120 (MacRaild et al., 2001), G77 adopts an unusual conformation that 
causes E78 and E79 to bend back alongside the C-terminal helix (Figure 2.6, middle).  
This aligns the glutamates with D69 to form an extended acidic surface. 
Residues 66-79 of apoC2 may be capable of disengaging from lipid surfaces.  In 
apoC2:SDS complexes (Zdunek et al., 2003), the C-terminal helix displayed elevated 
levels of motion on the nanosecond time scale, as compared to other helical regions of 
apoC2.  Experimental NMR constraints (NOEs, J-couplings) allow for a rolling motion 
of this helix from 0 to 50º, while the rolling motion of the other helical regions is 
restricted to ~20º.  In addition, the region around Y63 (±2 residues) showed a significant 
deviation from ideal helical structure in apoC2:DPC complexes (MacRaild et al., 2004). 
The central region of apoC2, spanning residues 45-58 gains helical content as the 
lipid:protein ratio increases.  Residues 45-58 form a rigid, helical rod in NMR spectra of  
apoC2 in the presence of a 1:760 molar ratio of SDS (Figure 2.6, bottom)  (Zdunek et al., 
2003).  This helical region is limited to residues 50-56 in the NMR spectra of apoC2 in 
the presence of a 1:120 molar ratio of SDS (MacRaild et al., 2001). In contrast, residues 
40-65 are largely unordered in NMR spectra of apoC2 in the presence of a 1:60 molar 
ratio of DPC (MacRaild et al., 2004).   These results indicate that the propensity of 
residues 45-58 to form a helix increases as the surface area per apoC2 increases on lipid. 
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2.2.3 ApoC3 Sequence and Structure 
ApoC3 is synthesized as a 99-amino acid peptide in the liver and, to a lesser 
extent, in the intestine (Bruns et al., 1984; Karathanasis, 1985).  The 20-residue signal 
sequence is cleaved in the ER, producing a mature protein of 79 amino acids of ~8.8 kDa 
(Table 2.1).  ApoC3 is glycosylated in the Golgi by polypeptide N-acetylgalactosaminyl-
transferase 2 (GALNT2) (Holleboom et al., 2011).  Protein is secreted to plasma as non-
sialylated, non-glycosylated (apoC-III0) and mono- and di-sialylated, glycosylated (apoC-
III1, apoC-III2) isoforms.  ApoC-III1 and apoC-III2 contain one oligosaccharide side chain 
bound to T74, as shown by techniques such as plasma desorption, MALDI-TOF, and ESI 
mass spectrometry, gas-liquid chromatography, periodate oxidation, and Smith 
degradation (Ito, Breslow, & Chait, 1989; Vaith, Assmann, & Uhlenbruck, 1978).   
ApoC-III0, apoC-III1, and apoC-III2 comprise  8-22%, 45-59%, and 27-35% of 
total apoC3 levels in circulation (Ito et al., 1989; Kashyap et al., 1981; Mauger et al., 
2006; Millar, 2001).  In normolipidemic subjects, 30% of plasma apoC3 is distributed 
among the TG-rich lipoproteins, while 60% is on HDL (Mann et al., 1997).  ApoC3 is the 
most significant contributor to the total sialic acid content of VLDL.  ApoC3 contributes 
110.8 mol sialic acid from an average of 87.2 mol protein per mol VLDL; or ~68% of the 
total sialic acid content of VLDL (Millar, 2001). 
Glycosylation of apoC3 reduces the plasma life of apoC3, but does not influence 
protein function.  Two studies (Huff, Fidge, Nestel, Billington, & Watson, 1981; Mauger 
et al., 2006), using either radioisotopes or L-(5, 5, 5,-D3)-leucine to monitor apoC3 
turnover in humans, showed that apoC-III1 and apoC-III2 had similar clearance rates 
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(FCR) from circulation (~0.6 pool/day).  In contrast, apoC-III0 had a longer plasma life, 
with an FCR of ~0.2 pool/day (Mauger et al., 2006).  The longer plasma-life of apoC-III0 
may be due to lack of sialic acid-induced protein targeting or its smaller pool size. 
Several studies indicate a minor physiological role, if any, for glycosylaction of 
apoC3.  Heterozygotes for a mutation of Thr74→Ala in the apoC3 gene had an unusually 
high plasma level of apoC-III0—this isoform was ~50% of serum apoC3 (Maeda et al., 
1987; Maeda et al., 1981).  However, total TG, cholesterol, and serum apoC3 levels were 
similar to those of non-carrier subjects, which suggests that apoC3 glycosylation does not 
influence function (Maeda et al., 1981).  In one set of in vitro assays, apoC-III0 and apoC-
III1, when pre-incubated with lipoproteins, inhibited uptake of VLDL and CM by 
perfused rat livers to the same extent (Windler, Chao, & Havel, 1980).   
ApoC3 is largely unfolded in solution and lipid-binding induces helical structure.  
At concentrations ≤0.2 mg/mL, lipid-free apoC3 contains 20-27% α-helix, as shown by 
CD (Liu et al., 2000; Morrisett, David, Pownall, & Gotto, 1973).  On binding to lipid 
(i.e., DMPC, SDS, or egg yolk PC), the helical content of apoC3 increases to 50-70% 
(Gangabadage et al., 2008; Larsson et al., 2013; Liu et al., 2000; Morrisett et al., 1973).  
Lipid-bound apoC3 contains three helices spanning residues 8-29, 34-43, and 47-66 
(Figure 2.3).  3D-NMR spectra of 
15
N/
13
C-labeled apoC3 (human apoC3 expressed in E. 
Coli and not glycosylated) were acquired in the presence of SDS at a 1:360 molar apoC3: 
SDS ratio and 42.7ºC (Gangabadage et al., 2008).  Short- and medium-range NOE and 
torsion angles indicate that the apoC3 backbone adopts α-helix structure from residues 8-
64, with breaks from this structure at residues 30-33, 44-45, and 19-22 (Figure 2.8).     
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Figure 2.8. NMR structure of apoC3 in complex with SDS micelles.  
(A) Cartoon representation of one of the closely-aligned ten NMR structures of apoC3 in 
complex with SDS (at a 1:360 molar ratio).  The N- and C-termini are labeled.   
ApoC3 contains four semi-flexible hinges (black).  On surfaces of low curvature, the first 
hinge is in the N-terminal region (residues 19-22) and likely does not break the long helix 
spanning residues 8-29.  The four helices in lipid-bound apoC3 are colored blue (helix 1, 
residues 8-29), magenta (helix 2, residues 34-43), orange (helix 3, residues 47-66), and 
green (helix 4, residues 74-79).  Structure from (Gangabadage et al., 2008).   
(B)  The same cartoon representation on the left is colored according to amino acids:  
apolar residues are yellow, basic residues are blue, and acidic residues are red.  The 
apolar faces of the three larger helices face inwards, but the arrangement of SDS around 
the protein is purely speculative.  Rare polymorphisms in the apoC3 gene feature 
mutations in Ala23, Lys58, or Thr74.  These residues are labeled on the structure.    
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The apoC3 backbone is unstructured from residues 67-73  (due to two prolines, 
P69 and P73), but contains a short helix from residues 74-79 (Gangabadage et al., 2008).  
This helix was stabilized by insertions of Leu80 and Glu81 in the recombinant apoC3 and 
plays a minor role in apoC3 association with SDS.  The four helices in apoC3 are 
connected via semi-flexible hinges, as identified by deviation from helical structure, and 
are curved (Figure 2.8).  The deviation in residues 19-22 was small, such that residues 8-
29 likely form one 22-residue helix on surfaces of less curvature, as predicted by 
sequence analysis (Figure 2.3) (Liu et al., 2000; Segrest et al., 1992).   
Based on the NMR assignments, helices 1 (residues 8-29), 2 (34-43), and 3 (47-
66) are modeled in Figure 2.9.  The first two helices are amphipathic class-G helices, 
containing apolar faces of varying length, but few charged residues that help anchor the 
helices to lipid surfaces (Gangabadage et al., 2008).  In contrast, helix 3 (residues 47-66) 
is a class A-amphipathic α-helix with several charged, lipid-anchoring residues and an 
apolar face rich in highly-hydrophobic aromatic residues.   
Several studies have shown that helix 3—due to its structure (Figure 2.9) and 
hydrophobicity (Table 2.1)—is the apoC3 region responsible for high affinity lipid 
binding.  In one study (Sparrow et al., 1977), apoC-III1 was cleaved by thrombin into 
fragments of residues 1-40 and 41-79.  As assessed by far- and near-UV CD, Both 
peptides were disordered in solution, but only residues 41-79 acquired helical structure 
on addition of DMPC or POPC SUVs.  In addition, the lipid binding of the apoC3 mutant 
F64A/W65A was severely impaired, as compared to that of WT and N-terminal mutants 
K21A and L9T/T20L apoC3 (Liu, Talmud, et al., 2000).  This was shown as slower  
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Figure 2.9.  ApoC3 sequence (bottom) and structure (top).   
(Bottom)  The sequence of apoC3 (79 amino acids) has a greater number of acidic (12) 
than basic (8) residues, colored red and blue, respectively, which gives the protein a net 
negative charge at neutral pH.  The C-terminal half of apoC3 contains 3 tryptophans, 
which are shown in bold in the sequence.   
(Top)  Helical wheel representations of the 3 large α-helices in lipid-bound apoC3, as 
determined by the NMR structures of apoC3:SDS complexes (Gangabadage et al., 2008).  
Helices 1 and 2 are class G-amphipathic α-helices, but contain apolar faces (marked by a 
dashed line) of 11 and 9 hydrophobic residues (yellow), respectively.  Ala23 in helix 1is 
critical for VLDL assembly (Sundaram, Zhong, Bou Khalil, Zhou, et al., 2010) and has a 
thick, red outline.  Helix 3 is a class-A amphipathic helix and features an apolar face 
(marked by a dashed line) of 8 residues, 3 lysines at the lipid/water interface, and 4 acidic 
residues in a linear array along its polar face.  Lys58 critical for VLDL assembly (Qin et 
al., 2011) and has a thick, blue outline.  Polar residues in all helices are gray; glycine is 
pink.  Hydrophobic residues W42 (helix 2) and F47, L50, W54, F61, F64, W65 (helix 3), 
have thick, black outlines, are highly conserved in mammals (Larsson et al., 2013), and 
were mutated to alanines in the studies described in chapter 6.  Double and triple 
substitutions of W42, F47, and L50 with alanines significantly reduced the ability of 
apoC3 to inhibit LPL (Larsson et al., 2013). 
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clearance of DMPC multilamellar vesicles and a larger amount of unbound apoC3 at the 
end of these assays.  All together, these results indicate that helix 3 of apoC3, which is 
rich in aromatic residues (Figure 2.9), mediates lipid-binding.  
Binding of helix 1 may stabilize apoC3 at lipid surfaces.  The apoC3 mutant 
A23T, which disrupts the apolar face of helix 1 (Figure 2.9), cleared DMPC at a 50% 
slower rate than WT apoC3 and the amount of unbound protein at the end of the assay 
was higher for the mutant (Liu, Labeur, et al., 2000).  As determined by size exclusion 
chromatography (SEC), complexes of F64A/W65A or A23T apoC3 with DMPC were 
10-20 Å larger than WT:DMPC complexes (Liu, Labeur, et al., 2000; Liu, Talmud, et al., 
2000), which indicates a decreased ability to insert into and remodel DMPC vesicles. 
In summary, the class-A amphipathic α-helix is the lipid-binding motif utilized by 
all three apoCs.  ApoC1 has two, class-A helices (Figure 2.5).  The shorter, 14-residue C-
terminal helix likely binds lipid with higher affinity than the longer, ~22-residue N-
terminal helix.  This is due to the clustering of aromatic residues in the C-terminal helix.  
ApoC2 contains a 25-residue, N-terminal class-A helix (Figure 2.7) that likely anchors 
the protein to lipid while the C-terminal, class-G helix exhibits a high degree of motion at 
lipid surfaces.  ApoC3 contains two class-G helices and a 19-residue, class-A C-terminal 
helix (Figure 2.9).  Seven of the eight residues in the apolar face are aromatic residues 
and this helix has the highest hydrophobicity of any apoC helix (Table 2.1).   
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2.3 The Roles of the ApoCs in Metabolism of ApoB-Containing Lipoproteins 
The apoCs play critical roles in HDL and LDL metabolism.  As will become 
evident in the next two sections, these roles are largely dependent on protein-lipid 
interactions.  In this thesis, we used oil-drop tensiometry (described in Chapter 3) to 
characterize the interaction of the apoCs with lipid surfaces.  Since the lipid surfaces we 
used resemble CM and VLDL, the roles of the apoCs in CM and VLDL metabolism are 
discussed here, while their roles in HDL metabolism are discussed in Appendix C. 
The apoCs play essential roles in the life cycles of VLDL and CM.  ApoC2 is the 
required cofactor of LPL, as discussed in Sections 2.4.1, 2.4.2.  Subjects with apoC2 
deficiency exhibit elevated serum TG, associated with elevated risk for premature 
atherosclerosis and acute pancreatitis.  In contrast, apoC1 and apoC3 inhibit LPL and 
inhibit the uptake of VLDL and CM, as discussed in Sections 2.5.1 to 2.5.3.  ApoC3 
plays a unique role in VLDL synthesis, as discussed in Section 2.5.4.  As a result of these 
pro-atherogenic functions, elevated apoC3 serum levels in humans are a strong predictor 
of cardiovascular disease.  
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2.4: The Role of ApoC2 in VLDL and CM Metabolism 
2.4.1 ApoC2 is the Required Cofactor of LPL:  Evidence 
In normolipidemic subjects, apoC2 is present at serum levels of 3-4 mg/dL (Table 
1.2).  ApoC2 is the cofactor for LPL and its presence is required for maximal rates of 
LPL-mediated lipolysis of TG-rich lipoproteins (LaRosa et al., 1970).  The importance of 
apoC2 is evident in subjects with defects in the structure or production of apoC2 (Table 
2.2).  These subjects exhibit phenotypes that mirror patients with LPL deficiency: high 
serum levels of TG-rich lipoproteins and lower levels of LDL, HDL, apoB, and apoA1. 
Most patients that exhibit hypertriglyceridemia or chylomicronemia due to apoC2 
deficiency inherit the genetic defect as an autosomal recessive trait (Cox, Breckenridge, 
& Little, 1978).  In several subjects with a homozygous apoC2 gene defect (rows 2-6 of 
Table 2.2), a single nucleotide base change introduced a premature stop codon and 
resulted in the synthesis of truncated apoC2, which was not secreted or rapidly cleared 
from circulation.  In other subjects, single-amino acid substitutions in both copies of the 
apoC2 gene resulted in the production of non-functional apoC2 (Table 2.2, rows 8-11).  
Some substitutions resulted in altered C-termini (Table 2.2, rows 8-10) in mature apoC2, 
which likely impairs interaction with LPL (Section 2.4.2).  Other substitutions 
(Trp26→Arg) interrupt the N-terminal helix of apoC2, which impairs lipid binding.In 
contrast, most heterozygotes for apoC2 deficiency are normolipidemic (Table 2.2).  One 
study showed that 7 heterozygous relatives of 7 homozygotes whose genetic mutations 
produce apoC2 deficiency had 30-50% of normal plasma apoC2 concentrations  
 53 
 
Molecular Defect Gene 
Mutation 
Lipoprotein 
Disorder 
Protein in 
Plasma 
Reference 
Introduction stop 
codon (Val18) 
Homozygous Familial 
chylomicronemia 
0 (Fojo, Stalenhoef, et al., 
1988) 
Stop codon (Arg19 in 
signal peptide) 
Homozygous Familial 
chylomicronemia 
0 (Parrott, et al., 1992) 
Introduction stop 
codon (Gln2) 
Homozygous Familial 
chylomicronemia 
0 (Xiong et al., 1991) 
Introduction stop 
codon (Tyr37) 
Homozygous Familial 
chylomicronemia 
0 (Crecchio, Capurso, & 
Pepe, 1990; Fojo, Lohse, et 
al., 1989) 
Met22→Val (signal 
peptide, initiation Met) 
Homozygous Familial 
chylomicronemia 
0 (Fojo, De Gennes, et al., 
1989) 
Intron 2 donor splice 
effect 
Homozygous Familial 
chylomicronemia 
14% mRNA 
vs. control 
(Fojo, Beisiegel, et al., 
1988) 
Asp69→Thr; C-
terminal end T69-K70-
F71-F72-L73-C74 
Homozygous Familial 
chylomicronemia 
Unchanged (Connelly, Maguire, 
Hofmann, & Little, 1987) 
Gln70→Pro; 17 
additional C-terminal 
residues 
Homozygous Familial 
chylomicronemia 
Unchanged (Connelly, Maguire, & 
Little, 1987) 
Leu72→Pro Homozygous Familial 
chylomicronemia 
Not 
determined 
(Lam, Yuen, Cheng, Chan, 
& Tong, 2006) 
Trp26→Arg Homozygous Familial 
chylomicronemia 
Decreased, 
<50% of WT 
(Inadera et al., 1993) 
Lys19→Thr Heterozygous Hyperlipidemia Unchanged (Huff et al., 1990) 
Glu38→Lys Heterozygous Hyperlipidemia Unchanged (Pullinger et al., 1993) 
Table 2.2. Mutations affecting the synthesis, secretion, or structure of apoC2.  
The molecular defect, nature of the genetic mutation (homo- or heterozygous) or how 
many mutated alleles the subject has, related lipoprotein disorder or abnormality, and 
plasma level of apoC2 compared to control, normolipidemic subjects are indicated. 
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but were normolipidemic (Cox et al., 1978).  In a separate study, 9 heterozygous subjects 
for familial apoC2 deficiency had lower apoC2 plasma levels (1.8±0.5 mg/dL vs. 2.9±0.9 
mg/dL in normolipidemic subjects), but normal fasting plasma levels of total lipids, 
lipoproteins, and other apolipoproteins (Breckenridge, Alaupovic, Cox, & Little, 1982).  
However, some heterozygotes for apoC2 deficiency exhibit elevated levels of 
plasma lipids.  Plasma TG and cholesterol levels were elevated in heterozygous carriers 
that were also heterozygous for the apoE4 allele, as compared to relatives who carried ≤1 
variant allele (Hegele et al., 1991). Heterozygous carriers of one mutant allele of Lys19→ 
Thr or Glu38→Lys substitutions in mature apoC2 exhibit hyper-lipidemia on an apoE ¾ 
background (Table 2.2, rows 12-13).  These results suggest that single apoC2 genetic 
mutations have an interactive effect on lipid phenotype and induce hypertriglyceridemia 
when they are co-inherited with a single mutation in the apoE gene.  
ApoC2 becomes increasingly important with substrates containing long acyl 
chains.  This was shown by in vitro assays monitoring LPL catalysis of micelles or 
emulsions containing phospholipids or TG of varied acyl chain length (Rapp & 
Olivecrona, 1978; Shinomiya, Jackson, & McLean, 1984).  LPL activity is high with 
short-chain substrates, such as tributyrin; and apoC2 has no effect on LPL kinetics (Rapp 
& Olivecrona, 1978).  By comparison, apoC2 reduces the free energy of activation and 
increases the rate of lipid hydrolysis with long-chain substrates (Shinomiya et al., 1984).  
These results indicate that, while short-chain lipids may diffuse to the catalytic site of 
LPL at the lipid/water interface, apoC2 facilitates this movement for long-chain lipids.  
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2.4.2  ApoC2 Activates LPL through Direct Interaction 
The molecular details of the mechanism of LPL activation by apoC2 are largely 
unknown.  However, significant progress has been made in elucidating the interactions 
between apoC2, LPL, and lipid required for LPL activation.  Our model for activation of 
LPL by apoC2 is shown in Figure 2.10, and the evidence for it is described here.  
ApoC2 activates LPL through direct interaction.  By measuring fluorescence 
anisotropy with fluorescently-labeled apoC2, Clarke and Holbrook showed that apoC2 
and LPL form a 1:1 complex in solution and on triolein globules (Clarke & Holbrook, 
1985).  The dissociation constant (kd) of the complex was 0.2x10
-6
 M and decreased to 7-
10x10
-9
 M in the presence of lipid.  Increasing salt or heparin concentration weakened the 
interaction between apoC2 and LPL in solution, but not on the lipid surface.   
The N-terminal region of apoC2 is responsible for lipid binding, while the C-
terminal one-third of the molecule contains the structures needed for interaction with and 
activation of LPL.  The structure of the N-terminal helix (Figure 2.7) indicates that it is 
well-suited for binding lipid.  Consistent with this, a peptide representing residues 19-38 
of apoC2 bound strongly to small unilamellar vesicles (SUVs) of egg yolk PC, as shown 
by anisotropy of fluorescently-labeled peptide (MacPhee, Howlett, & Sawyer, 1999).  
However, the N-terminal region of apoC2 is unable to activate LPL. In vitro studies 
(Kinnunen, Jackson, Smith, Gotto, & Sparrow, 1977; Musliner, Herbert, & Church, 
1979) showed that CNBR or synthetic apoC2 fragments of residues 1-9, 10-59, and 1-50 
were unable to stimulate LPL activity in the presence of substrate.   
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Figure 2.10. Mechanism of LPL activation by apoC2.   
The pictured mechanism can be extrapolated from the results of (Vainio, Virtanen, 
Kinnunen, Gotto, et al., 1983; Vainio, Virtanen, Kinnunen, Voyta, et al., 1983): 
(Left)  At low pressures (15 to 22 mN/m for a monolayer of diC12PG phospholipid), LPL 
interacts with lipid surfaces and catalyzes hydrolysis.  ApoC2 does not enhance LPL:lipid 
interactions, but promotes faster substrate turnover at the catalytic site of LPL.   
(Middle) Above the critical pressure of LPL (~22 mN/m), LPL binds to, but is inactive at 
lipid surfaces.  ApoC2 induces the active conformation in LPL above its critical 
pressure—perhaps through direct interactions mediated by the C-terminus of apoC2 
(Shen et al., 2002), thereby keeping the enzyme active.  
(Right) Above the exclusion pressure of apoC2 (~30 mN/m at a monolayer of diC12PG 
phospholipid), apoC2 desorbs resulting in the inactivation and potential dissociation of 
LPL from the lipid surface. 
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In contrast, the C-terminal region of apoC2 stimulates LPL activity.  Residues 60-
78, 55-78, and full-length apoC2 increased LPL hydrolysis by 4-, 12-, and 13-fold, 
respectively, in vitro (Kinnunen et al., 1977).  A separate study (Voyta et al., 1983) 
showed that apoC2 fragment 44-79 was able to stimulate LPL activity by 100% 
(compared to WT apoC2), while fragments 65-79, 61-79, and 56-79 stimulated LPL 
activity by 0, 20, and 70% in vitro.  These results indicate that the minimal region of 
apoC2 required for LPL activation is, roughly, residues 50-79.  However, residues 50-79 
were unable to promote LPL activity on CM isolated from an apoC2-deficient subject, 
while full-length apoC2 increased LPL activity 100-fold (Olivecrona & Beisiegel, 1997).  
This indicates that both direct interaction with LPL, mediated by the C-terminus, and 
lipid-binding, mediated by the N-terminus, are essential for apoC2 function.  
ApoC2 residues Y63, I66, D69, and Q70 form a binding site along one face of the 
C-terminal helix (Figure 2.7) for LPL.  In one study (Shen et al., 2010), in vitro activation 
and binding assays with LPL, apoC2 point mutants, and TG-rich emulsions or non-
hydrolyzable lipid vesicles were used to identify the residues of apoC2 critical for 
interaction with LPL.  Of the residues in the C-terminal that are conserved across at least 
10 animal species (A59, T62, Y63, G65, I66, D69, Q70), only mutations in Y63, I66, 
D69 and Q70 to alanine or other amino acids decreased LPL activation (by 2- to 4-fold) 
and/or weakened apoC2 interaction with LPL (shown as a 5- to 10-fold increase in kd).   
Y63 was the most sensitive of these residues to mutation—substitution to Leu, 
Ala, Trp, or Phe reduced LPL activity to near non-stimulated levels.  Substitution of D69 
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with Ser, Glu, or Asn did not show dramatic changes in LPL activation, which suggests 
that apoC2 tolerates variation in hydrophilic residues at this position.  Substitution of Q70 
with Glu abolished the ability of apoC2 to activate LPL, which suggests that apoC2 
association with LPL may be facilitated by charge-charge interactions.  Together, these 
results indicate that Y63, I66, D69 and Q70, form a binding site for LPL.   
ApoC2 does not influence the interaction of LPL with lipid surfaces, but enhances 
substrate turnover rate.  Two studies (Jackson, Tajima, Yamamura, Yokoyama, & 
Yamamoto, 1986; Olivecrona & Beisiegel, 1997) used in vitro assays to measure the 
effects of apoC2 on the lipolysis of apoC2-deficient, TG-rich lipoproteins and emulsions 
of triolein and egg yolk PC (at a 7:1 wt:wt ratio) by LPL.  For both substrates, maximal 
LPL activity occurred at a constant apoC2/PC mol ratio of 2.0x10
-4
 and at ~10% of 
plasma apoC2 levels in normolipidemic subjects (Jackson et al., 1986).  ApoC2 increased 
the maximum velocity (Vmax) of LPL by ≤10-fold with no change in the Michaelis 
constant of LPL binding to lipid (Jackson et al., 1986; Olivecrona & Beisiegel, 1997).  
Consistent with these results, apoC2 increased LPL velocity by 3-4 fold at pure 
phospholipid and mixed TG/PC monolayers (Vainio, Virtanen, Kinnunen, Gotto, et al., 
1983; Vainio, Virtanen, Kinnunen, Voyta, et al., 1983).  ApoC2 did not influence the 
binding of LPL to these interfaces, as marked by an interfacial enzyme concentration that 
was independent of the presence of apoC2.  Another study (Shirai, Matsuoka, & Jackson, 
1981) confirmed this finding by showing that the association of LPL (25 µg) with SUVs 
of dipalmitoyl-PC (DPPC;1 mg) was unaltered by apoC2.  Altogether, these results 
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indicate that apoC2 is not required for LPL binding to the lipid surface.  Rather, apoC2 
facilitates the substrate turnover of LPL (Figure 2.10).   
ApoC2 also extended the surface pressure range over which LPL is active at lipid 
surfaces, likely by interacting with the enzyme (Vainio, Virtanen, Kinnunen, Voyta, et 
al., 1983).  As LPL hydrolyzes TG and produces amphiphilic fatty acids and 
monoacylglycerols, these transiently accumulate increasing surface lipid density, or 
pressure.  LPL was active at mixed TG/ phospholipid and pure phospholipid monolayers 
of lower surface pressures, but required apoC2 for activity at pressures above a critical 
pressure (Vainio, Virtanen, Kinnunen, Gotto, et al., 1983; Vainio, Virtanen, Kinnunen, 
Voyta, et al., 1983).  These results, and others (Bengtsson & Olivecrona, 1980), suggest 
that apoC2 interacts with LPL to induce correct alignment of the complex at lipoprotein 
surfaces and facilitate substrate exposure to the catalytic site at higher surface pressures.   
From all of the above results, the model shown in Figure 2.10 was formed.  While 
it is not currently possible to measure, the surface pressure of newly secreted VLDL and 
CM is likely low.  TG comprises upwards of 90%, by weight, of VLDL (Cohen & Fisher, 
2013), such that amphipathic molecules are not as tightly packed at the surface.   Under 
these conditions, bound apoC2 can facilitate substrate turnover at the catalytic site of 
LPL.  As LPL hydrolyzes TG, transient accumulation of fatty acids and 
monoacylglycerols at the surface, coupled with loss of large amounts of core TG, results 
in high local surface pressure.  This increase in pressure induces conformational 
rearrangements in the C-terminal helix of apoC2, as less surface area is available to each 
protein molecule.  The C-terminal helix interacts with LPL to promote TG hydrolysis. 
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2.5: The Roles of ApoC1 and ApoC3 in VLDL and CM Metabolism 
2.5.1 Elevated Serum Levels of ApoC1 and ApoC3 are Linked to Hypertriglyceridemia 
Few polymorphisms in the human apoC1 gene have been identified that are linked 
to dyslipidemia or disease phenotypes.  In multiple populations, linkage disequilibrium 
has been established between apoE gene polymorphisms and the Hpa I polymorphism in 
the apoC1 gene (Seixas, Trovoada, & Rocha, 1999; C. Wang et al., 2006; Xu et al., 
1999).  A 4-bp CGTT insertion at 317 bp upstream of the apoC1 gene produces this 
polymorphism, decreasing binding of the negatively-acting transcription factor and 
increasing apoC1 gene expression by 57% (Wang et al., 2006; Xu et al., 1999).  Hpa I-
positive (H2) subjects exhibit elevated serum TG levels and increased risk for coronary 
artery disease, but only on a background of apoE ɛ4/4 and ɛ3/4 genotypes. These results 
indicate that apoC1 overexpression in H2 subjects impairs catabolism of VLDL and CM, 
but only when coupled with loss of apoE-mediated lipoprotein uptake.   
In contrast, elevated expression of apoC3 results in severe hypertriglyceridemia.  
Evidence from both clinical trials (Table 2.3) and subjects with genetic defects in apoC3 
(Table 2.4) indicate that apoC3 levels are a strong predictor of premature atherosclerosis 
in humans.  CLAS (Cholesterol-Lowering Atherosclerosis Study) and MARS (Monitored 
Atherosclerosis Regression Study) studies showed that levels of apoC3 in plasma and on 
apoB-containing lipoproteins (LpB) predicted the progression of coronary artery disease 
(CAD) (Table 2.3, rows 2, 3).  The CLAS study showed that a decrease in apoC3 not 
localized to LpB was a significant, independent predictor for increased progression of   
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1 Subjects Study Design Findings Reference 
2 162 men 
(50±10 yo) with 
previous 
coronary bypass 
surgery (CBS) 
and CAD 
CLAS study: global 
angiographic change 
measured in placebo and 
drug-treated groups 2 yr 
after treatment 
↑ apoC3 risk factor for progression 
of CAD in placebo group 
↑ Ratio of apoC3 in apoB- 
lipoproteins (LpB):HDL-apoC was 
associated with progression of 
CAD in placebo group  
 
(Blankenhorn 
et al., 1990) 
3 220 subjects 
(91% men; 
58±10 yo) with 
CAD and 
moderate 
dyslipidemia 
MARS study: Subjects on 
low-fat, low-cholesterol 
diet & lovastatin or 
placebo; Modeled 
association between risk 
factors & coronary lesions  
↑ LpB-apoC3 was independent 
predictor of CAD progression 
LpB-apoC3 was the single risk 
factor associated with progression 
of mild/moderate lesions 
 
 
(Hodis et al., 
1994) 
4 360 post-
myocardial 
infarction (MI) 
and 489 healthy 
male (age 25 to 
64) subjects  
ECITM study: assessed 
relationship between 
apoC3 + E distribution in 
lipoproteins and CAD 
Compared distribution of 
these apos between 2 trial 
groups 
↑ LpB-apoC3 and LpB-apoC3 to 
HDL-apoC3 ratio in subjects with 
CAD in univariate analysis 
↑ ApoC3 with (HDL-cholesterol + 
cholesterol + TG) or (apoA1 + 
apoB + TG) was highly predictive 
of CAD in multivariate analysis 
 
(Luc et al., 
1996) 
5 188 subjects 
(52% men; 
59±13 yo) with 
type II diabetes 
Analyzed relations 
between macro-
angiopathy (defined by ≥1 
of: coronary heart disease 
(CHD), peripheral 
vascular disease, cerebro-
vascular disease) and TG, 
apoC3, and LpB-apoC3 
Multivariate analysis showed that 
TG, apoC3, and LpB-apoC3 were 
independently associated with 
macrovascular complications 
↑ Odds ratios for macroangiopathy 
(1, 2.06, 3.45, 6.46) and CAD (1, 
2.71, 4.98, 4.45) as  ↑ LpB-apoC3 
(<10, <16, <23, and ≥23 mg/L) 
 
(Gervaise, 
Garrigue, 
Lasfargues, & 
Lecomte, 
2000) 
6 418 men with 
MI or CHD vs 
370 control 
patients 
CARE study: 5-yr study 
of placebo-controlled trial 
of pravastatin; 
lipid and lipoprotein 
levels were analyzed 
↑ LpB-apoC3 for ↑ CAD severity 
VLDL-apoB, LpB-apoC3, HDL-
apoE were predictors of CAD 
↑ LpB-apoC3 predicted CAD in-
dependent of TG, HDL-C, LDL-C 
 
(Sacks et al., 
2000) 
7 859 subjects 
(54% women; 
33 to 82 yo) 
with CHD 
Analyzed distribution of 
apoC3 among HDL and 
non-HDL particles as 
markers of CHD and 
metabolic syndrome 
↑ ApoC3 associated with CAD  
Non-HDL-apoC3  ≥7.0 mg/dL 
indicated CAD and 4.7-fold ↑ in 
likelihood of metabolic syndrome 
 
 
(Onat et al., 
2003) 
8 20 young 
subjects (85% 
men, 32.4±3.3 
yo) who 
survived MI; 20 
control subjects  
Analyzed the structural 
characteristics & 
components of HDL to 
measure qualitative HDL 
parameters associated 
with premature MI 
↓ HDL-apoA1:apoC3 ratio from 
4.9 (controls) to 0.24 (MI patients) 
↑ (2.5-fold) oxidation potential of 
HDL from MI group 
↓ pre-β and ↑ mature HDL levels 
in MI group 
 
(Kavo et al., 
2012) 
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Table 2.3.  ApoC3 is a significant predictor for Coronary Artery Disease (CAD).  
References from (Ooi, Barrett, Chan, & Watts, 2008; Zheng, 2014).  Abbreviations: MI, 
myocardial infarction; CBS, coronary bypass surgery; LpB, apoB-containing lipoprotein; 
TC, total cholesterol; HDL-C, HDL-cholesterol.  Abbreviations of trials expanded in text. 
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Molecular 
Defect 
Gene 
Mutation 
Lipid Phenotype  
(vs Non-Carriers) 
Protein in Plasma Reference 
C-482→T, 
T-455→C in IRE 
Heterozygous Hypertriglycerdemia, 
TG increased by 60% 
Increased; 130% of total 
apoC3 in non-carriers 
(Petersen et al., 
2010) 
Gln38→Lys Heterozygous Hypertriglyceridemia 
TG increased by 32% 
Variant level = normal, 
total increased by 34% 
(Pullinger et al., 
1997) 
G→A in highly 
conserved nt in 
splice site 
Heterozygous TG decreased by 
~50%, higher HDL-C 
Decreased by ~40% (Bochem et al., 
2014; Jørgensen 
et al., 2014) 
Introduction stop 
codon (Arg19, 
signal peptide) 
Heterozygous TG decreased by 
50%, higher HDL-C, 
lower LDL-C  
Decreased; 50% of total 
apoC3 in non-carriers  
(Pollin et al., 
2008) 
Ala23→Thr Heterozygous TG decreased to 25-
48% of normal 
Decreased; 70% of total 
apoC3 in non-carriers 
(Liu, Labeur, et 
al., 2000) 
Lys58→Glu Heterozygous Hypotriglyceridemia, 
low TG, high HDL-C 
Decreased by 30-40% (von Eckardstein 
et al., 1991) 
Thr74→Ala Heterozygous Normolipidemic Unchanged; 50% of total 
apoC3 is de-glycosylated 
(Maeda et al., 
1987; Maeda et 
al., 1981) 
Table 2.4. Mutations affecting the synthesis, secretion, or structure of apoC3. 
The molecular defect, nature of the genetic mutation (homo- or heterozygous), related 
lipoprotein disorder or abnormality, and plasma level of apoC3 compared to control, 
normolipidemic subjects (7-10 mg/dL) are indicated.  Abbreviations: TG, triacylglycerol; 
IRE, insulin response element; VLDL; very-low-density lipoprotein; HDL-C, HDL-
cholesterol; LDL-C, LDL-cholesterol; nt, nucleotide 
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coronary lesions (Table 2.3, row 2).  Likewise, an increase in apoC3 localized to LpB 
was a strong predictor of the progression of coronary lesions, independent of LDL-
cholesterol, as shown in the MARS study (Table 2.3, row 3).  The ECTIM (Etude Cas-
Temoin de l’Infarctus du Myocarde) and CARE (Cholesterol and Recurrent Events) trials 
showed that apoC3-LpB levels were a stronger predictor of coronary heart disease events 
than plasma TG levels (Table 2.3, rows 4, 6).  Altogether, these results indicate that the 
atherogenicity of apoB-containing lipoproteins depends on apoC3 content.  
In cross-sectional studies, high apoC3 levels were associated with increased CVD 
in subjects with CAD (Table 2.3, rows 2, 3), metabolic syndrome (Table 2.3, row 7), and 
type II diabetes (Table 2.3 row 5). All of the studies listed in Table 2.3 showed that 
elevated levels of apoC3 on LpB was a strong predictor of the progression of CAD.  In 
other trials (Chang et al., 2012; Jensen, Rimm, Furtado, & Sacks, 2012), HDL-apoC3 
levels were associated with a higher risk of CVD and the ratio of HDL-apoC3 to VLDL-
apoC3 was a better marker for predicting CVD than apoB and apoA1 levels.  High HDL-
apoC3 content likely inhibits the cardioprotective functions of HDL or renders HDL 
dysfunctional and/or atherogenic. 
Similar to the clinical data, subjects with gain-of-function, heterozygous 
mutations in one allele of the apoC3 gene exhibited hypertriglyceridemia that was 
associated with elevated plasma apoC3 (Table 2.4, rows 2, 3).  Insulin negatively 
regulates apoC3 expression (Appendix A), such that 76 heterozygotes for one, or both, 
single-base-mutations in the insulin response element (IRE) of the promoter region 
exhibited a 60% increase in plasma TG associated with a 30% increase in apoC3 (Table 
 65 
 
2.4, row 2).  16 carriers of the apoC3 Q38K mutation exhibited a significant increase in 
plasma TG, which correlated with increased apoC3 levels (Table 2.4, row 3).   
Conversely, subjects with loss-of-function, heterozygous mutations exhibited 
reduced plasma TG and apoC3 levels (Table 2.4, rows 4-7), which had a cardioprotective 
effect.  Heterozygous carriers of a mutation in the consensus splice site of the apoC3 gene 
that results in alternate splicing and loss of function exhibited lower TG and apoC3 levels 
(Table 2.4, row 4).  5% of the Amish population in Lancaster, PA, were heterozygous for 
an apoC3-null mutation: a C→T substitution at the terminal nucleotide of exon 3 that 
results in a premature stop codon in the signal peptide (Pollin et al., 2008).  Carriers 
exhibited 50% lower TG and apoC3 levels than non-carriers (Table 2.4, row 5).  The data 
presented above indicate that apoC3 and apoC1—at elevated levels in plasma—impair 
the catabolism of VLDL and CM; and apoC3 levels predict risk of atherosclerosis. 
The effects of apoC1 and apoC3 on serum lipid levels were mirrored in transgenic 
mice.  Mice that overexpress the human apoC1 gene (HuC1tg) exhibited hyperlipidemia, 
whether fasted or fed chow diets, as marked by elevated plasma levels of TG and total 
cholesterol (Berbée et al., 2005; Jong et al., 1996; Shachter et al., 1996; van der Hoogt et 
al., 2006). The main effect of apoC1 overexpression was on VLDL-TG, which increased 
by ≤12-fold, while VLDL-cholesterol increased by <2-fold.  Cross-breeding of HuC1tg 
mice on an apoE-deficient background induced more severe hypertriglyceridemia: 
plasma TG increased 55-fold, primarily in VLDL (Berbée et al., 2005).  In contrast, 
apoE-null mice developed atherosclerotic lesions at 10 weeks that were associated with 
severe hypercholesterolemia but only mild hypertriglyceridemia (Plump et al., 1992).   
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Likewise, apoC1-deficient mice, fed chow or mild hypercholesterolemic diets, do 
not exhibit dyslipidemia, as serum lipid levels were identical to those of WT mice (Jong 
et al., 1997; van Ree et al., 1995).  These results indicate that apoC1 overexpression 
primarily impairs TG metabolism in circulation, with only small effects on cholesterol 
metabolism.  TG metabolism is more severely impaired in the absence of apoE. 
ApoC3 transgenic mice also exhibited severe hypertriglyceridemia.  Mice 
expressing the human apoC3 transgene and fed chow diets developed atherosclerosis, in 
association with elevated TG, low HDL-cholesterol, and low apoA1 levels in circulation 
(Aalto-Setälä et al., 1992, 1996; Desilva et al., 1994; Ito, Azrolan, O’Connell, Walsh, & 
Breslow, 1990).  In one study (Ito et al., 1990), low- and high-expressor mice were 
generated, with 1-2 and 100 copies of the human apoC3 gene, respectively.  There was a 
strong correlation between serum TG and apoC3 levels from low- to high-expresser mice.  
High-expressor mice expressed apoC3 at 8-fold higher levels than WT mice and were 
severely hypertriglyceridemic, marked by a ~20-fold increase in plasma TG.      
In contrast, targeted disruption of the apoC3 gene promotes rapid catabolism of 
TG-rich lipoproteins (Jong et al., 2001; N. Maeda et al., 1994; Takahashi, Hirano, Okada, 
& Adachi, 2003). Heterozygous and homozygous apoC3-deficient mice had fasting 
plasma TG levels that were ~85 and 70% of those in WT mice.  These results indicate 
that overexpression of apoC3 impairs TG metabolism in plasma, but—unlike apoC1—the 
loss of apoC3 has a significant, anti-atherogenic effect on serum lipid levels.  The 
proposed pro-atherogenic functions of these apoCs are described in the next two sections.  
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2.5.2 ApoC1 and ApoC3 Inhibit ApoE-Mediated Uptake of VLDL and CM 
ApoC1 and apoC3 inhibit the catabolism of TG-rich lipoproteins through the 
inhibition of lipoprotein clearance (described below) and the inhibition of lipase (LPL, 
HL) activity (Section 2.5.3).  These effects on lipoprotein metabolism are shown for 
apoC3 in Figure 2.11. Evidence for effects of these apoCs on lipoprotein metabolism 
came from studies in transgenic mice and in vitro assays. 
Elevated expression of apoC1 induces hypertriglyceridemia, in part, by protein 
inhibition of the uptake of VLDL sub-fractions.  VLDL clearance—as monitored after 
injection of VLDL with radiolabeled TG or apoB100—was much slower in HuC1tg 
mice, as compared to WT mice (Shachter et al., 1996).  Since TG and apoB-100 
production rates were normal, this suggests that apoC1 overexpression inhibits VLDL 
lipolysis and clearance.   In another study (Jong et al., 1996), HuC1tg mice were bred on 
an LDLR-deficient (LDLR
-/-
) background.  Plasma VLDL-TG and cholesterol levels 
were greatly elevated in these mice, as compared to LDLR
-/-
 mice.  Since LDLR
-/-
 mice 
accumulate LDL but little TG in plasma, these results suggest that apoC1 accumulation 
inhibits the apoE-mediated uptake of VLDL subfractions by VLDLR or LRP.  Consistent 
with this, adenovirus-mediated delivery of LDLR, but not VLDLR, reversed 
hypertriglyceridemia in HuC1tg/(LDLR
-/-
 or LDLR
+/-
)
 
mice (Jong, van Dijk, et al., 1999). 
ApoC3 also elevates VLDL-TG levels through inhibition of VLDL uptake, as 
shown by in vivo studies with radiolabeled VLDL (Ito et al., 1990).  The VLDL fractional 
catabolic rate (FCR) was reduced from 7.67 pools/h in WT mice to 2.58 and 0.77 pools/h 
in low- and high-expressor HuC3tg mice, respectively.  In in vitro assays, the uptake of  
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Figure 2.11. The regulation of lipoprotein metabolism by apoC3.   
ApoC3 inhibits the catabolism of TG rich lipoproteins (i.e., CM and VLDL).  ApoC3 
inhibits TG hydrolysis by LPL and HL, as shown by orange arrows with negative (-) 
signs.  ApoC3 also inhibits uptake of IDL, LDL, and CM remnants by LDLR or other 
lipoprotein receptors, as shown by orange arrows with negative (-) signs.  Figure adopted 
from (Ooi et al., 2008). 
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apoC3-rich VLDL isolated from these mice by rat hepatoma cells and human fibroblasts 
was much slower than uptake of VLDL from WT mice (Aalto-Setälä et al., 1992; Ito et 
al., 1990).  This reduction in VLDL uptake was rescued in a dose-dependent manner by 
addition of apoE (Aalto-Setälä et al., 1992).  Altogether, these studies in apoC1 and 
apoC3 transgenic mice indicate that the proteins inhibit the apoE-mediated uptake of 
VLDL sub-fractions by VLDLR or LRP.    
Antisense inhibitors of apoC3 synthesis decreased plasma TG levels by 56-86% 
after 13 weeks of treatment to subjects who lacked functional LPL (Gaudet et al., 2014).  
To have this lipid-lowering effect, apoC3 must inhibit VLDL and CM catabolism through 
an LPL-independent pathway such as particle uptake.  In vitro assays confirmed that the 
apoCs inhibit lipoprotein uptake by impairing the binding of apoE to its receptors (LRP, 
VLDLR). In one study, β-VLDL was isolated from rabbits,  pre-incubated with human 
apoE3 and varying doses of apoCs, and incubated with fibroblasts unable to express 
LDLR (Weisgraber et al., 1990).  CE formation by fibroblasts, binding of β-VLDL to 
LRP, and apoC and apoE competition for binding to β-VLDL were measured.  By these 
standards, apoC1 was the most potent inhibitor of β-VLDL binding to LRP.  ApoC2 
inhibited β-VLDL/apoE stimulation of CE formation in human fibroblasts with 
significantly lower potency than apoC1; and apoC2 reduced apoE3 binding to β-VLDL 
by 48% at similar concentrations at which apoC1 abolished apoE3 binding.   
ApoC3 was unable to inhibit binding of β-VLDL to LRP or CE formation by 
fibroblasts (Weisgraber et al., 1990).  ApoC3 plays an essential role in the assembly of 
TG-rich VLDL (as described in Section 2.5.4), such that its ability to regulate lipoprotein 
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metabolism could be altered at the the cholesterol-rich surface of β-VLDL (~50% 
cholesterol by weight) (Fainaru, Mahley, Hamilton, & Innerarity, 1982). 
 Similar clearance assays (Sehayek & Eisenberg, 1991)—using WT human 
fibroblasts and VLDL sub-fractions isolated from plasma of subjects with apoE ε3/3 or 
ε4/3 profiles—showed that the ratio of exogenous apoE3 to apoC determined the level of 
lipoprotein uptake and degradation.  ApoC1 inhibited lipoprotein uptake and degradation 
by fibroblasts in a dose-dependent manner, with complete inhibition at a mix of 1:1:2.5 
apoC1:apoE3:VLDL protein (wt/wt).  ApoC2, apoCIII1, and apoC-III2 inhibited 
lipoprotein uptake and degradation with similar potency at all doses, but with 2- to 3-fold 
lower potency than apoC1.  ApoA1 and A2 did not inhibit uptake, at any dose.   
When VLDL sub-fractions were enriched in apoE3, a greater amount of apoC was 
required to inhibit uptake (Sehayek & Eisenberg, 1991).  For complete inhibition, 
apoC:apoE3 (wt/wt) was > 1:1 for individual or mixed apoCs—and this ratio increased 
with the amount of apoE3 on lipoproteins.  When VLDL sub-fractions were pre-
incubated with mixed apoCs, addition of apoE3 restored lipoprotein uptake in a dose-
dependent manner.  Together, results from clearance assays (Sehayek & Eisenberg, 1991; 
Weisgraber et al., 1990), indicate that the apoCs interfere with the uptake of VLDL when 
the ratio of apoC:apoE is much higher than in normolipidemic subjects.   
The mechanism by which the apoCs inhibit uptake is still largely unknown.  
Increased concentrations of apoCs on VLDL have been proposed to inhibit uptake 
through negative interactions with apoE or a high affinity for lipid (Sehayek & Eisenberg, 
1991).  In incubation conditions at which the mixed apoCs completely inhibited uptake of 
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VLDL sub-fractions, VLDL-apoE content was only 30-35% lower than in incubations 
with only apoE.  The amount of endogenous apoE associated with the particle should 
have facilitated particle uptake, such that inhibition may be through direct apoC-apoE 
interactions at the lipid surface.  These interactions would mask the receptor-binding 
domain.  Alternatively, apoC1 and apoC3—through higher lipid affinity or mass action—
could displace the receptor-binding domain of apoE from the lipid surface to inhibit 
particle uptake.  In summary, as the apoC1 and apoC3 concentration increases at the 
VLDL surface, apoE-binding is inhibited or its receptor-binding domain is masked, 
thereby preventing uptake of the lipoprotein particles by VLDLR or LRP.   
2.5.3  ApoC1 and ApoC3 Inhibit Lipoprotein Lipase 
The inhibition of VLDL and CM catabolism by apoC1 and apoC3 is not confined 
to uptake.  An apoE-independent mechanism must be responsible for the 55-fold increase 
in plasma TG from apoE
-/-
 to HuC1tg/apoE
-/-
 mice (Berbée et al., 2005).  Likewise, 
inhibition of lipoprotein uptake cannot explain the 3- to 4-fold increase in the serum TG 
levels of LRP
-/-
LDLR
-/-
 and LRP
-/-
LDLR
-/-
VLDLR
-/-
 mice, after administration of an 
apoC1 adenovirus (van der Hoogt et al., 2006).  More recent studies indicate that apoC1 
retards VLDL catabolism via inhibition of LPL (Berbée et al., 2005; van der Hoogt et al., 
2006).  [
3
H]TO-labeled protein-free VLDL-like emulsion particles had a 2-fold higher 
plasma half-life in HuC1tg mice versus WT mice, but postheparin LPL levels were 1.8-
fold higher in HuC1tg mice (Berbée et al., 2005).  In vitro LPL activity assays with these 
emulsion particles showed that pre-incubation of the particles with apoC1 inhibits LPL 
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activity in a dose-dependent manner.  These results indicate that, despite heightened 
levels of LPL in vivo, greater apoC1 serum levels inhibit enzyme activity. 
In vitro experiments indicate that apoC3 also inhibits LPL (Larsson et al., 2013; 
Wang et al., 1985).  In one study (Wang et al., 1985), the serum levels of apolipoproteins 
in 14 hypertriglyceridemic subjects (TG > 200 mg/dL) with normal postheparin plasma 
levels of LPL were analyzed.  The mean concentrations of apoB (53% higher), C2 
(120%), C3 (150%), and E (98%) were higher in hyper- versus normo-lipidemic subjects, 
but only apoC3 (r=0.78, P<0.005) and apoE (r=0.653, P<0.05) levels correlated 
significantly with fasting plasma TG levels.  In vitro assays with lipoproteins isolated 
from plasma of these subjects showed that LPL activity was negatively correlated with 
plasma apoC3 levels.  These data suggest that an increased level of apoC3 in plasma, and 
on TG-rich lipoproteins, is associated with severely impaired lipolysis. 
No interaction has been shown between apoC1 or apoC3 and LPL.  A recent 
study (Larsson et al., 2013) tested the hypothesis that apoC1 and apoC3 inhibit LPL via 
competition for binding to the lipoprotein surface in vitro.  At a fixed concentration of 
LPL, apoC1 and apoC3 each inhibited LPL binding to, and activity on, emulsion particles 
(10% (w/v) TG isolated from 10% or 20% Intralipid) in a dose-dependent manner.  These 
apoCs inhibited LPL binding and activity with similar potency at identical molar 
concentrations.  The amount of apoC required to inhibit LPL increased with increasing 
TG or pre-incubation of particles (rat lymph chylomicrons or emulsions pre-incubated 
with apoC2) with apoC2.  These results indicate that apoC1 and apoC3 compete with 
LPL for space on the lipid surface, while apoC2 promotes LPL insertion into the surface. 
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To determine the region of apoC3 responsible for lipid-binding and LPL 
inhibition, the ability of apoC3 mutants to inhibit LPL activity was measured (Larsson et 
al., 2013).  From the structures of apoC3, sites that are critical for lipid binding were 
identified as conserved residues in the apolar faces of the three helices (Figure 2.12).  
Nine apoC3 variants (Figure 2.12) were expressed, via site-directed mutagenesis, and the 
ability of each to compete with LPL for binding to emulsions was determined.  Most 
variants had lower lipid affinity (monitored by far-UV CD as differences from WT 
apoC3 in DMPC-bound helical content) that correlated with greater LPL activity.  LPL 
was most active in the presence of C-terminal mutants, which indicates that this region of 
apoC3 is essential for mediateing lipid binding and competing with LPL for substrate.  
These conclusions are supported by LPL activity assays with monolayer vesicles 
of non-hydrolyzable phospholipid ether, pyrene-labeled TG (1.7 mol %), and cholesterol 
(4.8 mol %), LPL, and full-length (apoC-III0, apoC-III1) or partial apoC3 (Lambert, 
Catapano, Smith, Sparrow, & Gotto, 1996).  These assays showed that, at a mix of 0.2 
µM protein, 0.12 µM LPL, and 72 µM lipid, full-length apoC3 inhibited LPL activity by 
85% and residues 41-79 inhibited LPL by 62%, but residues 1-40 did not inhibit LPL.   
In summary, apoC1 and apoC3—when overexpressed in humans—inhibit the 
LPL-mediated catabolism of TG-rich lipoproteins.  ApoC1 and apoC3 may compete with 
LPL for binding to the surface of these lipoproteins in circulation.  In addition, VLDL is 
enriched in apoC3 during assembly in hypertriglyceridemic states, such that the higher 
content of apoC3 on secreted VLDL may prevent LPL from accessing the surface.  This 
is discussed in the next section.   
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Figure 2.12.  Sequence alignment of apoC3 from 7 mammalian species.   
Sequence alignment revealed 9 highly conserved residues that are each present in the 
hydrophobic face of one of the helices of apoC3 (Figure 2.9).  These residues, in the 
human sequence, are L27, V35, W42, F47, L50, W54, F61, F64, and W65.  If the lipid-
binding of apoC3 is critical to the protein’s ability to inhibit lipoprotein lipase (LPL), 
mutations in these residues could disrupt the lipid-binding of apoC3 and reduce its ability 
to inhibit LPL.  To test this hypothesis, the human apoC3 variants L27A/V35A, 
W42A/F47A, F47A/L50A, W42A/F47A/L50A, L27A/V35A/W42A/F47A/L50A, 
W42A/F47A/F64A/W65A, and W54A/F61A/F64A/W65A were expressed in, and 
purified from, E. Coli (Larsson et al., 2013).  The ability of these mutants to bind to lipid 
and inhibit LPL was tested in in vitro assays described in (Larsson et al., 2013).  Figure 
adopted from (Larsson et al., 2013). 
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2.5.4 ApoC3 Promotes VLDL Assembly in Hypertriglyceridemic States 
The expression of apoC3, and its distribution among serum lipoproteins, 
significantly changes in the hypertriglyceridemic state.  In a typical individual, the 
plasma concentration of apoC3 is 80-100 μg/mL (Jong, Hofker, et al., 1999; Wang et al., 
1985).  At these concentrations, most (60%) of plasma apoC3 is localized to HDL 
(Fredenrich et al., 1997) and apoC3 has no inhibitory effect on LPL (Wang et al., 1981, 
1985).  In the hypertriglyceridemic state, apoC3 expression is up-regulated by glucose 
and loss of insulin sensitivity, as described in Figure 2.13 and in Appendix A.  Plasma 
apoC3 increases to > 300 μg/mL (Cohn, Patterson, Uffelman, Davignon, & Steiner, 2004; 
Huff, Breckenridge, Strong, & Wolfe, 1988).  ApoC3 on TG-rich lipoproteins increases 
from 20% of total protein to ≤60% in hypertriglyceridemic patients (Fredenrich et al., 
1997).  Mounting evidence suggests that this enrichment is due to the role of apoC3 in 
VLDL assembly, as reviewed in (Sundaram & Yao, 2012; Yao & Wang, 2012).   
VLDL particles produced de novo are heterogenous in lipid content and size.  The 
majority of VLDL secreted from hepatocytes are VLDL2 (Sf = 20-100), which contain a 
single molecule of apoB-100 (Yao & Wang, 2012).  Under pathological conditions, such 
as insulin resistance or hypertriglyceridemia, large VLDL1 (Sf > 100) are secreted, which 
contain a larger quantity of TG, a single molecule of apoB-100, and other exchangeable 
apolipoproteins.  Assembly of TG-rich VLDL1 is achieved through the accumulation of 
TG on pre-VLDL particles:  after MTP-mediated lipidation of apoB-100, nascent VLDLs 
are trafficked through ER/Golgi compartments to recruit TG.  In these compartments,  
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Figure 2.13.  Model for regulation of apoC3 expression and VLDL1 production.   
(a) Under normal hepatic signaling conditions, insulin signaling suppresses hepatic 
VLDL production.  Insulin promotes intracellular degradation of newly synthesized 
apoB, through the PI3K pathway, and suppresses expression of microsomal MTP and 
apoC3, through the FoxO1 pathway.  Insulin suppresses lipolysis, which decreases fatty 
acid influx into the liver.  VLDL that is produced is VLDL2. 
(b) Under dysregulated hepatic insulin signaling, insulin cannot render apoB susceptible 
to intracellular degradation, nor can it negatively regulate MTP and apoC3 suppression.  
De novo lipogenesis (DNL) is not suppressed and fatty acid influx increases.  In addition, 
glucose stimulates apoC3 expression, through hepatic nuclear factor (HNF)-4.  Increased 
levels of MTP, TG, and apoC3 create an optimal condition for VLDL1 assembly and 
secretion.  Figure adopted from (Yao & Wang, 2012). 
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VLDL1 maturation includes a ~1.4-fold increase in diameter (Gusarova et al., 2007).  The 
assembly of VLDL2 and VLDL1 is shown in Figure 2.14.    
Extensive transfection experiments with rat hepatoma McA-RH7777 cells showed 
that apoC3 promotes the assembly and secretion of VLDL1 (Qin et al., 2011; Sundaram, 
Zhong, Bou Khalil, Links, et al., 2010; Sundaram, Zhong, Bou Khalil, Zhou, et al., 2010).  
48 h post-transfection, McA-RH7777 cells were labeled with [
3
H]-glycerol for 2 h in the 
presence and absence of exogenous lipid (oleate).  Quantification of radioactivity in the 
media and cell showed that secretion of [
3
H]-TG was enhanced by apoC3 in a dose-
dependent manner, but only in lipid-rich culture.  ApoC3-stimulated TG secretion was 
associated with increased secretion of apoB-100 as VLDL1, as shown by [
35
S]-labeling of 
apoB-100.  In addition, apoC3 expression promoted VLDL1 secretion when MTP was 
inhibited after formation of lipid-poor apoB-100 particles.  These results indicate that, in 
the presence of excess lipid, apoC3 is involved in the second step of VLDL1 assembly: 
apoC3 facilitates TG mobilization to pre-VLDL particles from ER/Golgi compartments.   
ApoC3 promotes VLDL1 assembly through its N- and C-terminal helices.  The 
class-A C-teminal helix mediates lipid binding and formation of lumenal lipid droplets 
(LLD) in post-ER compartments, while the class-G N-terminal helix mediates the fusion 
of these LLDs with nascent VLDL. This was shown using two naturally-occurring apoC3 
point mutants, A23T and K58E, which disrupt the N- and C-terminal helices, 
respectively, and impaired the secretion of VLDL1 in McA-RH7777 cells (Qin et al., 
2011; Sundaram, Zhong, Bou Khalil, Zhou, et al., 2010).   
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Figure 2.14.  Model for hepatic assembly of VLDL1 and VLDL2.   
Initial lipid recruitment occurs during translation and translocation of apoB-100 across 
the membrane of the ER.  MTP is critical for the initial lipidation and proper folding of 
apoB-100.  ApoE may facilitate lipid utilization at the early stage of apoB lipidation; the 
rate of in vivo VLDL-TG production was reduced by 50 to 60% in apoE-null versus WT 
mice (Kuipers et al., 1997).  The rate of transit and particle expansion is modulated by 
apoA4, which prolongs the residence time of apoB within the ER-Golgi secretory 
compartments (Gallagher, Weinberg, & Shelness, 2004). These modifications produce 
VLDL2 (Sf = 20-100), which is secreted.  In insulin-resistant and hyper-triglyceridmeic 
states, apoC3 expression is elevated.  ApoC3 enhances the expression of MTP, which 
may stimulate production of TG-rich lumenal lipid droplets (LLD).  In post-ER structures 
(such as Golgi), apoC3-containing LLDs fuse with the VLDL precursor to produce 
VLDL1 (Sf > 100), which is secreted.  Figure adopted from (Sundaram & Yao, 2012).   
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The lumenal distribution of newly synthesized lipid was assessed in cells 
expressing A23T, K58E, and WT apoC3 (Qin et al., 2011; Sundaram, Zhong, Bou Khalil, 
Zhou, et al., 2010).  After 60-min labeling, [
3
H]-TG levels increased in the microsomal 
membrane and lumen by 180% and 60%, respectively, in cells expressing A23T apoC3, 
as compared to cells expressing WT apoC3 (Sundaram, Zhong, Bou Khalil, Zhou, et al., 
2010).  The increase in TG in these compartments was associated with accumulation of 
A23T apoC3, as monitored with [
35
S] A23T. The TG- and apoC3-rich particles that 
accumulated in microsomal lumens were classified as lumenal lipid droplets (LLDs),  and 
were similar in size and density to LDL/IDL.  This indicates that these LLDs were unable 
to fuse with nascent VLDL.   
In contrast the accumulation of [
3
H]-TG in LLDs decreased by 50% in cells 
expressing K58E apoC3, as compared to C3wt cells (Qin et al., 2011).  This loss-of-
function was attributed to weak lipid-binding in apoC3.  Compared to other apoC3 
variants, K58E apoC3 showed drastically reduced lipid binding in Fat Western lipid 
protein overlay assays (Qin et al., 2011).  WT, A23T, and K58R robustly bound to PE or 
PC phospholipids; and to a lesser extent cholesterol and diacylglycerol.  In contrast, 
K58E apoC3 weakly bound phospholipids and did not bind the other lipids.  These results 
indicate that the C-terminal helix of apoC3 mediates formation of LLDs.  
In summary, A23T apoC3 had the same lipid binding affinity as apoC3, but could 
not promote fusion between LLDs and nascent VLDL, which resulted in the 
accumulation of LLDs.  These results indicate that the class-G-amphipathic, N-terminal 
helix in apoC3 facilitates fusion with nascent VLDL.  In contrast, K58E apoC3 displayed 
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significantly reduced lipid binding and could not promote formation of LLDs.  These 
results indicate that the class-A-amphipathic, C-terminal helix mediates lipid binding and 
promotes formation of LLDs.  All of the experiments discussed above used rat hepatoma 
cells, which maintain a unique ability to produce VLDL1 under a high lipid load (Wang, 
Tran, & Yao, 1999).  A direct role of apoC3 in VLDL1 assembly has yet to be shown in 
human hepatocytes or in vivo.    
Altogether, the results discussed in this chapter provide evicence that apoC2 is the 
requisite cofactor for LPL, promotes the catabolism of TG-rich lipoproteins, and is anti-
atherogenic (Section 2.4).  The regulation of LPL by apoC2 depends on surface pressure.  
Several studies (Jackson et al., 1986; Olivecrona & Beisiegel, 1997; Vainio, Virtanen, 
Kinnunen, Gotto, et al., 1983; Vainio, Virtanen, Kinnunen, Voyta, et al., 1983) show that 
LPL requires apoC2 for rapid substrate turnover at low pressures, but requires apoC2 
interaction as pressure increases during the lipolysis of TG (Figure 2.10). 
In contrast, apoC1 and apoC3 are pro-atherogenic at high serum levels (Section 
2.3.3).  These proteins inhibit the LPL-mediated catabolism, and apoE-mediated uptake, 
of TG-rich lipoproteins (Sections 2.5.2, 2.5.3), largely through protein-lipid interactions 
(Larsson et al., 2013).  No direct interaction has been shown between these apoCs and 
apoE, apoB-100, LPL, or lipoprotein receptors.  Rather, interaction of apoC1 and apoC3 
with the surface of VLDL impairs apoE-mediated uptake (Sehayek & Eisenberg, 1991) 
and prevents TG exposure to LPL (Larsson et al., 2013).  In the hyper-triglyceridemic 
state, apoC3 promotes VLDL assembly and secretion (Section 2.5.4).  The C-terminal 
helix is required for formation of LLDs, which are required for synthesis of VLDL1.    
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2.6 Specific Research Aims 
The goals of this dissertation are to use oil-drop tensiometry to characterize the 
biophysical properties (i.e. adsorption, conformational rearrangement, desorption) of wild 
type and mutant variants of the apolipoprotein Cs at lipid/water interfaces in order to: 1) 
establish the characteristics of the amphipathic α-helices in the apoCs most critical for 
high-affinity lipid binding, 2) correlate atherogenic lipid phenotypes of hetero- and 
homozygous carriers of single polymorphisms in their apolipoprotein C2 or C3 gene with 
altered affinity of the proteins for lipid,  and 3) determine the dependence of the 
regulation of lipoprotein metabolism by the apoCs on surface pressure.   
 Surface pressure correlates with the density of amphipathic molecules at lipid 
surfaces and is defined in the next chapter.  It is not currently possible to directly measure 
the surface pressures of lipoprotein particles, but the composition of VLDL and CM 
(Table 1.1) suggest the pressure of these particles is low.  TG comprises upwards of 90%, 
by weight, of VLDL (Cohen & Fisher, 2013), such that amphipathic molecules are not as 
tightly packed at the surface (Ibdah, Lund-Katz, & Phillips, 1989).   As LPL and HL 
hydrolyze TG to produce VLDL subfractions and CM remnants, the lipoprotein core 
shrinks, the products (fatty acids and monacylglycerols) transiently accumulate at the 
surface, and the surface density of phospholipid and protein increases.   These changes 
result in higher pressures at the LDL surface (Ibdah et al., 1989; Slotte & Grönberg, 
1990).   
 In this thesis, we used Oil-Drop Tensiometry, a physical technique designed to 
monitor the surface pressure of lipid drops (discussed in Chapter 3), to characterize the 
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interaction of the apoCs with TG/water and phospholipid/TG/water interfaces.  These 
interfaces mimic the core and surface, respectively, of VLDL and CM.  For WT, point 
mutants, and fragments of the apoCs, we characterized the ability of these proteins to 
bind to, exhibit conformational rearrangements on, and dissociate from these surfaces.   
Our results provide novel implications for the regulation of lipoprotein 
metabolism by the apoCs in vivo. Differences in lipid affinity among peptide variants 
revealed the structural region, and conformations, of each apoC responsible for mediating 
binding to and retention at lipid surfaces.  Differences in lipid affinity among the WT 
apoCs revealed conformational changes in lipid-bound apoC2 that are likely required for 
LPL activation.  These results have further implications as to the physiologocial 
conditions at which apoC1 and apoC3 can inhibit LPL.  Differences in the affinity of 
apoC3 for different lipid types yielded novel insight into the ability of apoC3 to facilitate 
VLDL assembly in hypertriglyceridemic conditions.    
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3. Chapter 3:  Apolipoprotein Surface Chemistry Methods and Materials 
 This chapter will describe the Oil-Drop Tensiometer, an instrument put to novel 
use in Dr. Small’s laboratory to study the interactions of apolipoproteins with lipoprotein-
like lipid droplets (Small et al., 2009).  Section 3.1 defines surface tension and pressure, 
which are the physical parameters measured by the tensiometer.  Section 3.2 describes 
tensiometer design, lipid materials, and the main protocols used in our experiments.  
Section 3.3 describes the synthetic and recombinant proteins used in these studies. 
3.1 Defining Surface Tension 
Surface tension (γ) is the energy (or work) required to create one new cm2 of 
surface (Small et al., 2009): 
[1] 
where G is Gibbs free energy, A is surface area, T is temperature, P is pressure, and n is 
the molar composition of the surface. Surface tension is caused by the cohesion of like 
molecules near an interface.  Within the bulk phase of a liquid, molecules are surrounded 
on all sides by other molecules. Molecules are equally attracted to each other, such that 
cohesive forces are equal on all sides and there is zero net force acting on each molecule.  
At liquid/vapor and liquid/liquid interfaces, molecules have fewer binding partners and 
there is a net force acting on these molecules towards the interior of the liquid.  This 
inward force generates γ (i.e., force/distance or mN/m) to pull the surface together 
(Noogle, 1996).  The liquid surface contracts until repulsive, collisional forces from other 
molecules halt contraction.  At this point, surface area and γ are at a minimum.  If a liquid 
is not acted on by exterior forces the liquid sample forms a sphere. 
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Oil-in-water emulsions of hydrophobic lipids, such as TG and cholesterol ester, 
exhibit a high surface tension at the oil/water interface, since apolar lipids do not 
favorably interact with the aqueous phase.  Tension decreases as phospholipids and 
apolipoproteins are adsorbed to oil/water interface, since amphipathic molecules 
favorably interact with both the hydrophobic and hydrophilic phases. For example, in the 
presence of phospholipids, γ of lipid droplets can be reduced to 0.1-1 mN/m from γ 
upwards of 30 mN/m at an exposed interface, which significantly increases the stability 
of lipid droplets (Thiam, Farese, & Walther, 2013). 
Surface pressure (П) is the difference between γ of a pure oil/water interface and 
an interface with amphipathic molecules adsorbed:  
П = γclean– γ   [2] 
П is related to the energy of a surface with adsorbed molecules and increases as γ 
decreases (Gaines, 1966).  П correlates with the density of amphipathic molecules at the 
oil/water interface: as the surface area per amphipathic molecule decreases, П increases.  
In this dissertation, the units of γ and П are reported in mN/m (a force per distance that 
represents the inward force acting on molecules at the interface), which is equivalent to 
mJ/m
2
 (energy per unit area that represents the surface energy) and dynes/cm.   
 П is the two-dimensional equivalent of three-dimensional pressure (P).  Using this 
analogy, the principal of the universal gas law (PV=nRT) can be applied to two-
dimensional systems by substituting П for P and A for V, yielding ПA=nRT (Crisp, 
1949a, 1949b).  This equation indicates that, at constant temperature (T) and composition 
(n), П is inversely related to A for an ideal system.  The pressure versus area relationship 
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of a monolayer at constant temperature, called an isotherm, is an important indicator of 
monolayer properties (Mohwald, 1995).  For multi-component monolayers, the П/A 
isotherm yields compressibility (dП/dA), highlights phase transitions, and reveals 
molecular interactions that cause non-idealities during a compression (Mohwald, 1995). 
 The Pockels-Langmuir surface balance was designed to measure П exerted by 
insoluble lipid, protein, or mixed lipid/protein monolayers at an air/water interface 
(Gaines, 1966; Small, 1986).  The Langmuir trough is filled with a fluid (generally water) 
and is made of an inert hydrophobic material (generally teflon).  In practice, one adds a 
known number of amphipathic molecules, dissolved in solvent, to the system and these 
molecules spread evenly at the air/water interface.  The surface area is then gradually 
decreased by a movable barrier, which increases molecular density.  From the estimated 
area per molecule, a П/A isotherm is obtained throughout compression.  The П exerted 
by the surface film is measured by a barrier connected to a transducer, which reports П at 
any area, or by a Wilhelmy plate, which measures γ from the downward force exerted on 
the plate and converts γ measurements to П by equation 2  where γclean = γA/W, i.e. γ of the 
air/water interface (Small, 1986). 
 The Langmuir trough has several limitations, including non-uniform deformations 
and leakage of surface-active material past the moving barrier on interfacial compression 
or oscillation (Benjamins, Cagna, & Lucassen-Reynders, 1996); and substrate and 
physiological limitations in studies with lipolytic enzymes (Labourdenne et al., 1994, 
1997).  The advent of high-speed charged coupled device (CCD) cameras and modern 
computing have made oil-drop tensiometry a practical, and more physiologically 
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relevant, alternative to the Langmuir trough for fluid-fluid interfacial studies (Benjamins 
et al., 1996; Labourdenne et al., 1994, 1997; Small et al., 2009).  In this work, we used an 
oil-drop tensiometer from Teclis Instruments to measure γ of the triolein/water (TO/W) 
interface, as the adsorption or desorption of phospholipid (POPC) and apolipoproteins 
(the apoCs) altered interfacial properties. 
 
3.2 Oil-Drop Tensiometry 
3.2.1 Drop Shape Analysis 
 The oil-drop tensiometer utilizes a syringe that is filled with air or oil to create oil 
or air drops submerged in an aqueous phase (Figure 3.1).  The density (ρ) of the drop 
relative to the aqueous phase (ρ = 0.997 g/mL) determines if the drop is a hanging drop or 
inverted pendant drop.  This will dictate which syringe needle is used: a straight needle is 
used to analyze hanging drops of ρ > 0.997 g/mL (Andreas, Hauser, & Tucker, 1937; 
Stauffer, 1965; Svitova, Wetherbee, & Radke, 2003), while a curved, J-needle (Figure 
3.1) is used to analyze inverted pendant drops of ρ < 0.997 g/mL (Benjamins et al., 1996; 
Labourdenne et al., 1994, 1997).   
The shape of the drop depends on the forces of γ and gravity (Stauffer, 1965).  To 
minimize area, γ pulls the surface inward to promote the formation of a sphere.  The force 
of gravity (or buoyancy) elongates the drop and increase its surface area.  The difference 
in density between the drop and the aqueous phase is directly proportional to the apparent 
weight of the drop and determines the effects of gravity or buoyancy.   
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Figure 3.1. Schematic of the Oil-Drop Tensiometer.   
A) Basic features.  A J-needle is attached to a 0.25- mL Hamilton syringe.  The syringe is 
filled with oil (2a).  The needle tip is submerged in a thermostated cuvette filled with 
phosphate buffer (3a).  The syringe is attached to a motor, which changes drop volume by 
≥ 0.02 µL at various rates.  A light source (1a) illuminates bubbles at the needle tip.  The 
profile is recorded by a CCD camera (4a).  This outputs to a computer (5a) that reports γ.  
B)  Enlarged image of the thermostated cuvette.  Surface-active molecules are injected 
into the aqueous phase.  Buffer is stirred by a magnetic stir bar (shown by an arrow) (3b).  
Molecules are removed from the aqueous phase by a washout: new buffer flows into the 
cuvette (1b) through a long needle (4b), while buffer is removed by a needle at the top 
(5b).  These needles are attached to tubes in a pump system. C) The drop profile is 
analyzed by the Laplace equation adapted for a bubble.  The x- and z-axes are Cartesian 
coordinates; θ is the angle between the tangent to the bubble and the x-axis; b is the 
radius of curvature at the apex of the drop.  Figure adapted from (Mitsche et al., 2010). 
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 In 1806, Pierre-Simon Laplace established the relationship between γ, hydrostatic 
pressure (Δp), and the curvature of a fluid’s meniscus in a capillary tube: 
          [3]
 
where r1 and r2 are the radii of curvature in two perpendicular directions.  This equation 
states that the pressure caused by the curvature of the surface (or the hydrostatic pressure) 
is equal to the product of the boundary tension and the mean curvature (Andreas et al., 
1937).  For a drop, Δp at any point along the surface is: 
                     [4] 
 
where z is the vertical coordinate measured away from an origin placed at a point where 
the axis through the center meets the surface of the drop, b is the radius of curvature of 
the drop at the origin, g is the acceleration due to gravity, and ρ is the difference in 
densities between the drop and aqueous (or air) phases (Andreas et al., 1937). Equations 
3 and 4 were combined and adapted by Francis Bashforth and John Couch Adams in 
1883 (Andreas et al., 1937) to describe the curvature of a pendant drop: 
               [5] 
 
where x and z are the Cartesian coordinates at any point on the drop profile, b is the 
raidus of curvature at the drop apex, θ is the angle of the tangent to the drop profile at 
(x,z), and c is the capillarity constant, equal to: 
[6]   
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Figure 3.1 illustrates the parameters in equations [5] and [6].  The Bashforth and Adams 
equation [5] was first applied in 1938 to calculate the γ of hanging drops of water:sodium 
stearate or water:sodium oleate solutions created in air or mineral oil (Andreas et al., 
1937).  Shape factors based on empirical data were used to estimate the diameter of these 
drops and the differential equation was numerically solved to calculate γ.   
 Until the late 1980s, oil-drop tensiometry constituted taking pictures of drops to 
determine γ using the adapted Laplace equation [5] with accurately measured values for 
drop diameter (Labourdenne et al., 1997).  Major drawbacks of this technique included 
lengthy film processing and profile analysis; and a lack of real-time measurements.  The 
advent of high-speed CCD cameras and modern computing overcame these hurdles.  
New tensiometer designs were developed in which the oil-drop profile was automatically 
digitized and analyzed by image processing (Benjamins et al., 1996; S. Labourdenne et 
al., 1994, 1997).  These machines used iterative methods to align a drop profile with the 
Bashforth and Adams equation [5] to calculate γ, while also analyzing the shape to 
calculate the volume and surface areas of pendant drops.  The tensiometer in our lab is 
capable of simultaneous and nearly instantaneous calculation of drop γ, volume, and area. 
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3.2.2 Instrumentation 
In this thesis, the interfacial properties of apolipoproteins were determined at 
triolein/water (TO/W) and 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC)/TO/W 
interfaces.  The apparatus, creation of these interfaces, and several protocols we have 
used are described in (Labourdenne et al., 1994, 1997; Mitsche et al., 2010; Mitsche & 
Small, 2011; Small et al., 2009).  The tensiometer (shown in Figure 3.1) has five essential 
elements: 1) a light source, 2) a syringe filled with the drop phase (here, triolein), 3) a 
cuvette filled with phosphate buffer which is the aqueous, or bulk, phase, 4) a camera to 
record the drop profile, and 5) a computer to calculate drop γ, volume and surface area. 
As shown in Figure 3.1, a syringe with a J-needle is filled with triolein and the tip 
of the J-needle is submerged in a 10 cm x 20 cm x 45 cm glass cuvette filled with buffer.  
A J-needle is used because the density of triolein is approximately 0.91 g/mL. The 
syringe is attached to a motor, which controls drop volume by pulling down or up on the 
syringe and has a minimum sensitivity of 0.02 µL.  The motor receives input from the 
computer.  The cuvette is kept at a constant temperature by a circulating water bath.  A 
TO drop (typically, with an initial volume of 16 µL) is formed at the tip of the J-needle.  
A bright light source illuminates the drop profile, which is recorded by a CCD camera.  
The computer uses this profile to calculate γ, volume, and surface area of the drop.  The 
aqueous phase is mixed by a small magnetic stir bar at the bottom of the cuvette.   
A pump system facilitates buffer exchange (i.e., washouts):  fresh buffer (from a 
reservoir) flows through a needle into the bottom of the cuvette while buffer is removed 
through a second needle at the top of the air/water interface and is discarded in an outlet 
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reservoir (Figure 3.1B).  The volume is kept constant throughout a washout.  The rate and 
duration of washouts are controlled by inputs from the computer.  For washouts of 
sufficient volume (31-37 times the volume of the cuvette), 99.9% of the original buffer is 
replaced, as predicted by mass balance and shown by monitoring the concentration of a 
dye during washout. 
All of the tensiometry experiments in this thesis were conducted at 25.0±0.2 °C.  
In all of these experiments, the cuvette was filled with 6 or 7 mL of 2 or 5 mM sodium 
phosphate buffer (PB).  This volume was chosen due to the dimensions of the cuvette (20 
mm x 10 mm x 45 mm) and washout system (Figure 3.1B).  2 L phosphate buffer stock 
solutions of various pH from 5.9 to 7.4 were made.  In most of the experiments in this 
thesis, images for γ measurement were captured by the CCD camera at 5 frames per 
second (FPS), but in longer experiments images were captured at 2 FPS. 
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3.2.3 Lipid Materials 
In this dissertation, we characterized the behavior of WT and mutant forms of the 
human apoCs at TO/W and POPC/TO/W interfaces.  The apoCs used are described in 
section 3.4.  TO is a common TG and POPC is the most abundant phospholipid on 
lipoproteins.  The TO/W interface provides a model for protein interactions with a TG-
containing core, a component of all TG-rich lipoproteins.  POPC/TO/W interfaces better 
mimic the surface of nascent, cholesterol-poor lipoproteins (Miller & Small, 1983).   
Synthetic triolein (>99.7% pure) was purchased from NU-CHEK PREP, Inc. 
(Elysian, MN).  For short-term storage, the vial containing the triolein (TO) was purged 
with nitrogen for >5 min and stored at -20°C.  POPC, dissolved in chloroform at 25.0 
mg/mL, was purchased from Avanti Polar Lipids (Alabaster, Alabama) and stored at -
20°C.  Purity of both lipids was checked using high-dose thin layer chromatography.  For 
injection into the aqueous phase, POPC was constituted as small unilamellar vesicles 
(SUVs).  POPC was dried under nitrogen for >5 min and vacuum desiccated overnight, to 
purge POPC of chloroform.  POPC was re-suspended in PB to a concentration ranging 
from 1.0 to 5.0 mg/mL.  POPC in buffer was sonicated with a Branson tip sonicator for 
60 min on ice, with a pulsed duty cycle of 30%, as described in (Jiang, Gantz, Bullitt, & 
McKnight, 2006; Mitsche et al., 2010).  The SUVs had a diameter of ~ 22 nm, as verified 
by negative-stain EM.  Vesicles were stable for 2-3 days.  In drop-tensiometer 
experiments in which POPC SUVs were adsorbed to a TO drop interface, 0.5 to 1.25 mg 
of POPC SUVs were injected into the aqueous phase. 
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3.2.4 Experimental Protocols: Monitoring Protein Adsorption to Lipid/Water Interfaces 
 All tensiometry experiments in this thesis began by forming a 16-µL TO drop.  
This drop has an area of 30 mm
2
 (d ≈ 3.0 mm), which is 3 to 4 orders of magnitude larger 
than VLDL or CM.  The interfacial tension (γ) of the drop was monitored for ~15 min to 
confirm that the drop was clean and that the instrument was calibrated correctly.  The γ of 
a clean TO/W interface (γTO) was 32.01.0 mN/m.  If γTO deviated from this value by >1 
mN/m, the cuvette and syringe were replaced.  For studies at a TO/W interface, the drop 
was formed in the presence of protein, at various concentrations in the bulk phase.  γ was 
monitored continuously as protein adsorbed and γ fell to equilibrium (γeq) (Figure 3.2).  
 For studies at POPC/TO/W interface, the TO drop was formed in the presence of 
POPC.  POPC was typically added to the aqueous phase at concentrations ranging from 
0.083 to 0.18 mg/mL.  After POPC adsorption to the drop decreased γ, a washout of 250 
mL total, POPC-free buffer was performed to remove POPC from the aqueous phase 
(Figure 3.3A).  Apolipoprotein was added to the bulk phase and γ was monitored as 
protein adsorbed to the POPC/TO/W interface and γ fell to γeq (Figure 3.3A).   
 The ability of an apolipoprotein to bind to and modify the surface pressure of 
TO/W and POPC/TO/W interfaces reflect the ability of that protein to remodel 
lipoproteins.  This property was measured as adsorption-induced changes in surface 
pressure (ΔП) and exclusion pressure (ПEX).  Π was the difference between γTO and γ of 
the interface with bound POPC and/or protein (Π = γTO – γ), as in equation 2.  The initial 
pressures (Пi) of POPC/TO/W interfaces were calculated as the difference between γTO 
and γ after POPC adsorption and washout, while Пi = 0 mN/m for a TO/W interface.    
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Figure 3.2.  Apolipoprotein adsorption to a TO/W interface increases surface 
pressure by ΔП.   
(A) Sample γ versus time curves for apolipoprotein (here, apoC2) adsorption to a TO/W 
interface.  16 µL TO drops were formed in 7.0 mL of sodium phosphate buffer, pH 7.4.  
ApoC2 was present in the bulk phase at 1.25 μg/mL (black line) or 2.5 μg/mL (red line).  
Γ was monitored continuously as it fell from γ of a TO/W interface (γTO = 32.0±1.0 
mN/m) to equilibrium (γeq).  (Inset) γ values were converted to surface pressures (Π) to 
determine the change in Π (ΔΠ) due to protein adsorption.   
(B) Equilibrium pressures (Πeq) increase to a saturation value (ΠSAT) as the bulk phase 
concentration of apolipoprotein increases.  ApoC2 was added to a bulk phase of pH 7.4 at 
increasing concentrations.  The γeq values of the apoC2/TO/W interfaces were recorded.  
These values were converted to Πeq (black circles) and plotted against the bulk phase 
concentration of apoC2.  Y-error bars come from the average of data from n ≥ 3 
experiments.  At a TO/W interface, Пeq = ΔП.  A black, dashed line marks ΠSAT (22.1 
mN/m for apoC2). 
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Figure 3.3.  Calculation of exclusion pressure (ПEX) at POPC/TO/W interfaces.   
(A) Example of the protocol to monitor protein adsorption to, and desorption from, a 
POPC/TO/W interface.  POPC adsorbed to a 16 μL TO drop and lowered γ.  Beginning at 
33.4 min, POPC was removed from the bulk phase by a 250 mL washout at a rate of 8.35 
mL/min (marked by the first black bar).  After the washout, γ was 22.5 mN/m (Πi = 9.5 
mN/m).  TO drop volume could be increased or decreased to decrease or increase Πi, 
respectively.  Apolipoprotein (here, apoC2) was added to the bulk phase at 1.25 μg/mL 
and γ was monitored as it fell to γeq.  Starting at 101.7 min, apoC2 was removed from the 
bulk phase by a 150 mL washout at a rate of 8.35 mL/min (marked by the second black 
bar).  The drop volume underwent two sets of gradual expansions and compressions at a 
rate of 1.2 μL/min.   
(B) Determination of exclusion pressure (ПEX). To determine ПEX of an apolipoprotein 
(here, apoC2), a series of experiments similar to (A) were conducted over a range of Πi.  
ΔΠ was plotted against Πi.  The data was fit with a linear regression and the x-intercept is 
ΠEX, i.e. the pressure at which protein cannot insert into POPC/TO/W interfaces such that 
ΔП = 0 mN/m on addition of peptide to the bulk phase.  ΠEX  = 32.2 mN/m for apoC2. 
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 After protein adsorption, the equilibrium pressure (Пeq) of TO/W and POPC/TO/ 
W interfaces was calculated as Πeq = γTO – γeq.  ΔП of lipid/water interfaces from protein 
adsorption was ΔП = Пeq – Пi.  The saturation pressure (ПSAT) for an apolipoprotein at a 
TO/W interface was determined by measuring ΔП (which is equivalent to Пeq at this 
interface) over a range of bulk phase protein concentrations (Figure 3.2B). 
 Exclusion pressure (ΠEX) for an apolipoprotein is the П above which the protein 
cannot bind and insert into POPC/TO/W interfaces (Mitsche & Small, 2011; Weinberg et 
al., 2002).  At the ΠEX of a POPC/TO/W interface, addition of protein to the bulk phase 
leads to no adsorption-induced change in П (ΔΠ = 0 mN/m).  To determine ΠEX, ΔΠ was 
plotted against Пi for several POPC/TO/W interfaces. 
 After POPC adsorption and a 250 mL washout, the initial pressure of POPC/ 
TO/W interfaces was typically Πi = 5.5-9.5 mN/m (Figure 3.3A), depending on POPC 
bulk phase concentration and adsorption time.  To achieve a larger range, drop volume 
was increased or decreased at a rate of 1.2 μL/min to decrease or increase Π to new Πi 
values.  Protein was added to the bulk phase at 1.25 μg/mL and adsorption increased Π 
by ΔΠ.  ΔΠ values were plotted against Πi (Figure 3.2B).  Linear regression was applied 
to the data and the x-intercept was ΠEX.  The surface concentration of POPC (ΓPOPC) was 
calculated from i, as described in (Mitsche et al., 2010; Mitsche & Small, 2011). 
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3.2.5 Experimental Procols:  Monitoring Protein Desorption from Lipid/Water Interfaces 
 The ability of an apolipoprotein to remain bound to TO/W and POPC/TO/W 
interfaces as П increases reflects the ability of that protein to be retained on lipoproteins 
during metabolism.  Expansion and compression of these lipid/water interfaces revealed 
the pressures at which lipid-bound protein were ejected, called retention pressures.  The 
retention pressure for a protein at a given interface is the maximum pressure a protein can 
withstand before it is ejected from the interface.  Our lab has called retention pressure 
ПMAX (Wang, Atkinson, & Small, 2005; Wang et al., 2007) and ПENV (Mitsche & Small, 
2013; Mitsche et al., 2014), depending on which of two protocols are used. 
 The first protocol involved a series of interfacial compressions and expansions.  
After apolipoprotein adsorption lowered γ of either type of interface to γeq, the interface 
was rapidly compressed via decreases in TO drop volume (Figure 3.4).  This decrease in 
volume correlated with a decrease in surface area and resulted in an abrupt decrease in γ 
to a minimum value, γo.  These values are marked by asterisks for several pre-washout 
compressions at both types of interface in Figure 3.4.  The drop was held at a reduced 
volume for >5 min.  As protein desorbed from the interface, γ rose toward new γeq 
(observed as desorption curves) and the change in γ from γo was recorded as Δγ.  After 
>5 min, drop volume was rapidly increased back to 16 μL.  This correlated with an 
increase in area and resulted in an increase in γ to values above the initial γeq.  As protein 
re-adsorbed from solution, γ fell to the initial γeq (observed as re-adsorption curves).   
 Most experiments of this nature included a series of repeated compressions at 
expansions at progressively larger volumes (Figure 3.4).  Compressions typically varied  
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Figure 3.4.  Adsorption and desorption curves for an apoC at lipid/water interfaces.  
(A)  G15A apoC1 point mutant adsorption and desorption at a TO/W interface.  Protein 
was added to the bulk phase at 0.83 µg/mL.  After protein adsorption to a TO drop 
lowered γ to γeq = 13.5 mN/m, the drop was compressed and re-expanded in increments 
of ±1.6 μL, ±3.6 μL, ±4.6 μL, ±5.3 μL, and ±7.2 μL.  At 127.8 min, lipid-free protein was 
removed by a 200 mL washout at a rate of 10.7 mL/min (shown by the black bar).  The 
drop was compressed and re-expanded in increments of ±3.6 μL, ±5.3 μL, and ±7.2 μL.   
(B) G15A apoC1 adsorption and desorption at a POPC/TO/W interface.  POPC 
adsorption lowered γ to 25.2 mN/m (Пi = 6.8 mN/m).  At 2.9 min, POPC was removed 
from the bulk phase by a 250 mL washout at a rate of 10.9 mL/min (shown by the first 
bar).  The protein was added to the bulk phase at 0.83 µg/mL and adsorption lowered γ to 
γeq = 9.5 mN/m.  The TO drop was compressed and re-expanded in increments of ±1.6 
μL, ±3.6 μL (x2), ±4.4 μL, and ±5.2 μL.  At 371.3 min, lipid-free protein was removed 
by a 150 mL washout at a rate of 10.3 mL/min (shown by the second bar).  The drop was 
compressed and re-expanded in increments of ±1.6 μL, ±5.2 μL, ±7.2 μL, and ±9.2 μL.   
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in size from 5 to 60% of the initial volume.  A similar series of compressions and 
expansions was conducted after a washout to verify the exchangeability of protein at the 
interface (Figure 3.4).  If the protein was exchangeable, compressions ejected protein 
from the interface.  However, γ remained at an elevated level after re-expansion if protein 
was not present in the bulk phase (i.e., removed by washout) to bind to the surface. 
 Retention pressure (ПMAX) was calculated from pre-washout compressions as 
described in Figure 3.5. For each compression, the change in tension (Δγ) due to peptide 
desorption was plotted against Πo, where Пo = γTO – γo.  A linear regression was applied 
to the data.  ΠMAX is the x-intercept where Δγ = 0 mN/m, such that peptide only desorbs 
on compressions to Π ≥ ΠMAX (Wang et al., 2005; Wang, Hua, Atkinson, & Small, 2007). 
The other protocol to characterize protein desorption from TO/W or POPC/TO/W 
interfaces involved the gradual expansion and compression of these interfaces to generate 
П/A isotherms.  For a TO/W interface (Figure 3.6) or POPC/TO/W interfaces of various 
Πi (such as that in Figure 3.3A), protein was added to the bulk phase and protein 
adsorption lowered γ to γeq.  Buffer was exchanged with 150 mL of protein-free buffer, 
removing protein from the bulk phase.  Drop volume was increased at a rate of 1.2 
μL/min to V > 30 μL (Figures 3.3A, 3.6).  Volume was held constant for >2 min and 
decreased at 1.2 μL/min to various terminal volumes (Figure 3.6A).  Pressure-area (Π/A) 
isotherms were calculated from the γ and area (A) profiles of compressions and 
expansions (Figure 3.6B), as described previously (Mitsche & Small, 2011).  
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Figure 3.5.  Calculation of apoC retention pressure ПMAX from rapid compressions.  
(A) Important features of an interfacial compression.  A pre-washout compression (±7.2 
μL) from Figure 3.4A is pictured.  γo is the minimum interfacial tension immediately after 
a rapid interfacial compression.  γo is determined for individual compressions and 
converted to  Пo by the equation shown in the bottom right corner of this panel.  As 
protein desorbs to relax the interface, γ increases by Δγ to a new equilibrium γeq.   
(B)  Determination of ПMAX.  For a protein at a given interface, Δγ is plotted against Пo 
for interfacial compressions varying in size.  The data is fit with a linear regression and 
the x-intercept is ПMAX, defined as the maximum pressure bound protein can withstand.  
Increases in П to П> ПMAX results in protein desorption and non-zero Δγ.  Pictured here 
are sets of data for G15A apoC1 (added to the bulk phase at 0.83 or 1.66 µg/mL) at a 
TO/W interface (black circles) and a POPC/TO/W interface of Пi = 6.8±0.5 mN/m or 
ΓPOPC = 0.94±0.03 µmol/m
2
; 36.6±1.4% (red circles).   
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Figure 3.6.  П/A isotherms generated from gradual expansions and compressions.  
(A) Example of gradual, post-washout expansions and compressions of protein/TO/W 
interfaces.  Here, apoC2 was added to the bulk phase at 1.25 μg/mL.  After apoC2 
adsorption to a TO drop lowered γ to γeq = 14.4 mN/m, lipid-free apoC2 was removed by 
a 150 mL washout (black bar, 6.26 mL/min starting at 60.8 min).  Drop volume 
underwent a series of five gradual expansions and compressions at a rate of 1.2 μL/min.  
Each expansion ended at V = 31.8 μL.  Each compression ended at a smaller volume than 
the previous compression(s)—ending at V = 20.4, 15.6, 10.9, 8.0, and 4.7 μL.   
(B)  The compression /A isotherms of exchangeable apolipoproteins at TO/W 
interfaces show two significant inflection points.  From the experiment in (A), γ values 
during the gradual expansions and compressions were converted to Π values and plotted 
against area.  The expansions and compressions are labeled by color and number, starting 
at 1 for the first post-washout expansion and compression.  The direction of compression 
is shown by an arrow.  A spline fit of smoothing parameter 0.5 was applied to the Π/A 
isotherms.  The first derivative of the fits gave slope values (dΠ/dA), which were plotted 
against area for compression isotherms.    
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 To determine retention pressure (or envelope pressure; ΠENV) from this protocol, 
the compression Π/A isotherms were analyzed (Figure 3.6B).  A spline interpolation (i.e., 
a piecewise polynomial) with a smoothing parameter (p) between 0.25 and 0.6 was 
applied to each isotherm.  p = 0 is a least-squares straight-line fit to the data, while p = 1 
is a cubic spline interpolant.  The slope of the isotherm was determined by calculating the 
first derivative of the spline fit, using Matlab’s Curve Fitting toolbox.  The slope (dΠ/dA) 
of compression isotherms for the apoCs, in contrast to data for non-exchangeable 
peptides our laboratory has studied (Mitsche et al., 2014), followed this trend:   
1. The absolute value of the slope (│dΠ/dA│) increased as the change in pressure 
(dΠ) became more negative for incremental decreases in area (dA).  This occurred 
because vacant binding sites present on the expanded interface were eliminated 
and the density of surface-active amphipathic molecules increased. 
2. The slope reached a minimum.  This minimum is a turning point (AP, ΠP).  As 
area decreased below AP (and П increased above ПP), bound protein molecules at 
least partially desorbed to relax the surface and reduce dΠ for each dA.  As a 
result,│dΠ/dA│ decreased as dΠ became less negative for each dA at A<AP.   
3. The slope reached a plateau (near dΠ/dA = 0 at a TO/W interface).  This point is 
the envelope point (AENV, ΠENV).  As area decreased below AENV (and П increased 
above ПENV), П changes were minimal, which indicates that bound protein 
molecules completely desorbed in order to relax the surface. 
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To further test the stress-response of apolipoproteins at TO/W and POPC/TO/W 
interfaces, these interfaces were oscillated at various frequencies and amplitudes (Figure 
3.7) as previously described (Meyers et al., 2012; Mitsche et al., 2009; Wang et al., 
2005).  The viscoelasticity of the protein/lipid/water interfaces were determined from 
these data.  Viscoelasticity represents a surface’s ability to reduce deviations of γ from γeq 
by allowing for relaxation (Lucassen & Van Den Tempel, 1972).  Typical relaxation 
processes consist of periodic adsorption and desorption of surface-active material (here, 
protein) from expanded and compressed surface elements.  This causes a reduction in the 
amount of protein bound to the interface from the compression to expansion phase of 
oscillations.  As a result, marked hystereses are observed between these two phases in 
pressure-area (Π/A) isotherms generated from interfacial oscillations (Figure 3.7B).   
After γ approached γeq with apolipoprotein bound to either interface, the volume 
of the TO drop (16 µL prior to oscillation) was oscillated sinusoidally at various periods, 
typically ranging from 8 to 128 s, and various amplitudes, typically ranging from ± 1 μL 
(~6% of the initial volume) to ± 8 μL (50%).  Figure 3.7A models a set of 12, 5-cycle 
oscilations for the apoC3/TO/W interface.  As the volume was oscillated, interfacial A 
and γ were recorded continuously.  From these measurements, pressure-area (Π/A) 
isotherms were derived and plotted (Figure 3.7B).  These γ and A measurements yielded 
the interfacial elasticity modulus (ε) for each sinusoidal oscillation, defined as: 
      [7] 
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Figure 3.7.  Oscillation of a protein/lipid/water interface to generate П/A isotherms.   
(A) Oscillation protocol.  After apolipoprotein adsorbed to either type of interface, the 
interface was sinusoidally oscillated at various amplitudes and frequencies.  Here, apoC3 
was added to the bulk phase at 2.46 µg/mL and adsorbed to a TO/W interface.  The TO 
drop was then oscillated at amplitudes of ±0.7, ±1.7, ±2.8, and ±3.7 µL.  At each 
amplitude, the drop was oscillated for 5 cycles at frequencies of  0.125, 0.031, and 0.0078 
Hz.  Each 5-cycle oscillation was conducted 2.1 min after the previous oscillation.   
(B) П/A isotherms for interfacial oscillations.  For the 5-cycle oscillations pictured in 
(A), γ values were converted to П and plotted against area.  The oscillation П/A 
isotherms pictured are: ±1.7 µL at 0.125 Hz (black), ±1.7 µL at 0.031 Hz (red), ±1.7 µL 
at 0.0078 Hz (green), ±3.7 µL at 0.125 Hz (blue), ±3.7 µL at 0.031 Hz (cyan), and ±3.7 
µL at 0.0078 Hz (magenta). Compression and expansion phases of oscillation are labeled 
in magenta for the oscillations of amplitude 3.7 µL and frequency 0.0078 Hz. The 
hysteresis between these two phases is highlighted in navy.  The hysteresis between the 
compression and expansion phases increase with higher amplitude (i.e., greater П 
changes) and/or lower frequency (i.e., more time for relaxation processes to occur).   
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The elasticity modulus (ɛ) represents the responsivity of tension to changes in 
area.  At a surface more prone to relaxation processes, there will be a lag between area 
changes and tension responses, marked by smaller ε (a more visco-elastic surface).  In 
contrast, if proteins do not easily desorb from an interface the tension response will more 
rapidly coincide with changes in area, marked by higher ε (a more elastic suface).   
Via Fourier Transform analysis, the real (ε′  =│ε│cos(φ)) and imaginary (ε″ 
=│ε│sin(φ)) components of ε were determined, allowing for derivation of the phase 
angle (φ) between compression and expansion (Lucassen & Van Den Tempel, 1972).  
Lower φ values indicate an elastic surface, while higher φ values indicate a higher degree 
of surface visco-elasticity.  If a surface is more visco-elastic (i.e., protein more easily 
desorbs with different kinetics on interfacial compression), oscillation П/A isotherms will 
feature a larger hysteresis between the expansion and compression phases (Figure 3.7B). 
The oscillation protocol described above was largely used in work that will only 
be briefly discussed in this thesis.  This work can be found in (Meyers et al., 2012).  
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3.3 Materials 
WT and mutant forms of full-size human apoC1 with single Pro or Ala 
substitutions at selected sites (M38P, R23P, G15P, and G15A) were produced via solid-
state synthesis and purified by HPLC to 95-98% purity at 21
st
 Century Biochemicals, as 
described in (Gursky, 2001; Gursky, 1999).  Peptide termini were not chemically 
blocked.  Protein purity was confirmed by SDS polyacrylamide (PAGE) gel 
electrophoresis and mass spectrometry.  Stock solutions were prepared by dissolving 
lyophilized peptides in 2 mM PB, pH 7.4 to a concentration of 1.0 mg/mL, as measured 
by the absorbance at 280 nm and the Lowry protein assay. The helical content of these 
peptides was determined by far-UV CD (Benjwal et al., 2007; Mehta et al., 2003).  
ApoC1 variants were monomeric at all bulk phase concentrations used in the experiments 
in this dissertation. At ≤ 10 µg/mL, WT human apoC1 is fully monomeric in solution 
(Gursky, 2001; Gursky, 1999) and proline substitutions reduce the level of self-
association (Ladokhin & White, 2004). 
 Full-size human apoC2 and apoC3 variants were expressed in, and purified from, 
E. Coli by members of Dr. Gunilla Olivecrona’s laboratory, including Drs. Mikael 
Larsson and Solveig Nilsson.  Human apoC2 cDNA was cloned into pET29a(+) followed 
by an N-terminal 6xHis-tag (Shen et al., 2002).  Full-length cDNA for human apoC3 
including the sequence for a 6xHis-tag (preceded by a Leu and Glu) at the C-terminal end 
was cloned into pET23b(+) (Gangabadage et al., 2008; Larsson et al., 2013; Liu et al., 
2000).  All the apoC3 variants were generated by using the QuikChange Site-Directed 
Mutagenesis Kit (Stratagene), as described in (Liu et al., 2000).  50 ng of plasmid DNA 
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pET23b/apoC3 was used as a template in a 50 µL reaction.  Two synthetic 
oligonucleotide primers, which contained the desired mutation and were complementary 
to the opposite strands of the vector, were extended using Pfu Turbo DNA polymerase 
(Liu et al., 2000). 
 The pET-histag-hapoC2 and pET-histag-hapoC3 plasmids were transformed into 
E. Coli BL21-condonPlus (DE3)-RIL competent cells (Stratagene) as described in 
(Andersson et al., 1997; Larsson et al., 2013; Liu et al., 2000; Shen et al., 2002, 2010).  
Transformed bacteria were grown at 37 °C until OD600 = 0.6 (Larsson et al., 2013) or 1.0 
(Shen et al., 2002). Expression of apoC3 variants was induced with 1 mM isopropyl β-D-
1-thiogalactopyranoside (IPTG) for 1 h at 37 ºC (Larsson et al., 2013).  In comparison, 
temperature was lowered to 16 °C and, after 1.5 h, expression of apoC2 was induced 
overnight with 0.5 mM IPTG (Andersson et al., 1997; Shen et al., 2002).   
 In extraction and purification of apoC2, bacteria were harvested by centrifugation 
(3800 rpm, Beckman J-6B, for 20 min at 4 °C) and cell lysis was performed using 
denaturing conditions followed by purification by nickel (Ni
2+
)-nitrilotriacetic acid 
(NTA)-agarose as described in (Andersson et al., 1997; Shen et al., 2002).  Briefly, use of 
buffers containing 8 M urea, 0.1 M NaH2PO4, and 0.01 M Tris-Cl produced a 
discontinuous gradient from pH 8.0 to 4.5 (Andersson et al., 1997).  Fractions with high 
protein content (eluting at different pH) were pooled and dialyzed against 6M urea, 10 
mM Tris pH 8.0 followed by DEAE-ion exchange chromatography using a continuous 
Tris gradient ranging from 10 mM to 115 mM in 6 M urea, pH 8.2.  Fractions with the 
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expected molecular weight of the His-tag-hapoC2 as judged by SDS-PAGE were pooled 
and  dialyzed for 24 h at 4°C against ammonium bicarbonate and lyophilized.   
 In extraction and purification of apoC3 variants, bacteria cultures were 
centrifuged (3200 rpm, Beckman J-6B, for 20 min at 4 °C) and dissolved in 50 mM 
sodium phosphate buffer pH 7.4, containing 0.3 M NaCl, 6 M guanidine CL, and 5 mM 
imadizole, prior to freeze/thaw cell lysis at -80ºC as described in (Larsson et al., 2013).   
Human apoC3 was purified on a HisTrap
TM
 FF crude column (GE Healthcare) using a 
gradient of increasing concentrations of imidazole (10 to 500 mM) in 50 mM sodium 
phosphate buffer pH 7.4, containing 0.3 M NaCl and 6 M Urea.  Fractions that eluted late 
in the gradient and contained high protein content were dialyzed against 1 mM NH4HCO3 
and subsequently frozen at -20ºC prior to lyophilization (Larsson et al., 2013).  
 Lyophilized protein (apoC2 or apoC3) was divided into small aliquots and frozen 
at -20°C.   Protein was over 95% in purity, as assessed by SDS-PAGE gels, MALDI-TOF 
mass spectrometry, and high performance liquid chromatography (HPLC).   
Prior to interfacial studies, aliquots of apoC2 or apoC3 were thawed and 
solubilized with hexafluoro-2-proponal (HFIP) at a concentration of 2.5 mg/mLFor 
interfacial studies, protein was injected into 7 mL of PB at 0.2 to 12.5 μg/mL.  At these 
concentrations, HFIP was 0.005 to 0.5% of the total volume.  HFIP only influenced γ 
when present at HFIP:PB volume ratios ≥0.32; at these concentrations HFIP decreased γ 
by 1-2 mN/m.  Protein concentration was determined by the Lowry assay and absorption 
at 280 nm.  Far-UV CD showed that lipid-free apoC2 (at a concentration of 0.02 mg/mL 
in PB with 0.8% HFIP) had 21±5% α-helix, which is consistent with previous results 
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(Hatters et al., 2000; Shen et al., 2002).  Lipid-free apoC3 (at concentrations of 0.01 and 
0.1 mg/mL in PB with ≤1% HFIP) had 25±5% α-helix, which is consistent with previous 
results (Liu et al., 2000; Morrisett et al., 1973).  
Peptide fragments representing the 25 residues of the N-terminal helix 
(FLTQVKESLSSYWESAKTAAQNLYE) and 30 residues of the C-terminal region 
(RDLYSKSTAAMSTYTGIFTDQVLSVLKGEE) of apoC2 were obtained commercially 
by solid state synthesis and purified by HPLC to >91% purity at 21
st
 Century 
Biochemicals.  The amino- temini of the peptides were acetylated or dansylated.  The 
carboxy-termini of the 25-residue fragments were amidated.  The identity and purity of 
the proteins were confirmed by collision-induced dissociation (CID) tandem mass 
spectrometry.  Prior to interfacial studies, aliquots of peptide were solubilized at a 
concentration of 2 mg/mL in solutions of HFIP and 5 mM sodium phosphate buffer at a 
1:4 vol:vol ratio.      
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4. Chapter 4:  Changes in the Helical Parameters of ApoC1 Alter its Lipid Affinity  
4.1 Effects of Phospholipid on Apolipoprotein Affinity for Lipid/Water Interfaces 
Several studies, from our lab (Meyers et al., 2013, 2012; Mitsche & Small, 2013; 
Mitsche et al., 2009; Small et al., 2009; Wang et al., 2010, 2007, 2005, 2003; Wang & 
Small, 2004) and others (Ledford et al., 2009, 2006; Weinberg et al., 2010, 2003, 2000), 
have used oil-drop tensiometry to characterize the interactions of apolipoproteins with 
triacylglycerol/water (TG/W) interfaces, which provide a model for protein interactions 
with the core of TG-rich lipoproteins.  This interface can be refined to better mimic the 
lipoprotein surface by adding amphipathic lipids, such as phospholipid, cholesterol, and 
fatty acid.  To date, only a few studies (Ledford et al., 2009, 2006; Meyers et al., 2013, 
2012; Mitsche & Small, 2011; Mitsche et al., 2014; Wang et al., 2014) characterized 
apolipoproteins, or their consensus peptides, at phospholipid/TG/water interfaces.   
 In some of these studies (Ledford et al., 2009, 2006), 10 µL triolein (TO) drops 
were formed and Intralipid emulsions (which contained, by weight, 85% egg-yolk 
lecithins, 5% glycerol, and 10% tributyrylglycerol) were added to the bulk phase.  By 
comparison, in studies from our lab (Mitsche et al., 2010; Mitsche & Small, 2011), 16 µL 
TO drops were formed and small unilamellar vesicles (SUVs) of phospholipid (POPC or 
egg yolk PC) were added to the bulk phase.  In all cases, phospholipid adsorption to the 
TO drop was observed as a decrease in γ (Labourdenne et al., 1994) and, after γ 
stabilized, excess phospholipid was removed from the bulk phase by a washout (Ledford 
et al., 2009, 2006; Mitsche et al., 2010; Mitsche & Small, 2011).  A major limitation of 
studies at these phospholipid/TG/water interfaces is that the surface concentration (Γ) of 
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phospholipid cannot be measured directly since an unknown amount of phospholipid 
adsorbed to the surface. 
 To overcome this limitation, recent studies from our laboratory compared П/A 
isotherms of POPC/TO/W or egg yolk PC/TO/W interfaces generated by a Langmuir 
trough (at which the surface concentration of PC lipid is known) and the drop tensiometer 
(Mitsche et al., 2010; Mitsche & Small, 2011).  Compression isotherms for phospholipid/ 
TG/W interfaces generated from the two techniques were overlaid, by converting surface 
area measurements on the drop tensiometer (with an equation based on the collapse 
pressure of PC lipid) to area per molecule (APM) values and adjusting П from drop 
tensiometer measurements by accounting for the envelope pressure of TO (Mitsche et al., 
2010). The region of overlap occurred above the envelope pressure at which TO was 
ejected from PC/TO/W monolayers, but below the collapse pressure at which PC 
molecules were ejected.  APM values were converted to surface concentrations (Γ) and 
plotted against (unadjusted) П.  These data were fit by a quadratic equation in the range 
of 2 < П < 28 mN/m, which allows for determination of the Γ of phospholipid at any П. 
 With the development of these protocols, our lab characterized differences in the 
affinity of apolipoproteins and consensus peptides for POPC/TO/W versus TO/W 
interfaces (Meyers et al., 2012; Mitsche & Small, 2011; Mitsche et al., 2014; Wang et al., 
2014).  The presence of phospholipid increased the affinity of exchangeable, helical 
apolipoproteins (apoC1, apoA1) and peptides (truncated apoA1, N- and C-terminal 
fragments of apoA1) for the lipid surface (Meyers et al., 2012; Mitsche & Small, 2011; 
Wang et al., 2014).  While the magnitude of adsorption-induced pressure changes was 
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decreased, the rate of adsorption often increased for exchangeable proteins at POPC/TO/ 
W versus TO/W interfaces.  POPC also promoted the retention of exchangeable 
apolipoproteins and peptides at lipid surfaces.   The retention pressure (ПMAX, ПENV) 
increased as ΓPOPC increased (i.e., as the ratio of POPC:protein increased) (Meyers et al., 
2012; Mitsche & Small, 2011; Wang et al., 2014).  In addition, apoC1/ POPC/TO/W 
interfaces were significantly more elastic than the apoC1/TO/W interface, as marked by 
smaller hysteresis, larger elastic moduli (ε), and smaller phase angles (φ) in П/A 
oscillation isotherms (Meyers et al., 2012).  Characterizing differences in the affinity of 
apoC1 for TO/W versus POPC/TO/W interfaces was foundational to the research in this 
dissertation.  These results were published (Meyers et al., 2012) and, while some are 
incorporated into this chapter, they will not be discussed at length in this dissertation. 
 In contrast, PC lipid did not increase the affinity of non-exchangeable, β-strand-
rich peptides (Mitsche et al., 2014).  Our lab characterized the biophysical properties of 
regions of the βα1 domain of apoB at TO/W and POPC/TO/W interfaces (Mitsche et al., 
2014).  Helical fragments of this domain had exclusion pressures (ПEX) at POPC/TO/W 
interfaces that were significantly higher than their equilibrium pressures (Пeq) at a TO/W 
interface, but ПEX (POPC/TO/W) ≈ Пeq (TO/W) for β-strand-rich fragments (from the C-
sheet) of this domain.  This result indicates that an increasing ratio of PC:TG impedes the 
binding of the C-sheet of the βα1 domain of apoB to lipid surfaces until the PC:TG ratio 
is sufficiently high to prevent binding altogether.  
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4.2 ApoC1 as a Model for Probing the Role of Secondary Structure in Lipid Binding 
 The secondary structure motif of apolipoproteins responsible for reversible 
binding to lipid/water interfaces is the amphipathic α-helix (Segrest et al., 1992).  In 
solution, amphipathic α-helices are largely unfolded, as in apoA2 or the apoCs 
(Gangabadage et al., 2008; Rozek et al., 1999; Seelig, 2004; Shen et al., 2002), or folded 
in helix bundles, as in the N-terminal domains of apoE and apoA1 (Mei & Atkinson, 
2011; Wilson, Wardell, Weisgraber, Mahley, & Agard, 1991).  Studies of WT and mutant 
forms of apoE and apoLp3 showed that liposome clearance rates decreased with greater 
protein size, thermodynamic stability, or self-association, i.e., with increased tertiary or 
quaternary structure (Lu, Morrow, & Weisgraber, 2000; Pownall et al., 1981; Segall et 
al., 2002; Weers et al., 2003).  These results suggest that helix-helix interactions reduce 
lipid binding ability as helix bundles must open to expose apolar helical faces to lipid.   
The dependency of lipid surface binding on the tertiary structure and self-
association of apolipoproteins makes it difficult to probe the role of pre-existing 
secondary structure in lipid binding.  One approach to analyze the effects of helical 
propensity on protein-lipid interactions is to use large proteins, such as apoA1, from 
which individual helices were deleted (Saito, Dhanasekaran, et al., 2004).  However, 
these deletions change helical content, protein size, hydrophobicity, and tertiary structure, 
which all contribute to lipid binding.   
Alternatively, apolipoprotein-like peptides of 18-22 residues have been used to 
determine the effects of helical properties on the phospholipid affinity of α-helices 
(Anantharamaiah, Venkatachalapathi, Brouillette, & Segrest, 1985; Anantharamaiah, 
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Jones, et al., 1985; Brouillette et al., 2001; Chung, Anatharamaiah, Brouillette, Nishida, 
& Segrest, 1985; Datta et al., 2001; Epand et al., 1987; Krebs, Phillips, & Sparks, 1983; 
Ponsin et al., 1986; Sparrow & Gotto, 1980). Peptide-lipid interactions were analyzed by 
many techniques, including intrinsic tryptophan fluorescence, differential scanning 
calorimetry, equilibrium dialysis against HDL, and surface chemistry techniques.  These 
studies showed that changing the charge distribution, hydrophobicity, or helical 
propensity of α-helices altered phospholipid affinity.  One limitation of these approaches 
is that short peptides are unfolded in solution, such that the role of preexisting helical 
structure on phospholipid affinity cannot be determined.  In addition, these studies often 
used phospholipids that are found in low abundance on lipoproteins or failed to 
incorporate other lipoprotein constituents (TG, cholesterol, fatty acids, etc.). 
In the work presented in this chapter, we utilized a midway approach to determine 
the dependence of lipid affinity on secondary structure by using the smallest human 
apolipoprotein (apoC1) and its point mutants.  ApoC1 contains two class-A amphipathic 
α-helices spanning the residues 7-29 and 34-47 (Figure 4.1).  ApoC1 monomers in 
solution lack substantial tertiary structure, but adopt a fluctuating helix-turn-helix 
conformation with an average helical content of 31% (Gursky, 2001; Rozek et al., 1999).  
On binding to phospholipid, the average helical content of apoC1 increases to 65-75%.  
The helical content of apoC1 in solution and on phospholipid can be altered by single Ala 
or Pro substitutions in either α-helix (Table 4.1) (Benjwal et al., 2007; Gursky, 2001; 
Mehta et al., 2003). We speculate that this is unique to small apolipoproteins, as point 
mutations in single helices of larger proteins would likely have little effect on   
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Figure 4.1.  ApoC1 sequence (bottom) and structure (top).  
(Bottom) The sequence of mature apoC1 reveals a greater number of basic than acidic 
amino acids, which gives apoC1 a net positive charge at neutral pH.  The lone tryptophan 
(W41) is shown in bold in the sequence. 
(Top) Helical wheel representations of the two predicted class-A amphipathic α-helices in 
apoC1 (Benjwal et al., 2007; Gursky, 2001; Rozek et al., 1999). Helices are modeled as 
canonical α-helices with 3.6 residues per turn.  Apolar residues are colored in yellow, 
polar in gray, basic in blue, acidic in red, and glycine in pink. The hydrophobic face of 
each helix is indicated by dotted lines. In previous studies (Benjwal et al., 2007; Gursky, 
2001; Gursky, 1999; Mehta et al., 2003), the secondary structure of apoC1 was altered by 
single Ala or Pro substitutions.  The residues mutated to Ala or Pro in apoC1 variants 
used in this study have a thick, black outline.  This figure is the same as Figure 2.5.  
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Helical Content and Hydrophobic Moment of ApoC1 Variants 
Protein 
α-Helical Content at 24 °C [%] 
<µH> [kcal/mol residue] In Solution On DMPC 
G15A 48 75 0.30 
WT 31 65 0.30 
G15P 20 44 0.29 
R23P <5 40 0.29 
M38P <5 45 0.28 
Table 4.1:  Helical content and hydrophobic moment (<µH>) of apoC1 variants.  
Five apoC1 variants, WT and single-residue mutants were chosen for this study.  The 3 
residues that were mutated are located within the N- and C-terminal helices, as shown in 
Figure 4.1. α-helical content for each apoC1 variant was determined by far-UV circular 
dichroism (CD) from the measured value of [Θ222] with 5% accuracy as described 
previously (Gursky, 2001).  Results are from (Benjwal et al., 2007; Gursky, 2001; Mehta 
et al., 2003), but we verified the lipid-free helical content of each apoC1 form at identical 
protein concentrations (0.02 μg/mL).  Hydrophobic moments (µH) for the two predicted 
α-helices within each peptide were calculated as described previously (Bolanos-Garcia et 
al., 2008; Eisenberg et al., 1982) using the hydrophobicity scale of (Janin, 1979).  The 
average of these hydrophobic moments represent the mean hydrophobic moment (<µH>) 
for each peptide.  
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protein helical content.  For these reasons, apoC1 is well-suited for probing the role of 
secondary structure in lipid binding.   
Studies using apoC1 point mutants and discoidal lipoproteins reconstituted from 
1, 2-dimyristoylphosphatidylcholein (DMPC) showed that, as the α-helical content of 
apoC1 increased, the rate and temperature range of DMPC clearance increased (Benjwal 
et al., 2007; Gursky, 2001; Gursky, Ranjana, & Gantz, 2002; Gursky, 1999; Mehta et al., 
2003).  These studies were limited by a non-physiologic interface (DMPC is found only 
in trace amounts on lipoproteins (Mitsche et al., 2010; Mitsche & Small, 2011)) and the 
inability to monitor real-time surface modifications induced by protein binding.  
Here, we used WT and four point mutants of human apoC1 that differ in α-helical 
content in solution and on DMPC (Table 4.1).  Of the three residues mutated (Gly15, 
Arg23, and Met38), only Glycine 15 is conserved (Andersson et al., 1991).  Point 
mutants with similar hydrophobic moments as WT apoC1 (Table 4.1) were selected in 
order to correlate differences in lipid binding with the helical propensity of the peptides.  
G15P and M38P were selected to probe the contribution of the C- and N-terminal α-
helices, respectively, to lipid-binding.  R23P was selected to mimic the acidic charge of 
the unexpressed human apoC1 pseudogene (Andersson et al., 1991) and to probe the role 
of net charge in lipid-binding.   
To determine the role of helical content in apoC1 binding to interfaces that mimic 
lipoprotein surfaces, we used oil-drop tensiometry (section 3.2) to characterize the 
behavior of the apoC1 variants at TO/W and POPC/TO/W interfaces.  Most of this work 
was originally published in the Journal of Lipid Research (Meyers et al., 2013). 
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4.3  Results:  The Lipid Affinity of ApoC1 Increases with Greater Helical Propensity 
4.3.1 Modification of Lipid/Water Interfaces Depends on the α-Helical Content of ApoC1 
We aimed to compare ΔΠ of apoC1 variants at apolar TO/W and at more polar 
POPC/TO/W interfaces to assess how secondary structure in apoC1 affects binding to 
and modification of these interfaces.  As peptides with greater α-helical propensity form 
more extensive interactions with lipid (Gazzara et al., 1997), we hypothesized that greater 
α-helical propensity favors peptide adsorption to lipid surfaces, leading to larger ΔΠ.   
Figure 4.2 shows a set of interfacial tension-time curves for the apoC1 variants at 
TO/W (A) and POPC/TO/W (B) interfaces.  In each case, peptide was added to the 
aqueous phase at 1.7 µg/mL.  The initial γ of the POPC/TO/W interfaces was 25.0±0.5 
mN/m, such that ГPOPC = 0.95±0.03 µmol/m
2
 and POPC covers 37.0± 1.0% of the total 
surface area.  Adsorption of apoC1 variants to both interfaces showed a sigmoidal time 
course.  Adsorption curves were approximated by sigmoidal functions: 
    [8] 
where t1/2 is the midpoint corresponding to 50% decrease in γ due to peptide adsorption 
and w is the transition width.  The midpoint t1/2 is shown for G15A adsorption to a TO/W 
interface in Figure 4.2A.  This sigmoidal behavior indicates that, once peptide adsorbs to 
lipid interfaces at adequate concentrations to significantly change γ, γ decreases more 
rapidly as more peptide adsorbs (positive cooperativity) until binding reaches an 
equilibrium.  At γeq, lipid-bound peptide is in equilibrium with bulk peptide.   
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Figure 4.2.  Remodeling of lipid surfaces by apoC1 variants.   
(A)  Interfacial tension (γ) versus time curves for apoC1 variants at TO/W interfaces.  16 
μL TO drops were formed in 6.0 mL of sodium phosphate buffer pH 7.4 and peptides 
were added to the aqueous phase at 1.7 µg/mL.  Changes in γ as peptides adsorbed to TO 
drops were approximated by sigmoidal functions, where transition width t1/2 is the 
midpoint corresponding to 50% decrease in γ due to peptide adsorption as depicted for 
the G15A point mutant.   
(B) Interfacial tension versus time curves for apoC1 variants at POPC/TO/W interfaces. 
POPC was adsorbed to 16 μL TO drops and γ reached ~25 mN/m after buffer exchange. 
Peptides were added to the aqueous phase at 1.7 µg/mL at arbitrary time 0 sec.  The 
changes in γ as peptides adsorbed to POPC/TO drops were approximated by sigmoidal 
functions. 
  
 121 
 
Adsorption-Induced Π Modifications of TO/W and POPC/TO/W Interfaces by ApoC1 Variants 
Interface 
Peptide Conc. 
[µg/mL] 
ΔΠ [mN/m] 
G15A WT G15P R23P M38P 
TO/W 0.83 18.1±0.4 17.2±0.2 15.7±0.6 16.0±0.2 16.3±0.2 
1.7 18.8±0.2 17.9±0.5 16.5±0.3 16.5±0.3 16.3±0.2 
3.3 18.6±0.2 18.0±0.3 17.0±0.3 16.9±0.3 16.5±0.3 
<ΔΠ> 18.5±0.5 17.7±0.4 16.4±0.5 16.5±0.4 16.4±0.3 
POPC/TO/W 0.83 15.9±0.3 14.8±0.2 13.4±0.4 11.7±0.1 13.2±0.1 
1.7 16.4±0.3 15.4±0.5 13.8±0.5 12.3±0.2 13.4±0.4 
3.3 - 15.4±0.2 13.6±0.3 12.9±0.3 13.8±0.4 
<ΔΠ> 16.2±0.4 15.2±0.5 13.6±0.5 12.3±0.4 13.5±0.4 
Table 4.2.  Adsorption-induced surface pressure (П) modifications (ΔП) of TO/W 
and POPC/TO/W interfaces by apoC1 variants. 
ΔΠ is the change in surface pressure due to adsorption of the given peptide. Each ΔΠ is 
the average value from n = 3-4 experiments. Error for ΔΠ values is the standard deviation 
from data in these experiments.  <ΔΠ> is the average ΔΠ from all experiments at all 
concentrations for a peptide at a given interface (n = 9-12). Error for <ΔΠ> values is the 
standard deviation from data in all of these experiments.  At POPC/TO/W interfaces, Πi = 
7.0±0.5 mN/m (ГPOPC = 37.0±1.0%) prior to peptide adsorption.  Results from Figure 4.2 
are shown in bold. 
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At a TO/W interface (Figure 4.2A), all five apoC1 variants had similar adsorption 
kinetics (t1/2 varied from 4.4 to 6.7 min and w from 0.7 to 1.2 min).  The ability of apoC1 
to remodel the interface by changing Π followed the rank order: G15A > WT > G15P = 
R23P = M38P.  This order was observed for adsorption of peptide, added at multiple 
concentrations to the bulk phase, to a TO/W interface (Table 4.2).  All peptides have a pI 
of 7.9 and are basic in buffer of pH 7.4, except for R23P (pI = 6.2), which is acidic. To 
see if net charge affected apoC1 binding to a TO/W interface, identical protocol as in 
Figure 4.2A was repeated for WT and R23P in PB of pH 6.2.  Adsorption kinetics did not 
significantly change for either peptide between buffers (Figure 4.3).  This suggests that 
electrostatic peptide-peptide interactions do not alter adsorption at an apolar lipid surface. 
At a POPC/TO/W interface (Figure 4.2B), most peptides had similar adsorption 
kinetics (t1/2 varied from 2.9 to 3.5 min and w from 0.7 to 1.2 min), except for R23P, (t1/2 
= 7.2±1.5 min, w = 2.0±0.5 min).  This indicates that cooperative binding to POPC/TO/ 
W interfaces is significantly weaker for R23P than for the other peptides.  The rank order 
for ΔΠ was G15A > WT > G15P = M38P > R23P over multiple bulk phase peptide 
concentrations (Table 4.2).  This indicates that R23P remodels POPC/TO/W interfaces to 
a lower extent than G15P or M38P, despite their similar helical content (Table 4.1).  
To probe the differences in the adsorption behavior of R23P at apolar and more 
polar lipid surfaces, we incubated WT, G15P, and R23P with TO droplets, POPC SUV, 
and POPC:TO SUV for 1200-1500 seconds, similar to the time allowed for peptide 
adsorption in Figure 4.2.  Protein:lipid mixtures were analyzed by NDGE (Figure 4.4). 
Exchangeable apolipoproteins, such as apoC1, can spontaneously remodel phospholipid   
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Figure 4.3.  Adsorption kinetics at a TO/W interface are similar for WT and R23P 
apoC1 at pH 6.2; adsorption for both peptides is slightly slower than at pH 7.4. 
Tension (γ) versus time curves for WT and R23P apoC1 variants at TO/W interfaces.  16 
μL TO drops were formed in 6.0 mL of sodium phosphate buffer, pH 6.2, and peptides 
were added to the aqueous phase at 1.7 µg/mL.  Changes in γ as peptides adsorbed to TO 
drops were approximated by sigmoidal functions, where transition width t1/2 is the 
midpoint corresponding to 50% decrease in γ due to peptide adsorption as depicted for 
the G15A protein.  Adsorption kinetics for the two peptides were similar (t1/2 = 8.0±1.0 
min; w = 1.5±0.2 min) at this pH, but slightly slower than adsorption at pH 7.4 (see text).   
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Figure 4.4.  WT and G15P apoC1, but not R23P apoC1, can remodel lipid vesicles. 
Select apoC1 variants (WT, G15P, R23P) were incubated at 1:2.5 (wt/wt) ratios with 
POPC or POPC:TO SUV, or at 1:200 (wt/wt) ratios with TO for 20-25 minutes.  Sizes of 
the resulting protein: lipid particles were assessed by non-denaturing gel electrophoresis 
(NDGE) using 4-20% gradient gels.  Samples contained 10 μg of protein and were run 
for 2 h at 120 V.  The gels were stained with Denville protein stain.  Molecular size 
standards (Denville Scientific) are indicated on the left.  NDGE clearly differentiates 
between lipid-free apoC1 oligomers, apoC1:POPC HDL-like particles, and the protein 
adsorbed at the surface of SUV.   
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SUV and reconstitute them into 8-20 nm particles that mimic nascent HDL (Jonas, 1986).  
For apoC1 variants, this ability correlates with helical content (Mehta et al., 2003). In our 
experiments using WT apoC1 and POPC, reconstituted HDL-like particles were observed 
in a size range of 10-17 nm (Figure 4.4, lane WT:PC).  G15P apoC1 with POPC formed 
slightly larger particles (lane G15P:PC), but R23P apoC1 did not (lane R23P:PC).  A 
similar trend was observed for apoC1 variants incubated with POPC:TO SUV, but all 
particles adsorbed to these lipid surfaces (Figure 4.4, upper band).  The results in Figures 
4.2 and 4.4 suggest that peptide ability to reconstitute POPC vesicles into HDL-like 
particles, which likely correlates with the depth of interfacial insertion, may contribute to 
the observed differences between variants in ΔΠ at POPC/TO/W interfaces. The negative 
net charge of R23P could reduce its ability to insert into more polar lipid interfaces.  
Previous studies by Krebs and Phillips showed that the ability of various 
apolipoproteins to modify the surface pressure of an air/water interface did not correlate 
with the mean hydrophobic moment (<μH>) or helical content of the proteins (Krebs & 
Phillips, 1983, 1984).  However, larger Π changes correlated strongly with larger values 
of the product of the two variables.  Our results showed that, at both types of interface, 
ΔΠ results did not correlate with <μH>, as all peptides have similar <μH> (Table 4.1).  
However, differences in ΔΠ, at both types of interfaces, correlated strongly with 
differences in lipid-free or phospholipid (DMPC)-bound helical content and with 
differences in the product of helical content and <μH> (as <μH> effectively serves as a 
scale factor) (Figure 4.5).  These results suggest that peptides with greater α-helical 
propensity modify the surface pressure of lipoprotein surfaces to a greater extent. 
 126 
 
 
Figure 4.5.  The ability of apoC1 variants to remodel lipid surfaces correlates with 
their helical content or helical content scaled by mean hydrophobic moment.   
(A) <ΔП> values from Table 4.2 for the adsorption of apoC1 variants to TO/W (■) and 
POPC/TO/W (□) interfaces were plotted against the lipid-free helical content of the 
peptides.  Helical content values from Table 4.1 were divided by 100% and expressed as 
fractions, as in (Krebs & Phillips, 1983, 1984).   
(B)  <ΔП> values were plotted against the product of the mean hydrophobic moment 
(<µH>) from Table 4.1 and the lipid-free helical content of the apoC1 variants. Y-error 
bars in (A, B) represent the standard deviation from Table 4.2, while x-error bars arise 
from the uncertainty in helical content, as determined by far-UV CD.  Linear regressions 
were applied to the four data sets in (A, B), as shown by black lines.  These were 
significant (0.93 < R < 0.99, p < 0.02) and indicate that the ability of apoC1 variants to 
remodel П of a TO/W interface correlated strongly with lipid-free α-helical content.  This 
was also true of the relation between <ΔП> and phospholipid (DMPC)-bound helical 
content or the product of  DMPC-bound helical content and <µH> (Meyers et al., 2013).   
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4.3.2 At Lipid/Water Interfaces, Retention Pressure (ПMAX, ПENV) Correlates Strongly 
with the Phospholipid (DMPC)-Bound Helical Content of ApoC1 Variants 
Here, the first aim of the rapid compression and re-expansion protocol (described 
in section 3.2.5) was to show that each apoC1 variant was exchangeable at TO/W and 
POPC/TO/W interfaces, confirming the validity of our experimental approach.  The 
second aim was to compare peptide retention pressures (ПMAX) at these interfaces.  .  
Physiologic processes, such as lipoprotein catabolism, rapidly change lipoprotein size and 
Π.  The ability of apolipoproteins to be retained as Π increases dictates their regulatory 
effects on lipoprotein metabolism. Since hydrophobic lipid surfaces induce folding of 
amphipathic helices, we hypothesized that qualitative differences in the DMPC-bound 
helical content of the peptides would correlate with retention П on lipid/water interfaces. 
Figure 4.6 shows γ and area changes during the compression and re-expansion of 
G15A apoC1/TO/W (A) and G15A apoC1/POPC/TO/W (B) interfaces with and without 
peptide in the bulk phase (i.e., before and after a washout).  After protein adsorption 
lowered γ to γeq = 13.5 at a TO/W interface or 9.5 mN/m at a POPC/TO/W interface, the 
TO drop underwent a series of compressions and re-expansions, which corresponded to 
changes in volume ranging from 1.6 to 7.2 μL and changes in area ranging from 6 to 
32%.  Decreases in γ increased (as did Πo) with the magnitude of compression.  For most 
compressions, γ rose towards γeq at both types of interface when the compressed volume 
was held for >5 min. This meant that some lipid-bound peptide desorbed on compression.   
When the TO drop was re-expanded to 16 μL, γ increased above γeq (Figure 4.6), 
indicative of a lower amount of surface-active material present at the interface.  Tension  
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Figure 4.6.  Adsorption and desorption curves for an apoC at lipid/water interfaces.  
(A)  G15A apoC1 point mutant adsorption and desorption at a TO/W interface.  Protein 
was added to the bulk phase at 0.83 µg/mL.  After protein adsorption to a TO drop 
lowered γ to γeq = 13.5 mN/m, the drop was compressed and re-expanded in increments 
of ±1.6 μL, ±3.6 μL, ±4.6 μL, ±5.3 μL, and ±7.2 μL.  At 127.8 min, lipid-free protein was 
removed by a 200 mL washout at a rate of 10.7 mL/min (shown by the black bar).  The 
drop was compressed and re-expanded in increments of ±3.6 μL, ±5.3 μL, and ±7.2 μL.   
(B) G15A apoC1 adsorption and desorption at a POPC/TO/W interface.  POPC 
adsorption lowered γ to 25.2 mN/m (Пi = 6.8 mN/m).  At 2.9 min, POPC was removed 
from the bulk phase by a 250 mL washout at a rate of 10.9 mL/min (shown by the first 
bar).  The protein was added to the bulk phase at 0.83 µg/mL and adsorption lowered γ to 
γeq = 9.5 mN/m.  The TO drop was compressed and re-expanded in increments of ±1.6 
μL, ±3.6 μL (x2), ±4.4 μL, and ±5.2 μL.  At 371.3 min, lipid-free protein was removed 
by a 150 mL washout at a rate of 10.3 mL/min (shown by the second bar).  The drop was 
compressed and re-expanded in increments of ±1.6 μL, ±5.2 μL, ±7.2 μL, and ±9.2 μL.   
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fell to γeq at TO/W and POPC/TO/W interfaces as peptide in solution re-adsorbed to the 
newly exposed surface area.  If only one of the protein α-helices desorbed, while the 
other was still anchored to these lipid surfaces, peptide adsorption after each re-expansion 
would be fast and the re-adsorption slopes steeper than that of initial adsorption.  The 
slopes of all re-adsorption curves were identical to those of initial adsorption curves at 
both interfaces (Figure 4.7), which indicates that G15A apoC1 was fully exchangeable.   
To further test the reversible binding of G15A to TO/W and POPC/TO/W 
interfaces, rapid compression and expansion protocol was repeated after a 150 mL buffer 
exchange, which removed peptide from the bulk phase (shown by a bar in Figure 4.6A, 
B).  After each post-washout re-expansion, γ remained elevated at both interfaces (Figure 
4.6A, B; right).  If only one α-helix desorbed on compression, it would re-adsorb on re-
expansion and lower γ to γeq, even without peptide in the aqueous phase. Similar protocol 
showed the exchangeability of WT (Meyers et al., 2012), G15P, R23P, and M38P (data 
not shown).  We conclude that the binding of all apoC1 variants to TO/W and 
POPC/TO/W interfaces was reversible. 
To compare the retention of apoC1 mutants at both interfaces, ΠMAX was obtained 
for each at TO/W and POPC/TO/W (ГPOPC = 37.0±1.0%) interfaces (Figure 4.8).  The 
ΠMAX data for G15P and M38P at a TO/W interface are not shown, as they superimpose 
with R23P data. The rank orders for ΠMAX were G15A > WT > G15P = R23P = M38P at 
a TO/W interface and G15A > WT > G15P = M38P > R23P at a POPC/TO/W interface 
(Figure 4.8, Table 4.3).  We conclude that greater lipid-bound helical content increases 
the extent of apoC1 interactions with lipid, resulting in retention up to higher pressures. 
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Figure 4.7.  On expansion of compressed lipid surfaces, G15A apoC1 adsorbs to the 
newly-exposed area with kinetics that match initial protein adsorption.   
(A) The tension profile of the initial adsorption of G15A to a TO/W interface (Figure 
4.6A) was plotted.  After γ reached equilibrium (γeq = 13.5 mN/m), TO drop volume 
underwent a series of rapid compressions and re-expansions of increasing magnitude 
(ranging from ±1.6 to ±7.2 µL).  On each re-expansion, protein (from the bulk phase) re-
adsorbed to the drop, marked as a re-adsorption curve.  Re-adsorption curves from all 
five re-expansions were overlaid with the initial adsorption of protein to the interface.   
(B) The tension profile of the initial adsorption of G15A apoC1 to a POPC/TO/W 
interface of ΓPOPC = 36.6% (Figure 4.6B) was plotted.  After γ reached equilibrium (γeq = 
9.5 mN/m), TO drop volume underwent a series of five sets of rapid compressions and 
re-expansions of increasing magnitude (ranging from ±1.6 to ±5.2 µL).  On each re-
expansion, protein (present in the bulk phase) re-adsorbed to the drop, marked as a re-
adsorption curve.  The re-adsorption curves from all five re-expansions were overlayed 
with the initial adsorption of G15A apoC1 to the POPC/TO/W interface.    
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Figure 4.8.  The retention pressure (ПMAX) of apoC1 variants strongly correlates 
with lipid-bound helical content.   
ΠMAX of apoC1 variants at TO/W (A) and POPC/TO/W (B) interfaces.  Each interface 
was rapidly compressed to Πo.  The TO drop was held at that compressed volume for 
several minutes and the resulting Δγ was plotted against Πo (as described in Figure 3.5).  
Linear regression of the data at each interface gave x-intercepts at Δγ = 0 mN/m, marked 
by a box.  These linear regressions were significant (0.88 < R < 0.99, p < 0.0001).  X-
intercepts represent ΠMAX, the pressure at which peptides show no net desorption from 
the given interface. The data points for each peptide are from several compression and 
expansion experiments with aqueous peptide concentrations of 0.83 to 3.3 µg/mL. 
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Retention Pressures of ApoC1 Variants at TO/W and POPC/TO/W Interfaces
 
Peptide 
ГPOPC = 0% (TO/W) ГPOPC = 33.0±0.7%
 ГPOPC = 36.5±0.5%
 ГPOPC = 42.0±0.8%
 
ΠMAX 
[mN/m] 
ΠENV 
[mN/m] 
ΠENV 
[mN/m] 
ΠMAX 
[mN/m] 
ΠENV 
[mN/m] 
ΠENV 
[mN/m] 
G15A 18.0 18.3±0.3 22.4±0.3 22.6 22.9±0.3 24.2±0.3 
WT 16.8 17.0±0.4 21.1±0.1 20.7 21.4±0.8 23.0±0.3 
G15P 16.1 16.4±0.5 20.3±0.1 20.0 20.8±0.5 22.5±0.5 
R23P 16.4 16.5±0.4 17.9±0.2 18.2 18.7±0.3 20.3±0.3 
M38P 16.0 15.7±0.5 18.8±0.4 19.5 19.4±0.1 20.3±0.3 
Table 4.3.  The retention pressures (ПMAX, ПENV) of apoC1 variants at TO/W (ΓPOPC 
= 0%) and POPC/TO/W interfaces depend on helical propensity and net charge. 
Each ΠENV is the average value from n = 2-4 experiments.  Uncertainty for each ΠENV is 
the standard deviation.  ΠMAX and ΠENV values derived from Figures 4.8 and 4.9, 
respectively, are listed in bold.  The uncertainty for ГPOPC values (calculated from Πi as 
described in (Mitsche & Small, 2011)) comes from standard deviation in the Πi values of 
repeated experiments. 
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For most peptides, the slopes of the linear regressions used to find ΠMAX fell 
within 0.6-0.8 (Figure 4.8).  However, the regression used to find ΠMAX of WT apoC1 at 
a POPC/TO/W interface had a slope of 0.4. We speculate that the α-helices of apoC1 
could exhibit a cooperativity in desorbing from POPC/TO/W interfaces that is not 
preserved with single amino acid substitutions in either of the protein α-helices.   
In order to compare differences in peptide retention over a range of lipid/water 
interfaces, we determined envelope pressures (ΠENV) for apoC1 variants at interfaces of 
varied POPC surface concentration (ГPOPC).  Like ΠMAX, ΠENV is the surface pressure at 
which protein begins to be ejected from lipid/water interfaces as pressure increases. The 
dependence of retention pressure (ΠMAX and ΠENV) on ГPOPC is more easily derived from 
the protocol to find ΠENV (Mitsche & Small, 2011), which is described in Section 3.2.5.   
Figure 4.9 shows compression Π/A isotherms, and their slopes, for apoC1 variants 
absorbed to a POPC/TO/W interface of ГPOPC = 36.5±0.5%.  These were generated from 
the γ and surface area profiles when, following peptide adsorption and a 150 mL buffer 
exchange, the POPC/TO drop was expanded and compressed at ±1.2 μL/min, as in Figure 
3.6.  In Figure 4.9, the envelope point is the surface area per POPC molecule (APMENV) 
and pressure (ΠENV) at which peptide begins to be ejected from the interface on 
compression.  The envelope point is obtained from the slope of the П/A isotherm as 
described in Section 3.2.5.  For all peptides, APMENV = 168±2 Å
2
, indicating that each 
peptide occupied the same surface area after adsorption. Changes in the slope profile 
(dП/dAPM versus APM) are markedly smaller for R23P than the other apoC1 variants.  
This result suggests that R23P/POPC/TO/W interfaces are less sensitive to changes in  
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Figure 4.9. Π/A isotherms of the apoC1 variants at POPC/TO/W interfaces. 
Peptides, added at 0.83 µg/mL into the bulk phase, adsorbed to POPC/TO/W interfaces 
(ГPOPC = 36.5±0.5%).  After buffer exchange, the interface was slowly expanded and 
compressed.  Shown here are П/A compression isotherms, with an arrow marking the 
direction of compression. Area values were converted to area per POPC molecule (APM) 
as described previously (Mitsche & Small, 2011).  The isotherms were fit with a spline 
interpolation of smoothing parameter p = 0.5.  The first derivative of the spline was 
determined and plotted against area as described in Section 3.2.5.  On compressions to 
smaller areas and higher pressures than the envelope point (APMENV, ПENV), peptide 
begins to desorb from the interface and the П/A isotherm is no longer reversible (see 
Chapter 5).  An asterisk marks the envelope point on the plot of dП/dAPM versus APM. 
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surface than other apoC1/POPC/TO/W interfaces, perhaps due to the inability of R23P to 
insert into the surface (Figure 4.4).  ΠENV values from Figure 4.9 were similar to ΠMAX 
values (Table 4.3) with the rank order:  G15A > WT ≈ G15P > M38P > R23P. 
Figure 4.10 and Table 4.3 show that this ΠENV rank order was observed for apoC1 
variants at several POPC/TO/W interfaces, independent of ГPOPC.  For all peptides, 
APMENV (or AENV) was similar at each ГPOPC (data not shown), such that each peptide 
occupied the same area on adsorption.  Linear regressions of the data for all peptides, 
except R23P, had similar slopes (m = 0.11-0.14) and extrapolated to ΠENV at a TO/W 
interface (Figure 4.10).  This indicates that R23P has different desorption kinetics at 
TO/W and POPC/TO/W interfaces.  At POPC/TO/W interfaces, retention pressures of 
G15P were much higher than those of M38P, despite the similar phospholipid-bound 
helical content of the peptides (Table 4.3).  This indicates that the N- and C-terminal 
helices of apoC1 may have different lipid-binding affinities.    
Differences in peptide retention pressures (ΠENV, or the average of ΠMAX and 
ΠENV) at all of the lipid/water interfaces in Table 10 correlated strongly with differences 
in the phospholipid-bound helical content and the lipid-bound helical content scaled by 
<μH> of the peptides (Figure 4.11).  The exception to this trend is G15P, which had 
similar retention pressures as WT apoC1 at POPC/TO/W interfaces (Figure 4.10).  This 
indicates that the C-terminal helix of apoC1 may be responsible for high-affinity binding 
at the lipoprotein surface (see Section 4.4).  These data (Table 4.3, Figure 4.10) suggest 
that greater lipid-bound helical content increases the extent of protein:lipid interactions, 
resulting in apoC1 retention up to higher lipoprotein surface pressures.  
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Figure 4.10.  Retention pressure increases as the ratio of POPC:TO increases.   
ApoC1 variants, added at 0.83 µg/mL in the bulk phase, adsorbed to a TO/W interface or 
POPC/TO/W interfaces at varied ГPOPC values.  After washout, the interface was slowly 
expanded and compressed (at a rate of 1.2 µL/min). Envelope pressures (ΠENV) were 
found and plotted against ГPOPC.  ΠENV values at a TO/W interface (ГPOPC = 0%) are 
marked by a box. Each ΠENV represents the average from n = 2-4 experiments.  As a 
result, y-error bars are the standard deviation in ΠENV and x-error bars are the uncertainty 
in ΓPOPC extrapolated from the standard deviation in Πi.  Linear regressions were applied 
to the data (shown as solid or dashed lines) and were significant (0.96 < R < 0.99, p < 
0.003).  ΠENV at a TO/W interface was not included in the linear regression (blue, dashed 
line) for R23P data.   
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Figure 4.11.  The retention pressures of apoC1 variants at lipid/water interfaces 
correlate strongly with peptide phospholipid (DMPC)-bound helical content.  
(A) Retention pressures (ПENV or averages of ПENV and ПMAX) from Table 4.3 for apoC1 
variants at TO/W (■) or various POPC/TO/W (○,▲) interfaces were plotted against the 
DMPC-bound helical content of the peptides.  Helical content values in Table 4.1 were 
divided by 100% and expressed as a fraction as in (Krebs & Phillips, 1983, 1984).  
Retention pressures at an interface of ΓPOPC = 36.5±0.5% were not plotted.  
(B) Retention pressures were plotted against the product of the DMPC-bound helical 
content and mean hydrophobic moment (<µH>) of the apoC1 variants.  Y-error bars in 
(A, B) are the standard deviation values from Table 4.3, while x-error bars arise from the 
uncertainty in estimating helical content from far-UV CD spectra.  Linear regressions 
applied to all six sets of data in (A, B) were significant (0.82 < R < 0.98, p < 0.09).  
Linear regressions for the data at POPC/TO/W interfaces are not shown in (A, B) in order 
to emphasize that G15P apoC1 (green symbols), despite its lower helical content, has 
similar retention pressures as WT apoC1 (red symbols) at these interfaces.      
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4.3.3 The Exclusion Pressure (ПEX) of ApoC1 at POPC/TO/W Interfaces Depends on 
Helical Content and Net Charge 
We aimed to determine the effect of apoC1 point mutations on exclusion pressure 
(ΠEX).  ΠEX for a peptide is the Π of POPC/TO/W interfaces at which peptide cannot 
penetrate and bind to (i.e., is excluded from) the interface.  Physiologically, proteins with 
higher ΠEX are better able to bind to, and regulate the metabolism of, lipoproteins with 
high local surface pressures, such as nascent HDL or catabolic products of TG-rich 
lipoproteins (Weinberg et al., 2002).  We hypothesized that greater α-helical propensity 
would favor apoC1 binding to lipid interfaces, reflected in larger ΠEX.   
For each peptide, repetition of the ramping protocol over several values of Πi (or 
ГPOPC) gave a complementary set of ΔΠ values, as described in Figure 3.3.   Linear 
regression of the ΔΠ-Πi data for each peptide had a slope of |m| = 0.56-0.62 and gave ΠEX 
as the x-intercept where ΔΠ = 0 mN/m (Figure 4.12).  The rank order for ΠEX followed 
G15A = WT > M38P = G15P > R23P.  We conclude that Pro substitutions in the middle 
of either α-helix of apoC1 decrease overall α-helical content and, as a result, decrease the 
ability of apoC1 to bind to high-pressure lipoprotein surfaces.  Replacing Gly with Ala in 
the middle of the N-terminal α-helix increases α-helical content and the ability of apoC1 
to bind to high-pressure lipid surfaces. 
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Figure 4.12.  The exclusion pressures (ПEX) of apoC1 variants at POPC/TO/W 
interfaces vary with helical propensity and net charge.   
For a given peptide, adsorption to a TO/W interface of Πi = 0 mN/m, ГPOPC = 0%, or 
POPC/TO/W interfaces of various Πi or ГPOPC values increased ΔΠ to a different extent.  
For each peptide, peptide was added to the aqueous phase at 1.7 µg/mL and ΔΠ values 
were plotted against corresponding Πi values.  Linear regression of the data (shown as 
solid lines) gave x-intercepts at ΔΠ = 0 mN/m, marked by a box. These linear regressions 
were significant (-0.99 < R < -0.96, p < 0.0001).  X-intercepts represent ΠEX, the 
exclusion pressure at which a given peptide cannot bind POPC/TO/W interfaces. 
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4.4 Reduction in the Lipid Affinity of Point Mutants of the ApoCs Provides a 
Mechanism for Atherogenic Phenotypes 
In this work, we used oil-drop tensiometry to determine effects of single residue 
substitutions on the affinity of apoC1 for TO/W and POPC/TO/W interfaces.  Since 
apoC1 is the smallest human apolipoprotein (57 residues; Table 1.2) and lacks substantial 
tertiary structure, single Ala or Pro substitutions in the middle of its helices significantly 
alter its α-helical content in solution and on phospholipid (Table 4.1).  
The four apoC1 point mutants used in this study (Table 4.1) exhibited significant 
differences in their ability to bind to and modify TO/W and POPC/TO/W interfaces, as 
compared to WT apoC1.   Adsorption of apoC1 variants to TO/W (Figure 4.2A) and 
POPC/TO/W (Figure 4.2B) interfaces increased surface pressure by ΔΠ.  The magnitude 
of ΔΠ, at both types of interface, followed the rank order: G15A > WT > G15P = M38P 
≥ R23P (Figure 4.2, Table 4.2).  Plots of ΔΠ, at both types of interface, as a function of 
the lipid-free or DMPC-bound helical content of the peptides showed a significant 
correlation between the two variables (Figure 4.5).  Peptide length and mean hydrophobic 
moment (<μH>), which were similar for all peptides (Table 4.1), did not contribute to this 
correlation.  Together, these results suggest that higher helical propensity leads to more 
extensive protein-lipid interactions (Gazzara et al., 1997), resulting in a greater ability to 
bind to and increase the surface pressure of any lipoprotein surface (Figure 4.13). 
Consistent with this model, Pro substitutions in the middle of α-helices of 20-
residue apolipoprotein peptides disrupted helical content and peptide-phospholipid 
association (Ponsin et al., 1986).  All variants had similar APMENV (and AENV) values at  
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Figure 4.13.  Model of apoC1 adsorption and desorption at POPC/TO/W interfaces.   
The NMR structure of WT apoC1 in complex with SDS (Protein Data Bank entry 1IOJ 
(Rozek et al., 1999)) is colored according to secondary structure and, to represent less 
folded states, is modified to exhibit reduced helical content in its N-terminus.  POPC has 
red polar groups and yellow hydrocarbon tails.  TO is represented by a transparent yellow 
sphere.  In solution, WT and G15A apoC1 have a fluctuating helix-loop-helix 
conformation (A), but R23P, G15P, and M38P apoC1 are largely unfolded (B).   
(A) On binding to a POPC/TO/W interface (left), WT and G15A apoC1 increase in 
helical content, form extensive peptide-lipid interactions, and increase surface pressure.  
On small interfacial compressions (middle), the N-terminal α-helix of apoC1 may desorb 
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from the surface.  When the interface is compressed above the peptide’s retention 
pressure (right), peptide desorbs from the surface.   
(B) R23P, G15P, and M38P apoC1, bound to a POPC/TO/W interface (left), have less 
helical content than WT, resulting in less extensive peptide-lipid interactions and smaller 
pressure changes.  On interfacial compressions (middle), R23P, G15P, and M38P apoC1 
have lower retention pressures than WT and are ejected from the interface at lower 
pressures.  As the surface pressure of POPC/TO/W interfaces increases (right), these 
peptides are excluded from the interface at lower pressures than WT. 
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POPC/TO/W interfaces.  This suggests that differences in ΔΠ are due to the different 
helical properties of apoC1 peptides, and not differences in area coverage on adsorption.  
Previous studies showed that the ability of apoC1 point mutants to remodel 
discoidal lipoproteins reconstituted from DMPC increased with the α-helical content of 
apoC1 (Benjwal et al., 2007; Gursky, 2001; Gursky, Ranjana, & Gantz, 2002; Gursky, 
1999; Mehta et al., 2003).  These results indicate that conformational changes due to the 
folding of helices on lipid require the expenditure of free energy, rather than provide an 
energy source for binding (Olga Gursky, 2007).  For peptides of lower pre-existing 
helical structure, the favorable enthalpic contribution to complex formation is weighted 
against a more unfavorable entropic contribution, resulting in lower lipid binding affinity.    
Differences in exclusion pressure (ΠEX)—the surface pressure at which peptide 
cannot penetrate and bind to POPC/TO/W interfaces—also indicated differences in the 
ability of apoC1 to bind to lipid/water interfaces.  ΠEX followed the rank order: G15A = 
WT > G15P = M38P > R23P (Figure 4.12).  These ΠEX results suggest that exchangeable 
apolipoproteins with lipid-binding regions of greater helical propensities can bind to 
lipoproteins with higher surface concentrations of proteins and lipids (Figure 4.13).  As a 
result, these proteins are better able to regulate the metabolism of lipoproteins with higher 
local surface pressures—due to higher concentrations of surface-active molecules—such 
as HDL or the catabolic products of TG-rich lipoproteins. 
Despite the similar helical propensity of the peptides, R23P apoC1 binding to 
more polar POPC/TO/W interfaces greatly differed from that of G15P and M38P apoC1.  
At an interface of ГPOPC = 37.0%, <ΔΠ> for R23P apoC1 was 2 mN/m lower than that of 
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G15P or M38P apoC1 (Table 4.2, Figure 4.2). The ΠEX of R23P apoC1 was 2.4-3.3 
mN/m lower than that of G15P and M38P apoC1 (Figure 4.12). G15P apoC1, but not 
R23P apoC1, remodeled POPC:TO SUV into HDL-like particles of 10-17 nm (Figure 
4.4).  Together, these results suggest that M38P and G15P are better able to penetrate and 
modify the surface pressure of POPC/TO/W interfaces than R23P.   
As R23P, G15P, and M38P apoC1 remodel apolar TO/W interfaces to a similar 
extent, we speculate that differences in ΔΠ and ΠEX at more polar POPC/TO/W 
interfaces are due to the negative charge of R23P apoC1 at pH 7.4.  Arg23 could stabilize 
protein-phospholipid interactions at the POPC/TO/W interface as its alkyl side chains 
interact with apolar lipid moieties and ionic interactions form between its positive charge 
and the phosphates of phospholipid head groups (Anantharamaiah, Jones, et al., 1985; 
Epand et al., 1987).  Loss of Arg23 in R23P apoC1 would disrupt these interactions and 
lead to repulsive ionic interactions between acidic apoC1 and the phosphates of POPC 
head groups.  In addition, the negative net charge of R23P apoC1 at pH 7.4 could disrupt 
the positive cooperativity in peptide-peptide interactions that promote apoC1 binding to 
more polar lipid surfaces.  Reduced binding cooperativity of R23P apoC1 at 
POPC/TO/W interfaces, compared to the other apoC1 variants, was evident in sigmoidal 
curves with slower adsorption kinetics (Figure 4.3B). 
We also determined the effect of single residue substitutions on the ability of 
apoC1 to be retained on TO/W and POPC/TO/W interfaces as П increased.   From rapid 
or gradual compression of both types of interface, the retention pressures (ΠMAX, ΠENV) at 
which each peptide began to desorb were determined.  Retention pressures at these 
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interfaces correlated strongly with the phospholipid-bound α-helical content of the 
peptides (Figure 4.11).  The rank order for ΠMAX followed G15A > WT > G15P = M38P 
≥ R23P at TO/W and POPC/TO/W (ГPOPC=37.0%) interfaces (Figure 4.9, Table 4.3).   
From the protocol to find ΠENV, the rank order of G15A > WT ≈ G15P > M38P ≥ 
R23P was observed for apoC1 retention pressure at lipid/water interfaces of multiple 
POPC surface concentrations (ГPOPC) (Figure 4.10, Table 4.3).  The lower ΠENV values, 
and smaller compressibility (Figure 4.9), of R23P apoC1, as compared to G15P and 
M38P apoC1 at POPC/TO/W interfaces correspond to its reduced ability to insert into 
more polar lipid interfaces (Figure 4.4), such that it is ejected at lower surface pressures.   
In addition, the ΠENV of M38P apoC1 was 1.5-2.2 mN/m smaller than that of 
G15P apoC1 for ГPOPC > 0% (Table 4.3, Figures 4.9 and 4.10).  Since Pro in either 
position disrupts the phospholipid-bound helical content of apoC1 to the same extent 
(Table 4.1), we propose that the lower affinity of M38P apoC1 for lipid surfaces is due to 
disrupted packing of the aromatic cluster in the C-terminal α-helix of apoC1.  Near-UV 
CD showed that M38P, but not R23P, G15P or G15A substitution, significantly altered 
the packing of this cluster (Gursky, 2001).  These results are consistent with the idea that 
the C-terminal α-helix, due to its higher hydrophobicity, is the apoC1 α-helix that serves 
as the high affinity lipid anchor (Albers, Lin, & Roberts, 1979; Rozek et al., 1999).  C-
terminal anchoring would allow the N-terminal α-helix of apoC1 to desorb from the 
lipoprotein surface on small increases in П (Figure 4.13) or to interact with metabolic 
enzymes. 
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Combining ΠMAX and ΠENV data, plots of retention pressure versus the 
phospholipid-bound helical content of the apoC1 variants at multiple TO/W and 
POPC/TO/W interfaces showed a significant correlation between the two variables 
(Figure 4.11).  This indicates that the ability of an exchangeable apolipoprotein to be 
retained on lipoproteins and regulate metabolism correlates strongly with the lipid-bound 
helical content of the protein’s lipid-binding region.  Greater lipid-bound helical content 
allows for more extensive peptide-lipid interactions (Gazzara et al., 1997), such that 
peptide is retained up to higher surface pressures (Figure 4.13).  These results highlight a 
unique role of helical content in peptide retention at lipid surfaces that was not observed 
in previous studies (Benjwal et al., 2007; Mehta et al., 2003).  In those studies, greater 
helical content in apoC1 only weakly correlated with the stability of apoC1:DMPC 
complexes, as marked by denaturation temperatures and kinetics. 
In summary, we showed that changes in the α-helical content or charge of apoC1, 
due to point mutations in the middle of either α-helix, strongly influence the ability of 
apoC1 to bind to, modify, and be retained on lipoprotein-like interfaces.  These results 
have several physiological implications.  For one, increases in П occur in lipoprotein 
catabolism and change the conformation of bound apolipoproteins or force them off the 
surface.  For example, if lipoprotein lipase on TG-rich lipoproteins hydrolyzes a small 
amount of TG, lipoprotein volume shrinks and local П increases (exemplified by volume 
changes in Figure 4.13). Our results indicate that the helical propensity and charge of the 
amphipathic helices of apolipoproteins contribute to their ability to be retained at the 
surface of TG-rich lipoproteins during metabolism; and to regulate lipoprotein fate.     
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5. Chapter 5: A Model for Regulation of Lipoprotein Lipase by Apolipoprotein C2 
5.1 Probing the Mechanism of LPL Activation by ApoC2 
 Human apolipoprotein C2 (apoC2) is a 79-amino acid protein that circulates in 
plasma on HDL, VLDL, and CM (Jong, Hofker, et al., 1999; Kei, Filippatos, 
Tsimihodimos, & Elisaf, 2012; Wang, 1991).  ApoC2 plays an essential role in the 
metabolism of plasma lipid as the cofactor for LPL (Havel et al., 1973; LaRosa et al., 
1970).  LPL hydrolyzes TG and produces fatty acids and monoacylglycerol for uptake by 
adipose, muscle, and other peripheral tissues (Eckel, 1989).  Genetic defects altering the 
structure or production of apoC2 share the phenotype of LPL deficiency in humans, 
hypertriglyceridemia and chylomicronemia (Cox et al., 1978; Jong, Hofker, et al., 1999) 
  Significant progress has been made in elucidating the interactions between apoC2, 
LPL, and lipid required for LPL activation.  The N-terminal region of apoC2 is 
responsible for lipid binding, while the C-terminus activates LPL, as shown by in vitro 
assays using synthetic fragments of apoC2, lipid substrates, and LPL (Kinnunen et al., 
1977; MacPhee, Howlett, Sawyer, & Clayton, 1999; Sparrow & Gotto, 1980; Vainio, 
Virtanen, Kinnunen, Gotto, et al., 1983; Vainio, Virtanen, Kinnunen, Voyta, et al., 1983).  
Lipid-free apoC2 has little α-helical content, as shown by far-UV CD (Hatters & Howlett, 
2002).  Binding of apoC2 to SDS or DPC micelles induces ~60% fluctuating, α-helical 
structure in apoC2 (MacRaild et al., 2001, 2004; Zdunek et al., 2003). 
  NMR structural analyses of apoC2 bound to SDS micelles showed helical 
structure in both the N- and C-terminal regions of the molecule (MacRaild et al., 2001; 
Zdunek et al., 2003).  Residues 14-38 (the N-terminal helix) form a class-A α-helix, 
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while residues 50-54 and 63-76 (the C-terminal helix) form class-G α-helices (Figure 
5.1).  The C-terminal helix showed significantly higher levels of motion on the 
nanosecond time scale than the N-terminal helix on SDS micelles (Zdunek et al., 2003).  
This suggests that the C-terminal helix can detach from lipid surfaces, supported by the 
flexible structure of residues 58-63 (MacRaild et al., 2001; Zdunek et al., 2003).   
   Four residues (Y63, I66, D69, and Q70) on the same face of the C-terminal 
helix—and exposed to solvent in NMR structures—form a binding site for LPL (Figure 
5.1) (Shen et al., 2002, 2010).  In vitro assays showed that replacement of any of these 
residues with alanine decreases the affinity of apoC2 for LPL and the catalytic activity of 
the LPL: apoC2 complex (Shen et al., 2002).  Replacement of all four residues with 
alanine inhibits LPL activity.  Disruption of the secondary structure of the C-terminal 
helix—via proline substitutions or insertion of an alanine after Y63—in apoC2 also 
impairs LPL activation (Shen et al., 2010).  These results indicate that the C-terminal 
helix forms an LPL binding site, while the N-terminus of apoC2 binds lipid.   
  In vitro assays with LPL, apoC2-deficient CM, and apoC2 peptides show that 
lipid binding of the N-terminal helix is required for LPL activation (Olivecrona & 
Beisiegel, 1997).  In a recent study, a mimetic peptide that contained the C-terminal helix 
of apoC2 and a class A helix was designed (Amar et al., 2015).  This peptide enhanced 
cholesterol efflux from ABCA1-transfected cells and stimulated LPL-mediated lipolysis 
in many systems. 
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Figure 5.1.  ApoC2 sequence (bottom) and structure (top).  
(Bottom) The sequence of mature apoC2 has more acidic (red) than basic (blue) residues, 
giving apoC2 a negative charge at neutral pH.  The lone tryptophan (W26) is in bold.   
(Top) Helical wheel representations of the N-terminal (left) and C-terminal (right) α-
helices in apoC2.  These helices were similarly defined in NMR structures of apoC2 in 
complex with SDS or DPC (MacRaild et al., 2001, 2004; Zdunek et al., 2003).  The N-
terminal helix is a class-A helix, with an apolar face (marked by a dashed line) of nine 
residues (yellow). The C-terminal helix (right) is a class-G helix, and has a random radial 
distribution of basic and acidic residues.  The four residues that interact with LPL have a 
thick, black edge.  Polar residues are gray, glycine is pink.  
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  ApoC2 is not required for binding of LPL to lipid surfaces (Bengtsson & 
Olivecrona, 1980).  Rather, apoC2 regulates LPL activity at lipid surfaces in ways that 
are highly dependent on surface pressure, as shown by surface chemistry studies (Vainio, 
Virtanen, Kinnunen, Gotto, et al., 1983; Vainio, Virtanen, Kinnunen, Voyta, et al., 1983).  
As LPL hydrolyzes TG and produces amphipathic lipids, surface pressure () increases.  
LPL is active at mixed TG/phospholipid and pure phospholipid monolayers of lower , 
but requires apoC2 for activity above a critical pressure (Vainio, Virtanen, Kinnunen, 
Gotto, et al., 1983; Vainio, Virtanen, Kinnunen, Voyta, et al., 1983).  These results, and 
others (Bengtsson & Olivecrona, 1980), suggest that apoC2 interacts with LPL to induce 
correct alignment of the complex at the lipoprotein surface and facilitate substrate 
exposure to the catalytic site at higher .   
  We hypothesize that the lipid-bound conformation of apoC2 depends on .  As  
increases, the surface area per apoC2 molecule decreases (Mitsche & Small, 2013).  
Protein conformation likely changes and mobility of the C-terminal helix may promote 
interactions between apoC2 and LPL.  We speculate that the ability of apoC2 to remain 
bound to VLDL or CM remnants limits LPL activity.  Above the retention pressure of 
apoC2,  protein molecules desorb from these remnants and transfer to HDL (Jackson et 
al., 1986).  To probe the relation between apoC2 and lipoprotein П, we characterized the 
behavior of human apoC2 at lipid/water interfaces.  Compression of the interfaces reveals 
pressures at which bound apoC2 molecules undergo conformational rearrangements.  
These rearrangements were probed by study of N- and C-terminal apoC2 fragments.  
Portions of this work were published in (Meyers, Larsson, Olivecrona, & Small, 2015). 
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5.2  Results:  Lipid-Bound ApoC2 Adapts Multiple Conformations 
5.2.1  ApoC2 Binds Lipid Surfaces with High Affinity to Induce Large Pressure Changes 
 This study characterized the effect of apoC2 on the pressure of lipid/water 
interfaces, which reflects the ability of apoC2 to insert into the lipoprotein surface.  
Figure 5.2A shows tension (γ)-time curves for apoC2 at a TO/W interface.  Tension 
values were converted to pressure (П) (Figure 5.2A, inset).  For bulk concentrations of 
1.25 and 2.5 μg/mL, apoC2 adsorption increased П by ΔΠ = 18.2-19.0 mN/m.   
  The ability of apoC2 to modify a TO/W interface increased with lower bulk phase 
pH (Figure 5.2A) or greater bulk phase concentration (Figure 5.2B).  If pH of the bulk 
phase was decreased to approach the isoelectric point of apoC2 (pI = 5.6), adsorption to a 
TO/W interface resulted in greater ΔΠ.  At an apoC2 bulk phase concentration of 1.25 
and 2.5 μg/mL, ΔΠ increased to 20.1-20.7 mN/m (Figure 5.2A, inset).  The change in pH 
had no effect on γ of a clean TO/W interface.  The lower pH could reduce repulsive 
charge-charge interactions between lipid-bound apoC2 molecules and increase the 
surface packing and concentration of apoC2.  As a result, the adsorption-induced ΔΠ 
increases.  pH 7.4 was used for the remainder of experiments, unless otherwise noted.    
  As the concentration of apoC2 increased, equilibrium pressure (Πeq) increased up 
to saturation of ΠSAT = 22.1 mN/m at concentrations ≥ 7.2 μg/mL (Figure 5.2B).  This 
suggests that lipid-free and lipid-bound forms of apoC2 are in a concentration-dependent 
equilibrium that influences Πeq  until the surface is saturated—i.e., no binding sites are 
available (Mitsche & Small, 2013; Wang et al., 2007).  
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Figure 5.2.  Adsorption of apoC2 leads to significant remodeling of TO/W 
interfaces.  
(A) Interfacial tension (γ) versus time curves for apoC2 at a TO/W interface.  TO drops 
(16 μL) were formed in 7.0 mL of sodium phosphate buffer.  Peptides were added at 
concentrations of 1.25 (black, green lines) or 2.5 μg/mL (red, blue lines) to a bulk phase 
of pH 7.4 (black, red lines) or 5.9 (green, blue lines).  γ was monitored continuously as it 
fell from γ of a clean TO/W interface (γTO = 32.0±0.5 mN/m) to equilibrium (γeq).  (Inset) 
γ values were converted to surface pressures (Π) to determine the change in Π (ΔΠ) due 
to apoC2 adsorption.  At a TO/W interface, ΔΠ is equal to the equilibrium pressure (Πeq).    
(B) Equilibrium pressures (Πeq) increase to a saturation value (ΠSAT), while washout 
pressures (ΠWO) remain constant as apoC2 bulk phase concentration increases.  ApoC2 
was added at various concentrations to a bulk phase of pH 7.4 (black symbols) or pH 5.9 
(red symbols) and γ was monitored as it fell to γeq.  γ increased during a 150-mL washout 
and γ was recorded after that washout (γWO).  Values for γeq and γWO were converted to 
Πeq (circles) and ΠWO (squares) and plotted against the pre-washout bulk phase 
concentration of apoC2.  Dashed, black lines mark ΠSAT and ΠWO for pH 7.4. 
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  The ability of apoC2 to remodel POPC/TO/W interfaces was determined for 
several POPC surface concentrations (ΓPOPC).  ΔΠ values were recorded for apoC2 
adsorption to interfaces of various initial pressures (Пi) and ΓPOPC.  These ΔΠ values were 
plotted as a function of Πi in Figure 5.3.  A linear fit was applied to the data and the x-
intercept is the exclusion pressure (ΠEX).  The ΠEX of apoC2 was 32.2 mN/m, which is 
similar to ΠEX of apoC2 at an egg PC/air interface (~30 mN/m) (Vainio, Virtanen, 
Kinnunen, Voyta, et al., 1983).  
5.2.2  ApoC2 Desorbs from Lipid/Water Interfaces at High Surface Pressures 
 This study also characterized the effect of increases in П on the ability of apoC2 
to remain bound to lipid/water interfaces, which mimics the response of apoC2 to LPL 
activity at the lipoprotein surface.  Our results indicate that apoC2 dissociates from a 
TO/W interface on instantaneous increases in Π.  Figure 5.4A shows γ and area changes 
during rapid, pre-washout compressions and expansions of an apoC2/TO/W interface.  
Rapid compressions in volume correlated with decreases in surface area and resulted in 
sharp decreases in tension (marked by asterisks for the first two compressions in Figure 
5.4A).  In the 10-15 minutes after each compression, γ gradually returned to the initial 
equilibrium, γeq. This suggests that apoC2 molecules desorb from compressed interfaces.   
 Re-expansions from compressed volumes correlated with increases in surface 
area.  This resulted in sharp increases in surface tension to values higher than γeq, which 
indicates that vacant binding sites are present on the re-expanded surface.  As apoC2 in 
the bulk phase adsorbed to these binding sites, γ fell to the initial γeq.  The γ profile was  
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Figure 5.3.  Exclusion pressure (ПEX) of apoC2 at POPC/TO/W interfaces.   
(A) Example of the protocol to monitor protein adsorption to, and desorption from, a 
POPC/TO/W interface.  POPC adsorbed to a 16 μL TO drop and lowered γ.  Beginning at 
33.4 min, POPC was removed from the bulk phase by a 250 mL washout at a rate of 8.35 
mL/min (marked by the first black bar).  After the washout, γ was 22.5 mN/m (Πi = 9.5 
mN/m).  TO drop volume could be increased or decreased to decrease or increase Πi, 
respectively.  ApoC2 was added to the bulk phase at 1.25 μg/mL and γ was monitored as 
it fell to γeq.  Beginning at 101.7 min, apoC2 was removed from the bulk phase by a 150 
mL washout at a rate of 8.35 mL/min (marked by the second black bar).  The drop 
volume underwent two sets of gradual expansions and compressions at a rate of 1.2 
μL/min (shown as recordings of surface area in mm2, magenta line).   
(B) Determination of exclusion pressure (ПEX). To determine ПEX of apoC2 a series of 
experiments similar to (A) were conducted over a range of Πi.  ΔΠ was plotted against 
Πi.  The data was fit with a linear regression and the x-intercept is ΠEX, i.e. the pressure at 
which protein cannot insert into POPC/TO/W interfaces such that ΔП = 0 mN/m on 
addition of peptide to the bulk phase.  ΠEX  = 32.2 mN/m for apoC2. 
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Figure 5.4. Desorption of apoC2 from a TO/W interface is a two-step process.   
(A) Rapid and gradual compressions of apoC2/TO/W interfaces.  ApoC2 was added to 
the bulk phase at 2.5 μg/mL.  After apoC2 adsorption to a TO drop lowered γ to γeq = 
13.3 mN/m, the drop volume was rapidly compressed and re-expanded in increments of 
±1.5, ±3.3, ±5.3, and ±7.4 μL.  Asterisks mark the minimum γ for two compressions.  
ApoC2 was removed from the bulk phase by a 150 mL washout (black bar, 8.35 mL/min 
for 18 min starting at 320 min) and γ increased to 15.4 mN/m.  Drop volume was 
expanded at 1.2 μL/min to 30.3 μL (A = 45.8 mm2).  After several minutes, drop volume 
was compressed at 1.2 μL/min to 5.5 μL (A = 14.0 mm2).   
(B) The compression /A isotherm of apoC2/TO/W interfaces shows two inflection 
points.  From the experiment in (A), γ values during the gradual compression were 
converted to Π and plotted against area. This Π/A isotherm was smoothed by a spline 
interpolation.  The first derivative of the fit gave slope values (dΠ/dA), which were 
plotted.  The slope profile shows turning and envelope points at different areas.  П values 
that correspond to these areas on the П/A isotherm are marked by blue asterisks. 
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markedly different for rapid compressions and expansions of apoC2/TO/W interfaces 
after apoC2 was removed from the bulk phase by a washout (data not shown).  After each 
compression, γ rapidly decreased and then slowly increased as apoC2 desorbed from the 
surface.  After each expansion, γ rapidly increased above γeq and remained at elevated 
levels because no apoC2 was present in the aqueous phase to bind to the newly exposed 
binding sites.  Altogether, these results suggest that apoC2 molecules desorb from 
lipid/water interfaces as Π increases above the retention pressure of the protein. 
The right-hand side of Figure 5.4A shows γ and area changes during the gradual, 
post-washout expansion and compression of an apoC2/TO/W interface.  After a 150 mL 
washout, γ gradually increased (Π decreased) as the TO drop volume was expanded from 
16 μL to 30.3 μL.  This indicates that more TG is exposed at the surface as the drop is 
expanded, increasing the energy cost (γ) to maintain the TO/W interface.   
In contrast, γ gradually decreased (Π increased) as the TO drop volume was 
compressed from 30.3 μL to 5.5 μL.  The γ values during compression were converted to 
Π values and plotted against surface area (Figure 5.4B).  The slope (dΠ/dA) of the 
compression Π/A isotherm was determined and plotted (Figure 5.4B).  As area decreased, 
dΠ/dA decreased to a minimum value of -1.7 (mN/m)/mm2 at A = 31.7±0.3 mm2 (point 1 
in Figure 5.4B) and then increased as area decreased to 27.0 mm
2.   For A ≤ 27.0±0.3 
mm
2
 (point 2 in Figure 5.4B), dΠ/dA approached dΠ/dA = 0 (mN/m)/mm2.  Surface 
areas of 31.7±0.3 and 27.0±0.3 mm
2
 correspond to П = 16.7±0.2 and 20.3±0.3 mN/m on 
the П/A isotherm.  This experiment was repeated at various pre-washout concentrations 
of apoC2 and the shape, and inflection points, of compression isotherms were the same.  
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The changes in dП/dA as area decreases from an expanded interface of A ≈ 45 
mm
2
 (Figure 5.4A) suggest the following.  As area decreases to 31.7 mm
2
, TG partitions 
from the surface to the core and Π increases as γ decreases.  As a result, the absolute 
value of dΠ/dA increases.  If apoC2 desorbed from the interface, the absolute value of 
dΠ/dA would decrease due to surface relaxation .  At A = 31.7 mm2, Π returns to the 
post-washout Π of the apoC2 interface (see below), which suggests that all vacant 
binding sites created by expansion from A = 31.7 to 45 mm
2
 have been eliminated.  As 
area decreases to 27.0 mm
2
, apoC2 molecules partially or completely desorb from the 
interface to relax the surface.  As a result, the absolute value of dΠ/dA decreases.  As 
area decreases further, apoC2 molecules completely desorb from the interface such that 
dΠ/dA ≈ 0 (mN/m)/mm2.   
To probe the nature of apoC2 desorption between A = 31.7 and 27.0 mm
2
, 
experiments similar to that in Figure 5.4A were conducted, but with multiple sets of 
gradual expansions to V = 31.8 μL and compressions to various terminal volumes (Figure 
5.5).  Terminal volumes for the compressions in Figure 5.5A correlated with surface 
areas outside and within the region of interest: 27.0 mm
2
 ≤ A ≤ 31.7 mm2 (Figure 5.5B).  
The first compression (red) ends at A = 35.0 mm
2
 second compression (blue) ends at A = 
29.2 mm
2
 (Figure 5.5B).  The third expansion (cyan) overlays with the first expansion 
(black), which indicates that none of the apoC2 molecules bound to the interface after the 
washout have desorbed from the interface during the first or second compressions.    
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Figure 5.5. ApoC2 molecules can partially desorb from a TO/W interface. 
(A) Gradual expansions and compressions of apoC2/TO/W interfaces.  ApoC2 was added 
to the aqueous phase at 1.25 μg/mL.  After apoC2 adsorption to a TO drop (V = 16 μL) 
lowered γ to γeq = 14.4 mN/m, apoC2 was removed from the aqueous phase by a 150 mL 
washout (black bar, 6.26 mL/min for 25 min starting at 60.8 min).  Drop volume 
underwent a series of five gradual expansions and compressions at a rate of 1.2 μL/min.  
Each expansion ended at V = 31.8 μL, A =47.6 mm2.  Each compression ended at a 
smaller volume (i.e., area) than the previous compression(s)—ending at A = 35.0, 29.2, 
22.7, 18.2, and 13.1 mm
2
.  (B)  ApoC2 molecules partially desorb before completely 
desorbing from a TO/W interface.  From the experiment in (A), γ values during the 
expansions and compressions were converted to Π values and plotted against area.  The 
expansions and compressions are labeled by color and number, starting at 1 for the first 
post-washout expansion and compression.  The direction of compression is shown by an 
arrow.  A spline fit of smoothing parameter 0.5 was applied to the compression Π/A 
isotherms.  The first derivative gave slope values, which were plotted against area.   
 159 
 
The third compression (magenta) ends at A = 22.7 mm
2
 and overlays with the first 
compression (Figure 5.5B).  The П/A isotherms—and their slopes—closely overlay for 
the first three compressions.  These results strongly indicate that part of the lipid-bound 
apoC2 molecule desorbs between pressures of 16.7 mN/m (ПP) and 20.3 mN/m (ПENV), 
such that П/A isotherms are reversible to П < 20.3 mN/m (i.e. the region of the apoC2 
molecule that is off the surface can snap back on during re-expansion).  
As П exceeds 20.3 mN/m, apoC2 molecules desorb from a TO/W interface. With 
less apoC2 at the lipid/water interface, subsequent expansion and compression П/A 
isotherms are markedly shifted to the left (i.e., lower areas).  This was observed for the 
fourth and fifth sets of expansions and compressions in Figure 5.5B.  Similar results were 
observed on repetition of this experiment (n=4).  In sum, these results indicate that part of 
the apoC2 molecule begins to desorb from a TO/W interface at Π ≥ 16.7 mN/m.  The 
apoC2 molecule completely desorbs at Π ≥ 20.3 mN/m.   
These results provide a method to determine partial and envelope points of apoC2 
at any lipid surface.  As demonstrated by the interface in Figure 5.4B, the turning point 
on the dΠ/dA curve is the area (AP) at which apoC2 molecules begin to partially desorb.  
This value can be used to determine the partial pressure (ΠP) on the Π/A isotherm.  
Likewise, the retention—or envelope—point on the dΠ/dA curve is the area (AENV) at 
which apoC2 molecules begin to completely desorb from the interface.  This value can be 
used to determine the envelope pressure (ΠENV) on the Π/A isotherm.  The values of (AP, 
ΠP) and (AENV, ΠENV) on the Π/A isotherm are marked by blue asterisks in Figure 5.4B. 
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A two-step protein desorption was also evident in the Π/A compression isotherms 
of apoC2/POPC/TO/W interfaces (Figure 5.6).  Experiments similar to those in Figure 
5.3A were conducted over a range of Πi and ΓPOPC.  In addition to converting values of γ 
during compression to Π, area values were converted to area per POPC molecule (APM).  
Π/A compression isotherms were plotted for apoC2/POPC/TO/W interfaces of various 
ΓPOPC (Figure 5.6A).  As ΓPOPC increased, Π/A isotherms shifted to the left.  This 
indicates that apoC2 molecules desorb at smaller areas for greater POPC:apoC2 ratios at 
the lipid surface.  The pressures at which apoC2 molecules partially (ΠP) and completely 
(ΠENV) desorb from POPC/TO/W interfaces were plotted as a function of ΓPOPC (Figure 
5.6B).  Both ΠP and ΠENV increased as ΓPOPC increased.  This suggests that POPC 
increases the affinity of apoC2, in any conformational state, for the lipid/water interface.   
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Figure 5.6. ApoC2 molecules desorb from POPC/TO/W interfaces at higher 
pressures with greater POPC:ApoC2 ratios.  
(A) The retention areas of apoC2 decrease as POPC surface concentration (ΓPOPC) 
increases.  Experiments similar to those shown in Figure 5.3 were conducted over a range 
of Πi values.  Πi was converted to ΓPOPC.  γ values during compression were converted to 
Π values and plotted against the area per POPC molecule (APM).  The ΓPOPC for each 
compression isotherm, from left to right, is listed at the top of the graph.   
(B) The pressures at which apoC2 molecules partially (P) and completely (ENV) desorb 
from POPC/TO/W interfaces increase as ΓPOPC increases.  For each compression isotherm 
in (A), ΠP and ΠENV values were calculated as described in Figures 5.4 and 5.5.  ΠP (red, 
open circles) and ΠENV (black, filled circles) were plotted as a function of ΓPOPC.  X- and 
y-error bars are the standard deviation from n = 2-5 experiments. 
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5.2.3 The N-terminus of ApoC2 Mediates Binding to Lipid Surfaces 
 Compression isotherms (Figures 5.4-5.6) indicate that that lipid-bound apoC2 
exhibits various conformations differing in the area occupied at the lipid surface.  To test 
the hypothesis that the N-terminal helix anchors apoC2 to the lipid surface, while the C-
terminal helix exhibits multiple conformational states, we characterized the adsorption 
and desorption of peptide fragments at the TO/W interface (Figure 5.7).   
  Two peptides were synthesized to model the N- and C-terminal helices of apoC2, 
as described in Section 3.3: Materials.  These peptides represent residues 14-38 (i.e., the 
N-terminal helix) and residues 50-79, of which residues 63-76 comprise the C-terminal 
helix (Figure 5.1).  Each peptide was added to the aqueous phase at 2.85 μg/mL and 
adsorbed to a TO drop (Figure 5.7).  The N-terminal peptide induced ΔП = 13.7 mN/m 
(Figure 5.7A), while Δ was 8.9 mN/m for the C-terminal peptide (Figure 5.7B).  These 
ΔП were smaller than that of full-length apoC2 at a similar concentration (ΔП= 18.7 
mN/m), which indicates that both helices coordinate lipid-binding of apoC2.    
  Two sets of experiments were conducted to see if the N-terminal peptide could 
displace the C-terminal peptide from lipid surfaces.  In one set, the C-terminal peptide 
was added to the aqueous phase after the N-terminal peptide had adsorbed to the TO/W 
interface and decreased  to eq = 18.3 mN/m (Figure 5.7A).  Tension did not change, 
which indicates that the C-terminal helix cannot insert into the interface and displace the 
N-terminal helix.  In the second set of experiments, the N-terminal peptide was added to 
the aqueous phase after adsorption of the C-terminal peptide decreased  to eq = 23.10.1 
mN/m (Figure 5.7B).  Tension decreased to eq = 18.5 mN/m, which corresponds to a net  
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Figure 5.7. The N-terminus of apoC2 mediates binding to the TO/W interface.   
(A) The C-terminus of apoC2 is unable to displace the N-terminus.  The N-terminal 
peptide was added to the aqueous phase at 2.85 μg/mL.  Adsorption to a TO/W interface 
lowered γ to γeq = 18.3 mN/m.  The C-terminal peptide was added to the bulk phase at 
25.8 and 49.8 min (marked by arrows) to concentrations of 2.85 and 5.70 μg/mL.  There 
were no changes in .  Drop volume was compressed and re-expanded in increments of 
±2.1, ±4.0, ±6.0, and ±8.0 μL.  Re-adsorption decreased γ to γeq = 18.20.1 mN/m.   
(B) The N-terminus of apoC2 displaces the C-terminus.  C-terminal peptide was added to 
the bulk phase at 2.85 μg/mL.  Adsorption to the TO/W interface lowered γ to γeq = 23.1 
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mN/m.  N-terminal peptide was added to the bulk phase at 31.1 min (shown by an arrow) 
to a concentration of 2.85 μg/mL.   decreased to γeq = 18.5 mN/m.  Peptide was removed 
from the bulk phase by a washout (black bar, 6.26 mL/min for 25 min starting at 65.5 
min).  Drop volume underwent two sets of expansions and compressions at 1.2 μL/min.  
These volume changes corresponded to real-time changes in surface area (magenta).    
(C) The N-terminus adsorbs faster than the C-terminus.  The N- and C-terminal peptides 
were added in equal weight ratios to the aqueous phase at 4.6 μg/mL.  Adsorption to the 
TO/W interface lowered γ to γeq = 18.6 mN/m.  The drop volume was rapidly compressed 
and re-expanded in increments of ±3.8, ±5.7, ±8.0, and ±8.7 μL.  In each case, re-
adsorption decreased γ to γeq = 18.6 mN/m.  Peptide was removed from the bulk phase by 
a washout (black bar, 6.26 mL/min for 25 min starting at 93.5 min).  Drop volume 
underwent two sets of expansions and compressions at 1.2 μL/min.    
(D) The N-terminus desorbs at higher pressures than the C-terminus.  From experiments 
similar to those in (B), Π/A compression isotherms were generated for the N- and C-
termini at the TO/W interface.  These were plotted with an isotherm for full-length 
apoC2.  A spline fit of smoothing parameter 0.38 was applied to the isotherms.  The 
derivative of the fits gave slope values (dΠ/dA), which were plotted against area. 
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Δ = 13.5 mN/m that mirrors that of N-terminal adsorption to the TO/W interface in the 
absence of the C-terminal helix.  These trends were also observed at POPC/TO/W 
interfaces (Figure 5.8).  These results indicate that the N-terminal helix remodels lipid 
surfaces with higher affinity, while the C-terminal helix is more easily displaced. 
  To probe adsorption kinetics, the two peptides were added to the aqueous phase 
simultaneously at the beginning of an experiment (Figure 5.7C).  Tension of the TO/W 
interface decreased to eq = 18.6 mN/m and the rate of adsorption mirrored that of the N-
terminal helix alone.  In another experiment (Figure 5.7A), the C-terminal peptide was 
added to the aqueous phase after the N-terminal peptide had adsorbed to the TO/W 
interface.  The final concentration of the C-terminal peptide was twofold higher than the 
N-terminal peptide.  This interface was rapidly compressed and expanded by various 
amplitudes to induce desorption of the N-terminal helix (Figure 5.7A).  On re-expansion, 
 decreased to eq = 18.20.1 mN/m with similar kinetics as the initial adsorption of the 
N-terminal helix.  These data indicate that the N-terminal helix adsorbs to lipid surfaces 
at a faster rate and prevents binding of the C-terminal helix, even at lower concentrations.   
  To probe the desorption behavior of these peptides, П/A isotherms were generated 
from the post-washout, gradual expansion and compression of peptide/TO/W interfaces.  
П/A isotherms for compressions to A<AENV—along with their slope profile—were 
plotted for each peptide fragment and full-length apoC2 (Figure 5.7D).  The short 
peptides desorbed from the TO/W interface at retention areas and pressures smaller than 
those of full-length apoC2.  This indicates that the N- and C-terminal helices occupy 
smaller surface areas than full-length apoC2 at lipid surfaces.   
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Figure 5.8. The N-terminus of apoC2 mediates binding to POPC/TO/W interfaces.  
(A) The C-terminus of apoC2 cannot displace the N-terminus.  After washout (marked by 
a black bar), Пi = 6.6 mN/m for the POPC/TO/W interface.  N-terminal peptide was 
added to the bulk phase at 77.2 min (marked by an arrow) to 1.90 μg/mL.  Adsorption 
lowered γ to γeq = 13.5 mN/m.  C-terminal peptide was added to the bulk phase at 187.5 
and 193.1 min (marked by arrows) to 2.29 and 4.57 μg/mL.  There were no changes in .  
Peptide was removed from the bulk phase by a washout (marked by the second black 
bar).  Drop volume underwent four expansions and compressions at 1.2 μL/min.     
(B) The N-terminus of apoC2 displaces the C-terminus.  After washout (marked by a 
black bar), Пi = 5.7 mN/m for the POPC/TO/W interface.  C-terminal peptide was added 
to the bulk phase at 89.8 min (marked by an arrow) to 2.29 μg/mL.  Adsorption lowered γ 
to γeq = 19.0 mN/m.  N-terminal peptide was added to the bulk phase at 136.7 min 
(shown by an arrow) to 1.90 μg/mL.   decreased to γeq = 13.9 mN/m.  Peptide was 
removed from the bulk phase by washout (black bar, 6.26 mL/min for 25 min starting at 
155 min).  Drop volume was expanded to 30 µL before compression to 6.5 µL.  
 167 
 
  The N-terminal peptide desorbed at higher pressures (П ENV=11.90.3 mN/m) 
than the C-terminal peptide (П ENV=8.40.3  mN/m).  The slope profile of isotherms for 
both peptides showed poorly-defined minima at dП/dA  -0.6 (mN/m)/mm2, threefold 
lower than that of full-length apoC2.  These data indicate that the N-terminal helix 
anchors apoC2 to lipid surfaces and the conformational rearrangement of apoC2 requires 
both helices.  In addition, compression П/A isotherms from experiments in which N-
terminal peptide was added after C-terminal peptide adsorbed to POPC/TO/W or TO/W 
interfaces) overlaid with isotherms from experiments in which N-terminal peptide was 
adsorbed to a clean interface (Figure 5.9).  The hysteresis in early phases of compression 
isotherms at a POPC/TO/W interface (Figure 5.9B) were due to differences in ΓPOPC. This 
confirms that the N-terminus of apoC2 can displace the C-terminus from lipid surfaces. 
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Figure 5.9.  The N-terminus of apoC2 displaces the C-terminus from lipid surfaces.  
(A) Surface Pressure/Area (П/A) isotherms were plotted for the compression of five 
TO/W interfaces, differing in peptide content.  Compressions ended at areas smaller than 
the retention area (A << AENV) for each peptide.  Interfacial peptide content of the 
isotherms was: apoC2, the C-terminal peptide, and the N-terminal peptide.  In two 
experiments (Figure 5.7B, 5.7C), N-terminal peptide adsorbed to a TO/W interface 
containing bound C-terminal peptide (blue) or was added simultaneously with C-terminal 
peptide (cyan) to the aqueous phase.   
(B) П/A isotherms were plotted for the compression of N-terminal peptide at two 
POPC/TO/W interfaces.  Compressions ended at areas smaller than the retention area 
(APM << APMENV) for each peptide.  In one experiment (Figure 5.7A), N-terminal 
peptide adsorbed to a clean POPC/TO/W interface (black), while in the other (Figure 
5.7B) N-terminal peptide adsorbed to a POPC/TO/W interface containing bound C-
terminal peptide (red).  In both (A, B) Slope values were determined from spline fits 
(smoothing parameter 0.38) applied to the isotherms and plotted against surface area.   
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5.2.4 ApoC2 Exhibits Multiple Conformations at Lipid/Water Interface 
We further examined the conformational adaptability of apoC2 by analyzing the 
Π(t) profiles of apoC2/TO/W interfaces during a washout.  After adsorption to TO/W or 
POPC/TO/W interfaces, apoC2 was removed from the bulk phase by a washout.  During 
washouts,  of apoC2/lipid/water interfaces increased.  This suggests that apoC2 
molecules desorb as the lipid-free concentration of protein is reduced to zero.   
The (t) profiles of apoC2/TO/W interfaces at various, pre-washout eq were 
recorded during a 150-mL washout and converted to П(t) profiles (Figure 5.10).  eq 
values were converted to equilibrium pressures (Пeq).  While Πeq increased with the pre-
washout concentration of lipid-free apoC2, the pressure after a washout (ΠWO) was 
independent of pre-washout apoC2 bulk phase concentration or Πeq (Figure 5.10, Table 
5.1).  The difference between Πeq and ΠWO increased as Πeq increased, but ΠWO remained 
constant at 16.6±0.2 mN/m (Table 5.1).   
Members of our lab speculated that the independence of WO from Пeq suggests 
that—for exchangeable, helical peptides—at least one population of lipid-bound peptide 
is not in a concentration-dependent equilibrium with lipid-free peptide (Mitsche & Small, 
2013).  A second population of lipid-bound peptide must be in a concentration-dependent 
equilibrium with lipid-free peptide as Пeq increases with bulk-phase concentration 
(Meyers et al., 2012, 2015; Mitsche & Small, 2013; Wang et al., 2007).  The two 
populations may differ in conformation and are in a surface pressure-dependent 
equilibrium with each other.  This model is shown for apoC2 in Figure 5.11.  
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Figure 5.10. The surface pressure of apoC2/TO/W interfaces after a washout (ΠWO) 
is independent of the pressures before a washout (Πeq).   
П(t) profiles during washouts are plotted for five apoC2/TO/W interfaces of different pre-
washout equilibrium pressures (Пeq).  Пeq varied from 16.7 mN/m (black) to 21.8 mN/m 
(cyan).  To acquire each П(t) profile, γ was monitored continuously during a 150 mL-
washout.  Washout rate was 8.35 mL/min.  γ values were converted to Π values and 
plotted against washout time.  Π is on the y-axis and decreases from large to small values.  
ΠWO = 16.6±0.2 mN/m, independent of Πeq or washout rate.   
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ApoC2 Pre-
Washout 
Concentration 
[μg/mL] 
Experimental Parameters Parameters from Exponential Fit 
Πeq 
[mN/m] 
ΠWO 
[mN/m] 
Πeq-ΠWO 
[mN/m] 
ΠWO 
[mN/m] 
Πeq-ΠWO 
[mN/m] 
kd     
[min
-1
] 
R
2
 
0.2 16.7 16.2 0.5 N/A 
1.25 18.2 16.5 1.7     
2.5 19.1 16.5 2.6     
5.0 19.3 16.8 2.5     
6.1 20.4 16.6 3.8 16.8 4.07 0.305 0.97 
11.0 21.7 16.3 5.4 16.5 5.76 0.370 0.99 
12.5 21.8 16.7 5.1 16.8 5.51 0.433 0.97 
Averages  16.6±0.2      
Table 5.1.  Dissociation rate (kd) of apoC2 from TO/W interfaces during a washout 
depends on initial surface concentration of apoC2.   
Adsorption and washout data (Пeq, ПWO, Пeq-ПWO) are shown for apoC2 adsorption from 
a bulk phase of varied protein concentration to the TO/W interface and 150-mL washouts 
at a rate of 8.35 mL/min.  The data plotted in Figure 5.10 are in italics and colored 
according to the figure.  The washout П(t) curves that correspond to these data were 
approximated by a monoexponential decay function. The exponential curve had the form 
П(t)=(Пeq-ПWO)*e
-kd*t
+ПWO, where Пeq is the pre-washout equilibrium pressure, ПWO is 
the post-washout pressure, and kd is the dissociation rate constant.  Experimental values 
of Пeq and ПWO are compared to those from the exponential fit, for washout data of low 
noise (high R
2) and large amplitude (i.e., Пeq-ПWO).   
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Figure 5.11.  П-induced conformational rearrangement of lipid-bound apoC2.   
The two-surface state thermodynamic model of short, helical peptides at a TO/W 
interface was described in (Mitsche & Small, 2013) and a model is shown for apoC2.  
(Top, Left) ApoC2 is largely unfolded in solution.  The soluble (S) protein is in 
equilibrium with a lipid-bound, exchangeable (EX) form.  This equilibrium depends on 
the concentration of soluble protein.  At least two lipid-bound, exchangeable and non-
exchangeable (NE), forms of peptide are in a Π-dependent equilibrium.  The EX form 
occupies less surface area than the NE form—for apoC2 we speculate that the N-terminal 
helix inserts into lipid in the EX form, while both helices insert into lipid in the NE form.   
(Top, Right)  At saturation, all lipid-bound peptide molecules are in the EX form. 
(Bottom) As apoC2 is removed from solution during a washout, bound peptide desorbs 
from the EX form and Π decreases.  This promotes the NE form of bound peptide. 
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In this model, lipid-bound peptide in the second, less-exchangeable population 
remain bound, while molecules in the first, more exchangeable population desorb during 
a washout as the concentration of lipid-free peptide approaches zero (Mitsche & Small, 
2013).  A corollary of this conclusion is that lipid-bound peptide in the less-exchangeable 
population occupy a larger area than molecules in the more-exchangeable population.  If 
this model is correct, we propose that the N-terminal helix of apoC2 mediates binding to 
lipid surfaces while the C-terminal helix can be bound to or detached from the surface, 
depending on surface pressure. 
To determine the dissociation rate (kd) of apoC2 from a TO/W interface during a 
washout, a single exponential was fit to the Π(t) profile of apoC2/TO/W interfaces during 
a washout (Table 5.1).  For every Π(t) profile in Figure 5.10, ПWO is reached at similar 
time points (4-6 min).  This indicates that the time constant τ, and therefore kd, are similar 
for each curve.  From exponential fits applied to data of low noise (high R
2
) and larger 
amplitude (i.e., Пeq-ПWO), kd of apoC2 from the lipid surface was 0.37±0.06 min
-1
.     
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5.2.5 Desorption of ApoC2 Removes Phosphatidylcholines from Lipid/Water Interfaces 
 A previous study at the PC/air/water interface showed that apoC2, when injected 
into the subphase, decreased the surface radioactivity of monolayers of egg 
phosphatidyl[
14
C]choline (Jackson, Pattus, & Demel, 1979).  This decrease in 
radioactivity was specific to phosphatidylcholine (PC) monolayers, as the radioactivity of 
monolayers of [
14
C]cholesterol and phosphatidyl[
14
C] inositol did not change on injection 
of apoC2 to the subphase.  In addition, surface radioactivity decreased at a faster rate if 
HDL or VLDL were added to the subphase one hour after addition of apoC2.  These 
results suggest that apoC2 removes PC lipids from VLDL and CM during lipoprotein 
catabolism and transfers to interfaces of lower Π, such as the surface of HDL or nascent 
VLDL (Jackson et al., 1979). 
Consistent with these findings, apoC2 removed POPC from POPC/TO/W 
interfaces (Figure 5.12).  Rapid compression and re-expansion of apoC2/POPC/TO/W 
interfaces with apoC2 in the bulk phase resulted in desorption of lipid-bound apoC2 
molecules and re-adsorption of lipid-free protein.  However, the equilibrium tension (γeq) 
after re-adsorption of protein to re-expanded POPC/TO/W interfaces increased for each 
subsequent compression and re-expansion (Figure 5.12A).  This suggests that apoC2 
removes POPC on desorption from the interface, such that replacement of lipid-bound 
apoC2 with lipid-free apoC2 after re-expansion decreases ΓPOPC and increases γeq.  The 
γeq of each re-adsorption was the same as the γeq of initial adsorption to POPC/TO/W 
interfaces for apoA1 (Wang et al., 2014), apoC1 (Figure 4.6), and apoC3 (data not 
shown), which suggests that these proteins do not remove PC in these conditions.   
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Figure 5.12. On desorption, apoC2 removes POPC from PC/TO/W interfaces.  
(A) Rapid compressions and expansions of an apoC2/PC/TO/W interface.  POPC SUVs 
with 1-2% PNPC—a fluorescently-labeled derivative of POPC—adsorbed to a 16 μL TO 
drop.  POPC/PNPC was removed from the bulk phase by a 250 mL washout (black bar, 
8.35 mL min for 30 min starting at 40 min).  After the washout, γi = 24.7 mN/m (Πi = 7.3 
mN/m).  At 71.1 minutes, TO drop volume was increased by 3 μL to V = 19.0 μL.  Πi 
decreased to 5.5 mN/m.  ApoC2 was added to the aquesous phase at 1.25 μg/mL and γ 
fell to γeq = 9.1 mN/m (dotted line). The TO drop (V = 19.0 μL) was compressed and re-
expanded in increments of ±1.6, ±2.7, ±3.7, ±4.7, and ±7.8 μL.  On each re-expansion, γ 
fell to γeq > 9.2 mN/m.   
(B)  Fluorescent signal from PNPC in the bulk phase increases as apoC2 removes PC 
from the PC/TO/W interface.  3-mL aliquots were removed from the bulk phase at points 
1-3 in (A).  These aliquots were placed in a FluoroMax-2 and the emission spectrum from 
490-600 nm (λem = 533 nm for PNPC) was captured with λex=474 nm.  The emission 
spectra from aliquot 1 (solid line), before apoC2 was added, and from aliquot 3 (dashed 
line), after a series of rapid compressions and expansions, are shown.  The dotted line is 
the difference between the two spectra.  Aliquot 2 had the same spectrum as aliquot 1.  
(Inset) ApoC1 and apoC3 remove relatively little POPC.  The net change in emission 
spectra of aliquots from the bulk phase between peptide injection and interfacial 
compressions and expansions were determined as in B for the other apoCs.  These spectra 
were plotted for each apoC at POPC/TO/W interfaces of similar PC surface concentration 
(POPC = 34.5+1.3%).  
 177 
 
However, other in vitro studies have shown that excess phospholipid and 
cholesterol that accumulates due to LPL activity can dissociate from VLDL and CM 
remnants with apoA1, apoE, and the apoCs to form HDL-like disks (Krimbou, Marcil, 
Chiba, & Genest, 2003; Krimbou, Tremblay, Jacques, Davignon, & Cohn, 1998; 
Musliner et al., 1991). 
To verify that apoC2 removes POPC, PNPC—a derivative of POPC with an NBD 
fluorescent label at carbon 12 of its sn-2 acyl chain—was used.  PNPC was incorporated 
at 1-2 wt % of POPC SUVs.  These SUVs were used in experiments similar to that shown 
in Figure 5.12A.  Aliquots were taken from the bulk phase after phospholipid was 
removed from the bulk phase (1), after apoC2 adsorbed to the interface (2), and after a 
cycle of rapid interfacial compressions and expansions (3).  Aliquots were analyzed for 
fluorescence of PNPC.   
The first aliquot exhibited low fluorescence, which indicates that most of the 
phospholipid in the bulk phase was removed by the washout (Figure 5.12B, solid line).  
The second aliquot also exhibited low fluorescence (not shown), which indicates that 
apoC2 adsorption does not displace POPC from the interface.  The third aliquot exhibited 
a 7-8 fold increase in fluorescence (Figure 5.12B, dashed and dotted lines), which 
indicates that apoC2 desorption removes PC lipids from the interface.  In similar 
experiments, apoC3 removed little to no PC while apoC1 removed < 50% of the PC lipid 
removed by apoC2 (Figure 5.12B, inset). 
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5.3 The C-terminus of ApoC2 Desorbs from Lipid to Interact with LPL 
Since surface pressure increases significantly at the site of LPL activity on 
lipoprotein surfaces, we hypothesized that the enzyme’s cofactor apoC2 must have a high 
affinity for lipids.  To test this hypothesis, we used oil-drop tensiometry to characterize 
the ability of apoC2 to remodel lipoprotein-like TO/W and POPC/TO/W interfaces.  We 
also characterized the ability of apoC2 to be retained as these interfaces were compressed 
and surface pressure increased, which mimics the actions of LPL.   
We can compare these results to those from similar experiments with other 
exchangeable apolipoproteins and peptides, such as apoC1 (Chapter 4), apoC3 (Chapter 
6), apoA1 (Wang et al., 2005, 2014), and the N- and C-terminal domains of apoA1 
(Mitsche & Small, 2011, 2013; Wang et al., 2007).  This comparison reveals the ability of 
apoC2—relative to these proteins—to bind and travel with TG-rich lipoproteins during 
lipoprotein metabolism.  The C-terminal region of apoA1 (C46) is predicted to be the 
most lipophilic region of apoA1 and has a higher lipid affinity than the N-terminal region 
(Brouillette et al., 2001; Laccotripe, Makrides, Jonas, & Zannis, 1997; Mitsche & Small, 
2011; Wang et al., 2007; Zhu & Atkinson, 2007).     
The results in Table 5.2 and Figure 5.13 show that apoC2 has a higher lipid 
affinity than all other exchangeable, helical peptides we have studied.  The ability of 
apoC2 to bind to and remodel TO/W and POPC/TO/W interfaces is markedly greater 
than that of full-length apoA1 and C46, as marked by greater surface remodeling (ΔП), 
saturation pressures (ПSAT), and exclusion pressures (ПEX) (Table 5.2).  By comparison, 
apoC1 and apoC3 remodeled TO/W and POPC/TO/W interfaces to a similar extent as   
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Protein TO/W POPC/TO/W  TO/W Γ =32% Γ =35% Γ =40% Γ=46% 
ΔП* 
[mN/m] 
ПSAT 
[mN/m] 
ПEX  
[mN/m] 
Retention Pressure (ENV) [mN/m] 
ApoC2 18.50.5 22.1 32.2 20.30.3 23.30.3 23.90.3 25.30.3 26.60.3 
ApoC3 19.50.2 22.5 33.0 20.40.3 21.90.3 22.30.3 23.70.3 24.30.3 
ApoC1 18.00.2 21.5 34.4 18.50.5 21.30.3 21.80.5 23.20.3 24.30.3 
ApoA1 14.00.5 16.2 22.6 18.00.4 21.20.5 22.00.5   
C46 15.30.3 15.0 25.8 16.20.4 17.00.4  18.00.5  
Table 5.2. Comparison of the affinities of exchangeable apolipoproteins (ApoCs, 
full-length ApoA1, and the C-terminus (C46) of ApoA1) for lipid/water interfaces.   
Parameters ΔП, ПSAT, and ПEX correlate with the abilities of the proteins to bind to and 
remodel TO/W and POPC/TO/W interfaces.  The parameter ПENV correlates with the 
abilities of the proteins to remain bound to lipid/water interfaces of various POPC surface 
concentrations (Γ).  Expressed as a percentage, Γ (or ΓPOPC) is the percent of total surface 
area covered by POPC.  This assumes a surface area per PC head group of 65 Å
2
 
(Mitsche & Small, 2011).  Values of these parameters for apoC1, apoA1, and C46 were 
obtained from References (Meyers et al., 2013; Mitsche & Small, 2013; Mitsche & 
Small, 2011; Wang et al., 2005, 2007, 2014), while values for apoC3 are found in Section 
6.2.  *ΔП values at a TO/W interface were recorded for an aqueous phase protein 
concentration of 1.25 or 2.5 μg/mL. 
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Figure 5.13.  ApoC2 is retained at POPC/TO/W interfaces to higher pressures than 
the other apoCs.   
Retention pressures (ENV) for apoC2, apoC3, and apoC1 were plotted against the POPC 
surface concentration (POPC) of various interfaces (POPC = 0% for a TO/W interface).  
Values for apoC1 were obtained from (Meyers et al., 2013), while values for apoC3 are 
found in Section 6.2.2. 
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apoC2 (Table 5.2).  Similar ΔП,  ПSAT, and ПEX values suggest that the apoCs—perhaps 
due to their similar sizes, structures, and hydrophobic moments (Bolanos-Garcia et al., 
2008; Gangabadage et al., 2008)—remodel lipid surface to a similar extent and saturate 
the surfaces at similar pressures.   
However, apoC2 has the highest retention pressures at lipid/water interfaces of the 
exchangeable peptides we have studied (Table 5.2, Figure 5.13).  The rank order of 
retention pressures for exchangeable proteins at POPC/TO/W interfaces was apoC2 > 
apoC3 ≥ apoC1 > apoA1 > C46.  This indicates that the apoCs are retained up to higher 
surface pressures than many other exchangeable apolipoproteins at the surface of VLDL 
and CM remnants.  ApoC2 has markedly higher retention pressures than apoC1 and 
apoC3 at POPC/TO/W interfaces (Figure 5.13).  The heightened affinity of apoC2 for PC 
lipids is reflected in the ability of apoC2 to remove significantly more PC than the other 
apoCs, on desorption from lipid surfaces (Figure 5.12, inset).  Together, these results 
indicate that protein-phospholipid interactions at the TG surface are strongest between 
apoC2 and PC, giving rise to greater retention pressures than those of the other apoCs.   
Our results suggest that—in normolipidemic subjects—lipid-bound apoC2 can 
activate LPL as the TG in VLDL or CM is consumed and pressure increases.  Strong 
interactions between apoC2 and PC—or the lower pH near the active site of LPL (see 
below)—allow apoC2 to remain bound and activate LPL above pressures at which LPL is 
inactive (Vainio, Virtanen, Kinnunen, Voyta, et al., 1983). This occurs even as other 
proteins with weaker lipid affinity, such as apoC1 and apoC3, desorb from the surface.   
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ApoC3 inhibits LPL (Brown & Baginsky, 1972; Ekman & Nilsson-Ehle, 1975; 
Wang et al., 1985), lipoprotein assembly and secretion (Sundaram, Zhong, Bou Khalil, 
Links, et al., 2010), and lipoprotein remnant uptake (Sehayek & Eisenberg, 1991) and is a 
strong independent predictor of cardiovascular disease (Ooi et al., 2008).  The 
mechanism of LPL inhibition by apoC3 (and apoC1) is unknown, but we speculated that 
apoC1 and apoC3 have a higher affinity that allows them to displace apoC2 from 
lipoproteins and inhibit LPL (Meyers et al., 2013).  Our results (Table 5.2, Figure 5.13) 
invalidate this hypothesis: apoC2 has the greatest affinity for lipoproteins as shown by 
ПENV.  Rather, the plasma concentrations of the apoCs must determine their relative 
ability to bind to—or displace each other from—the surface of TG-rich lipoproteins.   
In a typical individual, plasma concentrations of the apoCs are 80-100 μg/mL 
(apoC3), 60 μg/mL (apoC1), and 30-40 μg/mL (apoC2) (Jong, Hofker, et al., 1999).  At 
these concentrations, the apoCs have no inhibitory effect on LPL in normolipidemic 
subjects (Wang et al., 1981, 1985).  In hypertriglyceridemic patients, plasma apoC3 
levels can increase to > 300 μg/mL while apoC2 levels increase to 50-60 μg/mL (Cohn et 
al., 2004; Huff et al., 1988).  The percentage of total apoC3 on VLDL and CM increases 
from 20% to 50% in normo- versus hyper-triglyceridemic patients (Fredenrich et al., 
1997).  Likewise, LPL was inhibited in vitro by plasma from hypertriglyceridemic 
subjects; and the degree of inhibition correlated with apoC3 levels (Wang et al., 1985).   
At concentrations 5 or 6-fold higher than apoC2, apoC3 may out-compete apoC2 
or LPL through mass-action for binding at the surface of VLDL or CM.  Consistent with 
this, in vitro experiments showed that apoC3 and apoC1 compete with LPL for binding to 
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Intralipid emulsions in a concentration-dependent manner (Larsson et al., 2013).  More 
apoC1 or apoC3 was needed to expel LPL from the surface in the presence of apoC-2.  In 
incubation conditions of 10:1 (wt/wt) apoC3:apoC2, only 30% of aqueous LPL bound to 
Intralipid and there was a 40% reduction in LPL activity compared to incubation 
conditions without apoC3. Other assays showed that LPL activity was abolished at a 20:1 
apoC3:apoC2 molar ratio on co-incubation of apoC3 with apoC2, LPL, and 
phospholipid/TG (1:20 molar ratio) emulsion particles (Jackson et al., 1986).    
We also hypothesized that lipid-bound apoC2 must be flexibile in order to 
regulate LPL.  To test this hypothesis, we used recently-developed protocol (Mitsche & 
Small, 2013; Mitsche et al., 2014) to analyze the surface pressure response of apoC2 at 
TO/W and POPC/TO/W interfaces to washout and compression.  While the pre-washout 
equilibrium pressure (Пeq) varied with the bulk phase concentration of apoC2, the post-
washout pressure of apoC2/TO/W interfaces was a constant (ПWO = 16.60.2 mN/m) 
(Figure 5.10).  These results indicate that there are at least two populations of lipid-bound 
apoC2:  one that is in a concentration-dependent equilibrium with lipid-free apoC2 and 
one that is not.   
Analysis of П/A isotherms of apoC2/lipid/water interfaces during compression 
(Figures 5.4-5.6) shows that the lipid-bound populations of apoC2 differ in conformation.  
As surface pressure increased, apoC2 molecules partially desorbed from lipid/water 
interfaces at areas A ≤ AP and П ≥ ПP, where AP, ПP is a turning point in the isotherms.   
ПP = ПWO, such that apoC2 molecules are in a conformation that maximizes available 
surface area at lower pressures. ApoC2 molecules irreversibly desorb from lipid surfaces 
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at area A ≤ AENV and П ≥ ПENV, where AENV and ПENV are the retention areas and 
pressures.  Between ПP and ПENV, the surface area per apoC2 molecule is decreased and 
apoC2 adopts a second conformation to remain bound to the surface.  ApoC2 helices 
exhibit cooperative binding to lipid surfaces, such that N- and C-terminal fragments of 
apoC2 were unable to adopt multiple conformations on changes in П (Figure 5.7D).     
Since the conformation that is favored at higher pressures occupies less surface 
area, and it is at higher pressures that apoC2 interaction with LPL is critical for lipolysis, 
we speculate that the C-terminal helix of apoC2 desorbs from the lipid-water interface to 
interact with LPL and keep it in an active conformation.  The C-terminal helix of apoC2 
in apoC2:SDS complexes exhibits high levels of motion (Zdunek et al., 2003) and has a 
much lower hydrophobic moment than the N-terminal helix (Amar et al., 2015).  We 
showed that the N-terminal helix of apoC2 has a higher lipid affinity than the C-terminal 
helix; and mediates protein binding to and desorption from lipid surfaces (Figure 5.7).  In 
contrast, the C-terminal helix can be easily displaced from the interface by increases in П, 
such as those induced by adsorption of other protein (Figure 5.7B) or TG hydrolysis.  
 We propose the model in Figure 5.14 for the regulation of LPL by apoC2.  ApoC2 
binds to nascent VLDL and CM and increases the local surface pressure.  Composition 
and looser lipid-packing indicate that CM and VLDL have relatively low П (Ibdah et al., 
1989; Slotte & Grönberg, 1990).  At low П, LPL is active independent of apoC2 (Vainio, 
Virtanen, Kinnunen, Voyta, et al., 1983).  ApoC2 adopts multiple conformations 
differing in residues bound (Figure 5.14).  At lower pressures, apoC2 maximizes 
available surface area such that the both helices are bound to lipid.   
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Figure 5.14. The regulation of LPL by apoC2 strongly depends on lipoprotein П.   
(Left) Newly secreted CM and VLDL have lower surface pressure (П), allowing soluble 
apolipoproteins to bind as they interact in blood plasma.  ApoC2 adsorption increases 
local lipoprotein П.  At low П, bound apoC2 can maximize available surface area and 
both helices are on the lipid surface.  (Middle) As LPL hydrolyzes TG, the lipoprotein 
core shrinks and the surface density of amphipathic molecules increases.  Transient 
accumulation of fatty acids and monoacylglycerols at the surface, coupled with loss of 
large amounts of TG, results in high local П.  This increase in pressure induces 
desorption of the C-terminal helix of apoC2 as less surface area is available to each 
protein molecule.  The C-terminal helix interacts with LPL to promote TG hydrolysis. 
(Right)  ApoC2 desorbs from the lipoprotein surface above its retention (or envelope) 
pressure, and removes some PC lipids with it.  At high П, LPL is inactive without its 
cofactor (marked by a red x).  LPL dissociates from the VLDL or CM remnant. 
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We speculate that apoC2 has stronger affinity for lipid near the site of LPL 
activity, due to lower surface pH.   During LPL activity, fatty acids accumulate at the 
surface.  At a plasma pH (7.4), long-chain fatty acids are one-half ionized, i.e. they form 
an acid soap (Cistola, Atkinson, Hamilton, & Small, 1986; Cistola, Hamilton, Jackson, & 
Small, 1988).  Thus, some fatty acid is deprotonated, i.e. loses a hydrogen ion, as it is 
enzymatically released from the reaction site to the interface.  This release of hydrogen 
lowers the local interfacial pH and could allow apoC2 to bind more strongly.  Our results 
indicate that the lipid affinity of apoC2 increases at lower pH (Figure 5.2A).   
ApoC2 may interact with LPL at lower pressures.  As П increases above the 
partial pressure (ПP) of apoC2, the C-terminal helix of apoC2 desorbs from the 
lipoprotein surface.  This promotes interactions between apoC2 and LPL that keep the 
enzyme in a lipid-bound, active state above its critical pressure (Figure 5.14) (Vainio, 
Virtanen, Kinnunen, Voyta, et al., 1983).  As П increases above the retention pressure 
(ПENV) of apoC2, protein desorbs.  On desorption, apoC2 removes PC (Figure 5.14) and 
transfers to HDL.  HDL accelerated desorption of apoC2:PC lipid complexes from 
phospholipid/water monolayers (Jackson et al., 1979).  In vitro assays also showed that 
apoC2 can transfer from VLDL to HDL during lipolysis (Murdoch & Breckenridge, 
1996).  As apoC2 molecules desorb from VLDL and CM remnants, we speculate that the 
local П is too high for unaided LPL to hydrolyze TG and LPL activity ceases.   
The complex formed by apoC2 and LPL has not been well characterized, since 
the lipid-free forms interact weakly (Shen et al., 2002).  Catalytically active LPL (448 
amino acids) is a non-covalent, unstable homodimer oriented head-to-tail (Osborne, 
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Bengtsson-Olivecrona, Lee, & Olivecrona, 1985; Zhang, Lookene, Wu, & Olivecrona, 
2005).  LPL monomers contain two folding domains—an N-terminal domain (residues 1-
310) that contains the catalytic site and a shorter C-terminal domain (residues 311-448) 
that mediates lipid-binding (Zhang et al., 2005).  However, no high resolution structure of 
LPL is available—only molecular models (Kobayashi, Nakajima, & Inoue, 2002)—and 
the effects of apoC2 on the enzyme’s structure are largely unknown. 
Several results suggest that LPL remains bound to lipoproteins as apoC2 
molecules desorb.  LPL has a higher ПEX than apoC2 at a phospholipid/water interface 
(Vainio, Virtanen, Kinnunen, Voyta, et al., 1983).  Binding assays which monitored 
tryptophan fluorescence showed that LPL has a dissociation constant from vesicles of 
non-hydrolyzable phospholipid that is >100-fold smaller than that of apoC2 (McLean & 
Jackson, 1985).  In experiments using Intralipid, apoC2, apoC3, and LPL, the main 
inhibitory effect of apoC3 on LPL activity was due to decreased binding of LPL to the 
lipid particles, while the presence of apoC2 rescued LPL from being expelled (Larsson et 
al., 2013).  If LPL remains bound to VLDL remnants after apoC2 desorbs, adoption of an 
inactive conformation may facilitate inactivation and disassociation from the surface. 
In summary, we have shown that the apoCs have a higher affinity for lipid than 
many other apolipoproteins, such as apoA1.  ApoC2 has the highest retention pressure at 
lipid/water interfaces, which allows the protein to remain bound to TG-rich lipoproteins 
up to higher pressures as LPL activity increases local surface pressure.  We showed that 
apoC2 exhibits at least two conformations at the lipoprotein surface.  This may allow the 
protein to regulate LPL in a variety of ways that are dependent on surface pressure.      
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6. Chapter 6:  ApoC3 Competes with Lipoprotein Lipase for Lipid Access 
6.1 Probing the Mechanism of Lipoprotein Lipase Inhibition by Apolipoprotein C3 
 Apolipoprotein C3 is a small (79 amino acid), O-glycosylated, secretory protein 
that is synthesized in the liver and intestine from the apoA5/A4/C3/A1 gene locus (Yao 
& Wang, 2012).  ApoC3 is the most abundant apoC in humans that transfers between 
VLDL, chylomicrons, and HDL in circulation (Jong, Hofker, et al., 1999; 
Narayanaswami & Ryan, 2000; Saito, Lund-Katz, & Phillips, 2004). 
Animal and human studies have established a strong, positive correlation between 
plasma apoC3 and TG concentrations, as reviewed in (Ooi et al., 2008; Yao & Wang, 
2012).  The overexpression of human apoC3 in mice enhanced the development of 
atherosclerosis and was associated with elevated TG, low HDL-cholesterol, and low 
apoA1 serum levels (Ito et al., 1990).  Elevated serum apoC3 in transgenic mice was also 
associated with increased rates of hepatic VLDL-TG production, decreased rates of 
VLDL catabolism, and decreased binding of TG-rich lipoproteins to the proteoglycan 
matrix on the surface of endothelial cells (Aalto-Setälä et al., 1992; Desilva et al., 1994).   
 Clinical studies have established the importance of apoC3 as a predictor of 
cardiovascular disease (CVD) outcomes.  Increased serum levels of apoC3 are associated 
with elevated TG levels and in turn insulin resistance, CVD, and type II diabetes 
(Blankenhorn et al., 1990; Gervaise et al., 2000; Hodis et al., 1994; Onat et al., 2003). 
Plasma levels of apoC3 and apoC3 on apoB-containing lipoproteins independently 
predict risk for coronary heart disease, even after control for blood lipids (Blankenhorn et 
al., 1990; Sacks et al., 2000).  Consistent with this, subjects with gain-of-function 
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mutations in the apoC3 gene exhibited hypertriglyceridemia associated with elevated 
plasma levels of apoC3 (Petersen et al., 2010; Pullinger et al., 1997).  In contrast, subjects 
with loss-of-function mutations in the apoC3 gene exhibited reduced plasma TG and 
apoC3 levels (Bochem et al., 2014; Jørgensen et al., 2014; Liu, Labeur, et al., 2000; 
Pollin et al., 2008; von Eckardstein et al., 1991), which had a cardioprotective effect.   
The hypertriglyceridemic effect of human apoC3 is due to its intracellular and 
extracellular roles in TG metabolism, as reviewed in (Ooi et al., 2008; Yao & Wang, 
2012; Zheng, 2014).  Intracellularly, apoC3 promotes TG synthesis and utilization for 
VLDL assembly within the secretory pathway of the ER and Golgi under lipid-rich 
conditions (Sundaram, Zhong, Bou Khalil, Links, et al., 2010).  In insulin-resistant and 
hypertriglyceridemic states, apoC3 expression increases and apoC3 promotes the 
assembly of large VLDL1.  VLDL1 contain a single molecule of apoB-100, other 
apolipoproteins, and a larger quantity of TG than VLDL2, which is typically secreted by 
hepatocytes (Yao & Wang, 2012).  
Extracellularly, plasma apoC3 inhibits the hydrolysis of VLDL and CM by LPL 
and impairs lipoprotein clearance by the liver (Ginsberg & Brown, 2011).  Subjects that 
lack apoC3 have low plasma levels of TG-rich lipoproteins, which were associated with 
highly efficient TG hydrolysis by LPL (Ginsberg et al., 1986).  In one study (Wang et al., 
1985) elevated serum levels of apoC3—but not other apolipoproteins—were strongly 
correlated (r=0.78, P<0.005) with fasting TG levels in hypertriglyceridemic subjects (TG 
> 200 mg/dL).  LPL activity negatively correlated with plasma apoC3 levels, as shown 
by in vitro assays with plasma from these subjects.   
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The mechanism of LPL inhibition by apoC3 is not resolved.  No direct interaction 
has been shown between LPL and apoC3, but evidence indicates that the C-terminal 
domain of apoC3 is responsible for inhibition.  NMR structures of apoC3:SDS complexes 
(Gangabadage et al., 2008) revealed amphipathic helices in the N-terminal (residues 8-
29), central (34-43), and C-terminal (47-66) domains of apoC3 (Figure 6.1).  The C-
terminal helix is a class-A helix rich in aromatic residues (Figure 6.1) and well-suited for 
lipid binding (Segrest et al., 1992).  The other two helices are class G-helices (Figure 
6.1).  The structure of lipid-bound apoC3 is extensively discussed in Section 2.2.3.   
Previous studies (Lambert et al., 1996; Sparrow et al., 1977) used thrombin to 
cleave apoC3 into N- and C-terminal fragments (residues 1-40 and 41-78) and assessed 
their lipid binding and ability to inhibit LPL.  Both peptides were disordered in solution 
and only residues 41-79 showed significant binding to DMPC or POPC vesicles (Sparrow 
et al., 1977).  Helical content increased to 38% at a lipid:protein wt/wt ratio of 3:1 and the 
intrinsic tryptophan fluorescence maximum shifted from 352 to 340 nm, as shown by 
CD.  These results indicate that helical folding is induced as apolar residues in the peptide 
insert into the lipid surfaces.  
A subsequent study (Lambert et al., 1996) showed that residues 41-79 inhibited 
LPL activity in vitro with 73% of the efficacy of full-length apoC3, while residues 1-40 
did not inhibit LPL.  These results indicate that the C-terminal half of apoC3 mediates 
LPL inhibition.  In another study (Liu, Talmud, et al., 2000), lipid binding of the apoC3 
F64A/W65A mutant was impaired, as shown by slower DMPC clearance and larger 
apoC3:DMPC complexes than WT apoC3.  F64A/W65A had greater helical content in  
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Figure 6.1.  ApoC3 sequence (bottom) and structure (top).   
(Bottom)  The sequence of apoC3 (79 amino acids) has a greater number of acidic (12) 
than basic (8) residues, colored red and blue, respectively, which gives the protein a net 
negative charge at neutral pH.  The C-terminal half of apoC3 contains 3 tryptophans, 
which are shown in bold in the sequence.   
(Top)  Helical wheel representations of the 3 large α-helices in lipid-bound apoC3, as 
determined by the NMR structures of apoC3:SDS complexes (Gangabadage et al., 2008).  
Helices 1 and 2 are class G-amphipathic α-helices, but contain apolar faces (marked by a 
dashed line) of 11 and 9 hydrophobic residues (yellow), respectively.  Ala23 in helix 1is 
critical for VLDL assembly (Sundaram, Zhong, Bou Khalil, Zhou, et al., 2010) and has a 
thick, red outline.  Helix 3 is a class-A amphipathic helix and features an apolar face 
(marked by a dashed line) of 8 residues, 3 lysines at the lipid/water interface, and 4 acidic 
residues in a linear array along its polar face.  Lys58 critical for VLDL assembly (Qin et 
al., 2011) and has a thick, blue outline.  Polar residues in all helices are gray; glycine is 
pink.  Hydrophobic residues W42 (helix 2) and F47, L50, W54, F61, F64, W65 (helix 3), 
have thick, black outlines, are highly conserved in mammals (Larsson et al., 2013), and 
were mutated to alanines in the studies described here.  Double and triple substitutions of 
W42, F47, and L50 with alanines significantly reduced the ability of apoC3 to inhibit 
LPL (Larsson et al., 2013). 
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trifluoroethanol (TFE) and a higher inhibitory effect on LPL than WT apoC3.  This 
suggests that apoC3 structure must be retained to inhibit LPL. 
A recent study (Larsson et al., 2013) tested the hypothesis that apoC3 inhibits 
LPL via competition for lipid.  In vitro assays measured the rate of LPL activity and the  
ability of LPL to bind lipid in incubations with apoC3 variants.  Nine apoC3 variants 
were used (Figure 6.2) that differed in the number or location of alanine substitutions at 
highly conserved hydrophobic residues.  These residues were predicted to mediate lipid-
binding; and are L27, V35, W42, F47, L50, W54, F61, F64, and W65.  
In the assays, emulsion particles (10% (w/v) TG isolated from 10% or 20% 
Intralipid) or rat lymph chylomicrons were incubated with LPL and the apoC3 variants 
for 30-45 min.  Lipid hydrolysis was stopped with 10% Triton X-100 and the non-
esterified fatty acids (NEFA) released by LPL activity were monitored using the Wako 
NEFA-HR(2) reagent kit.  Trace amounts of 
125
I-labelled LPL were mixed with LPL and 
added to the same incubation.  After 2 min, the mixture was filtered through a 0.22 μM 
syringe filter, which blocked passage of large, but not smaller, emulsions.  Radioactivity 
in the filtrate corresponded to unbound LPL or LPL bound to small emulsions.   
At a fixed concentration of LPL, apoC3 inhibited LPL binding to, and activity on, 
lipid particles in a dose-dependent manner (Figure 6.3) (Larsson et al., 2013).  The apoC3 
variants showed a decreased ability to inhibit LPL activity (Figure 6.3A), which 
corresponded to a decrease in unbound LPL in the filtrate (Figure 6.3B).  These results 
suggest that apoC3 competes with LPL for space on the lipid surface and prevents LPL 
access to substrate.    
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Figure 6.2.  Sequence alignment of apoC3 from 7 mammalian species.   
Sequence alignment revealed 9 highly conserved residues that are each present in the 
hydrophobic face of one of the helices of apoC3 (Figure 6.1).  These residues, in the 
human sequence, are L27, V35, W42, F47, L50, W54, F61, F64, and W65.  If the lipid-
binding of apoC3 is critical to the protein’s ability to inhibit LPL, mutations in these 
residues could disrupt the lipid-binding of apoC3 and reduce its ability to inhibit LPL.  
To test this hypothesis, the human apoC3 variants L27A/V35A, W42A/F47A, 
F47A/L50A, W42A/F47A/L50A, L27A/V35A/W42A/F47A/L50A, 
W42A/F47A/F64A/W65A, and W54A/F61A/F64A/W65A were expressed in, and 
purified from, E. Coli (Larsson et al., 2013).  The ability of these mutants to bind to lipid 
and inhibit LPL was tested in the in vitro assays described in (Larsson et al., 2013).  
Figure adopted from (Larsson et al., 2013). 
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Figure 6.3.  ApoC3 variants were unable to inhibit LPL activity (A) or prevent LPL 
interaction with lipid particles (B) with the potency of WT apoC3.   
(A) LPL at a concentration of 24 nM was incubated with emulsion particles at a 
concentration of 2 mg TG/mL and apoC3 variants at increasing concentrations.  Protein 
and lipid were incubated for 45 min at room temperature. Free fatty acids were quantified 
via the NEFA-HR(2) reagent kit to determine LPL activity.  ApoC3 variants are listed in 
the plot.  LPL activity decreases as LPL is prevented by apoC3 from binding lipid.    
(B) Trace amounts of 
125
I-labelled LPL were mixed with LPL and LPL was incubated 
with lipid and apoC3 variants as described in (A).  For each incubation condition, the 
radioactivity in the filtrate was measured as a percentage of the radioactivity of the LPL 
added to the incubation and plotted as a function of 100%.  Radioactivity increases as 
LPL is prevented from accessing lipid by apoC3.  Here, data was plotted for WT apoC3 
(♦) and the least inhibitory variant in (A), L27A/V35A/W42A/F47A/L50A (▲).  Figure 
adopted from (Larsson et al., 2013). 
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Changes in the inhibitory potential of apoC3 on LPL activity were paralleled by 
decreases in hydrophobicity (Table 6.1) and induction of helical structure on binding 
DMPC, as monitored by far-UV CD (Figure 6.4).  This result indicates that the 
hydrophobicity and helical structure of apoC3 dictate its ability to bind lipid with 
sufficient affinity to displace LPL. 
In the current work, we used oil-drop tensiometry to study six apoC3 variants: 
WT, F47A/L50A, W42A/F47A, W42A/F47A/L50A, W42A/F47A/F64A/W65A, 
W42A/F47A/F64A/W65A.  This work advanced the previous work (Larsson et al., 2013) 
in several ways:  1) we elucidated the role of helical content on binding of apoC3 to 
interfaces that mimic lipoprotein surfaces; 2) we determined the structure and residues 
essential for apoC3 desorption from lipid, which must occur in the hypertriglyceridemic 
state if LPL is to access the surface of apoC3-rich VLDL; and 3) we showed that lipid 
binding may be necessary for inhibition of LPL, but it is not sufficient.    
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Figure 6.4.  Disruptions in apoC3 secondary structure (A-D) strongly correlate with 
a decreased ability of apoC3 to inhibit LPL (Figure 6.3). 
Far-UV CD spectra were recorded for apoC3 variants at a concentration of 0.2 mg/mL in 
the absence of lipid (○) or in the presence of increasing concentrations of DMPC.  DMPC 
liposomes were added to final concentrations of 0.25 mg/mL (♦), 0.5 mg/mL (Δ), 0.75 
mg (●), or 1 mg/mL (▽).  ApoC3 variants analyzed by CD were WT (A), W42A/F47A 
(B), F47A/L50A (C), and L27A/V35A/W42A/F47A/L50A (D).  Helical content values, 
which are listed in the inset of each panel, were estimated from the spectra by 
CDPro/CDSSTR.  Each spectrum is an average of three scans.  Figure adopted from 
(Larsson et al., 2013).  
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ApoC3 Variant Residues in α-
helices* 
ΔGbi→w [kcal mol
-1
 / res] 
 
ΔGw→o [kcal mol
-1
 / res] 
WT 34-43 0.47 -1.5 
47-65 1.10 -2.6 
 
F47A/L50A 34-43 0.47 -1.5 
 47-65 0.91 -2.1 
 
W42A/F47A 34-43 0.13 -0.9 
 47-65 0.96 -2.4 
 
W42A/F47A/L50A 34-43 0.13 -0.9 
 47-65 0.91 -2.1 
 
W42A/F47A/ 
F64A/W65A 
34-43 0.13 -0.9 
47-65 0.91 -2.1 
 
W54A/F61A/ 
F64A/W65A 
34-43 0.47 -1.5 
47-65 0.42 -1.4 
 
Table 6.1. Transfer free energies of the apolar faces of helices in the apoC3 variants.   
Residues in α-helices were determined from NMR structures and CD analysis, as 
described in Section 2.2.1.  *Residues 8-29 form the N-terminal helix and not directly 
affected by the mutations in the apoC3 variants.  ΔGbi→w = -1.3 and ΔGw→o = -0.42 
kcal/mol*res for this helix.  Here, ΔGbi→w is the average free energy change per residue 
for the hydrophobic face of a helix on transition from a lipid bilayer to water, as 
calculated from the Wimley & White scale (Wimley & White, 1996).  ΔGw→o is the 
average change in free energy per residue for the hydrophobic face of each helix on 
transition from water to oil with values from the Goldman, Engelman, & Steitz scale 
(Engelman et al., 1986).  Positive ΔGbi→w marks an energetically unfavorable transition 
to the lipid-free state, while negative ΔGw→o marks an energetically favorable transition 
to the lipid-bound state.   
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6.2 Results: Aromatic Residues in the C-terminal of ApoC3 Mediate Lipid-Binding 
6.2.1 C-terminal Tryptophans Mediate Modification of Lipid/Water Interfaces by ApoC3 
 This study characterized the effects of the adsorption of six apoC3 variants on the 
surface pressure (П) of lipoprotein-like lipid/water interfaces.  These data reflect the 
ability of apoC3 peptides to bind and insert into the interfaces.  Figure 6.5A shows 
interfacial tension (γ)-time curves for adsorption of the apoC3 variants to the TO/W 
interface.  Peptide adsorption decreased γ to various equilibrium values (γeq) (Figure 
6.5A).  Adsorption curves—similar to those of apoC1 variants—were approximated by 
sigmoidal functions, as described in section 4.3.1.  This sigmoidal behavior indicates that, 
once peptide adsorbs to lipid interfaces at adequate concentrations to change γ, γ 
decreases more rapidly as more peptide adsorbs (i.e., positive cooperativity) until binding 
reaches an equilibrium.  At γeq, lipid-bound peptide is in equilibrium with bulk peptide. 
At a TO/W interface (Figure 6.5), WT apoC3 and double or triple apoC3 point 
mutants showed similar adsorption kinetics (t1/2 varied from 4.1 to 7.1 min and half-width 
w from 1.1 to 1.4 min).  The quadruple point mutants had slower adsorption kinetics, 
marked by larger values of half-time (t1/2= 7.75+0.15 min) and half-width (w= 1.8 min).  
This indicates that the binding of these mutants to apolar lipid surfaces is less cooperative 
than binding of the other apoC3 variants. 
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Figure 6.5.  Loss of C-terminal aromatic residues decreases the ability of apoC3 to 
remodel the TO/W interface:  evidence from equilibrium pressures.  
(A) Representative interfacial tension (γ) versus time curves for adsorption of the six 
apoC3 variants to TO/W interfaces.  16 μL TO drops were formed in 7.0 mL of sodium 
phosphate buffer pH 7.4 and peptides were added to the aqueous (bulk) phase at 
concentrations ranging from 1.2 to 1.5 µg/mL.  γ decreased from the tension of a clean 
TO/W interface (γTO) to an equilibrium value (γeq).  This corresponded to an increase in 
surface pressure (П) from 0 mN/m to Пeq.  Adsorption curves—or, the changes in γ over 
time as peptides adsorbed to TO drops—were approximated by sigmoidal functions: 
γ(t) = γeq + (γi – γeq) / {1 + exp[(t – t1/2) / w ]} 
(B)  For each of the six apoC3 point mutants (colored as in (A)), peptide was injected into 
the bulk phase at various concentrations in a series of experiments similar to those shown 
in (A).  Equilibrium pressure (Пeq) values were plotted against bulk phase concentrations 
of peptide for the six apoC3 variants. 
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 The ability of apoC3 variants to modify the TO/W interface increased with greater 
bulk phase concentration (Figure 6.5B).  As peptide concentration increased, equilibrium 
pressure (Πeq) increased up to a saturation pressure (ΠSAT) at concentrations ≥5 µg/mL.  
These results indicate that lipid-free and lipid-bound forms of apoC3 variants are in a 
concentration-dependent equilibrium that influences Πeq (Mitsche & Small, 2013; Wang 
et al., 2007).  As the concentration of lipid-free peptide increases, so does that of lipid-
bound peptide until—at saturation—no binding sites are available at the lipid surface.  
All peptides saturated the TO/W interface at similar ΠSAT, except WT apoC3 which had a 
ПSAT that was 3 to 5 mN/m higher than ПSAT of the others (Table 6.2). 
 Below saturation, the ability of apoC3 to remodel the TO/W interface—as marked 
by Пeq and multiple bulk phase concentrations—followed the order: WT > F47A/L50A = 
W42A/F47A > W42A/F47A/L50A > W42A/F47A/F64A/ W65A = 
W54A/F61A/F64A/W65A (Figure 6.5B).  This order correlates with the number of 
alanine substitutions, hydrophobicity (Table 6.1), DMPC-bound helical content (Figure 
6.4), and LPL inhibitory potency (Figure 6.3) of the peptides.  
After peptide adsorbs to a TO/W interface, >99% of lipid-free peptide in the bulk 
phase can be removed by a washout of 150 mL (Figure 6.6A).  During a washout, γ of the 
apoC3/TO/W interface increased as peptide desorbed.  Since the lipid-free and lipid-
bound forms of apoC3 variants are in a concentration-dependent equilibrium (Figure 
6.5B), some lipid-bound peptide desorbs from the TO/W interface during washout as 
bulk phase concentration of peptide is reduced to 0 µg/mL.   
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Figure 6.6. Loss of C-terminal aromatic residues decreases the ability of apoC3 to 
remodel the TO/W interface:  evidence from washout pressures.  
(A)  Changes in γ during three washouts after WT apoC3 adsorbed to a TO/W interface.  
WT apoC3 was added to the bulk phase at three time points:  time = 0 min at a 
concentration of 1.43 µg/mL, t = 68 min at 4.29 µg/mL (marked by an asterisk), and t = 
129.5 min at 7.14 µg/mL (marked by an asterisk).  After each addition, apoC3 adsorbed 
to the TO drop and modified γ (or П) by a different amount, dependent on bulk phase 
concentration.   After each adsorption, a washout was conducted (marked by a black bar), 
at a rate of 4.18 mL/min for 36 min to exchange a total of 150.5 mL.  γ increased to a 
post-washout tension (γWO) after each washout, which indicates desorption.  
(B)  For each apoC3 peptide, the post-washout pressure (ПWO) was a constant—
independent of the pre-washout, bulk phase concentration of peptide and Пeq.   For each 
of the six apoC3 variants, a series of experiments similar to (A) were conducted that 
varied in bulk phase concentrations and washout rate and duration.  γWO values were 
converted to ПWO and plotted against pre-washout, bulk phase peptide concentration.    
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Peptide ПSAT 
[mN/m] 
ПWO 
[mN/m] 
WT ApoC3 22.0±0.2 17.7±0.4 
F47A/L50A 18.1±0.2 15.2±0.4 
W42A/F47A 19.0±0.3 15.2±0.3 
W42A/F47A/L50A 17.3±0.4 13.8±0.3 
W42A/F47A/F64A/W65A 18.0±0.3 12.5±0.2 
W54A/F61A/F64A/W65A  13.0±0.4 
Table 6.2.  Properties of the apoC3 variants at the TO/W interface.   
Saturation pressures (ПSAT) were calculated from the data in Figure 6.5 and error bars 
were derived from n=2-3 experiments at saturating concentrations of peptide in the bulk 
phase.  Washout pressures (ПWO) were calculated from the data in Figure 6.6 and error 
bars are the standard deviations from all the data for each peptide.  
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The lower pressure after a washout (ПWO) indicates that protein is at a lower 
surface concentration at the lipid surface.  All apoC3 variants had ПWO values that were 
independent of Пeq (Figure 6.6B, Table 6.2).  This indicates that, for each variant, the 
concentration of peptide at the lipid surface is fixed as the concentration of lipid-free 
peptide is reduced to zero.   Other work from our lab showed that this was true for apoC2 
(Section 5.2.4) and the C-terminal 46 residues (C46) of apoA1 (Mitsche & Small, 2013).  
This suggests that the post-washout, surface peptide concentration does not depend on the 
pre-washout surface concentration for short, helical peptides in general.   
ПWO followed the rank order: WT apoC3 > F47A/L50A = W42A/F47A > 
W42A/F47A/L50A > W54A/F61A/F64A/W65A ≥ W42A/F47A/F64A/W65A.  Together 
with Пeq data (Figure 6.5), this result indicates that, independent of surface concentration 
(which is higher before washout), the apoC3 variants show a reduced ability to insert into 
and modify the TO/W interface.  The severity of impaired lipid binding increases with 
lower lipid (DMPC)-bound structure (Figure 6.4) and hydrophobicity (Table 6.1); and 
correlates with a reduction in the ability of these peptides to compete with LPL for 
binding to TG/PC emulsion particles (Figure 6.3) and CM (Larsson et al., 2013). 
 The ability of apoC3 variants to remodel POPC/TO/W interfaces was determined 
for interfaces of various initial pressures (Пi).  Пi corresponds to POPC surface 
concentration (ΓPOPC), such that ΓPOPC increases with Пi as described in section 3.2.4.  For 
adsorption of each peptide to several POPC/TO/W interfaces, changes in pressure (ΔΠ) 
from Пi to Пeq were recorded and plotted as a function of Πi (Figure 6.7).  Each data set 
was approximated by a linear function to derive exclusion pressures (ΠEX).  
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Figure 6.7.  Loss of C-terminal aromatic residues decreases the ability of apoC3 to 
remodel POPC/TO/W interfaces. 
For a given peptide, adsorption to POPC/TO/W interfaces of various Πi or ГPOPC values 
increased ΔΠ to a different extent.  Each peptide was added to the aqueous phase at 1.25 
or 1.43 µg/mL and ΔΠ values were plotted against corresponding Πi values.  Linear 
regression of the data (shown as solid lines) gave x-intercepts at ΔΠ = 0 mN/m, marked 
by a box. These linear regressions were significant (-0.99 < R < -0.96, p < 0.0001).  X-
intercepts represent ΠEX, the exclusion pressure at which a given peptide cannot bind 
POPC/TO/W interfaces. 
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At most POPC/TO/W interfaces, ΔП followed the same rank order as at a TO/W 
interface (where ΔП = Пeq): WT apoC3 > F47A/L50A = W42A/F47A > W42A/F47A/ 
L50A > W42A/ F47A/F64A/W65A = W54A/F61A/F64A/W65A (Figure 6.7). ПEX 
followed a similar rank order.  At interfaces of higher Пi, the triple and quadruple apoC3 
mutants remodeled the surface to a similar extent, as reflected in ΔП values.  As a result, 
the differences in ПEX for triple and quadruple mutants were insignificant.   
6.2.2 Retention of ApoC3 at Lipid/Water Interfaces is Impaired by C-terminal Mutations 
 This study also characterized the effect of increases in surface pressure on the 
ability of apoC3 variants to remain bound to lipoprotein-like lipid/water interfaces.  
Gradual compressions of apoC3/lipid/water interfaces revealed the pressure range in 
which peptide remained bound to the interfaces and the retention pressures (ПENV) at 
which peptide desorbed.  These volume compressions were recorded and plotted as 
changes in surface area, and mimic LPL activity at the VLDL or chylomicron surface.   
 WT apoC3 and the double and triple mutants showed reversible, conformational 
rearrangement below the retention pressures of lipid surfaces.  Figures 6.8A, 6.9A show γ 
and area changes during gradual, post-washout expansions and compressions of WT 
apoC3 and W42A/F47A/TO/W interfaces.  Peptide adsorbed to the interface and 150 mL 
of buffer was exchanged by a washout to remove peptide from the bulk phase.  After 
washout, the TO drop underwent a series of gradual (1.2 µL/min) expansions and 
compressions (expressed as changes in surface area in Figures 6.8A, 6.9A).   
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Figure 6.8.  WT apoC3 molecules only leave a TO/W interface above ENV.  
(A) Gradual, post-washout expansions and compressions of apoC3/TO/W interfaces.  
ApoC3 was added to the bulk phase at 2.14 μg/mL.  After adsorption to a TO drop 
lowered γ to γeq = 12.1 mN/m, apoC3 was removed from the bulk phase by a 150 mL 
washout (black bar, 6.26 mL/min for 25 min starting at 23.3 min).  Drop volume 
underwent a series of four gradual expansions and compressions, at 1.2 μL/min.  Each 
expansion ended at V = 30.4 μL.  Each compression ended at a smaller volume than the 
previous compression(s)—ending at V = 18.7, 14.1, 9.5, and 6.2 µL. 
(B)  ApoC3 molecules partially desorb before completely desorbing from a TO/W 
interface.  γ values during expansions and compressions in (A) were converted to Π and 
plotted against area.  Expansions and compressions are labeled by color and number, 
starting at 1 for the first post-washout set.  The compression isotherms were smoothed by 
using a spline interpolation of smoothing parameter 0.38.  The first derivative gave slope 
values (dП/dA), which were plotted against area.  dП/dA plots show 1 or 2 two 
significant inflection points, as marked for the third compression isotherm (magenta).  
 209 
 
 
 
Figure 6.9. W42A/F47A apoC3 molecules only leave a TO/W interface above  ENV.   
(A) Gradual, post-washout expansions and compressions of W42A/F47A/TO/ W 
interfaces.  W42A/F47A was added to the bulk phase at 1.94 μg/mL.  Adsorption to a TO 
drop lowered γ to γeq = 13.8 mN/m.  W42A/F47A was removed from the bulk phase by a 
150 mL washout (black bar, 6.26 mL/min for 25 min starting at 31.6 min).  Drop volume 
underwent four gradual expansions and compressions, at 1.2 μL/min.  Expansions ended 
at V ≥ 31.0 μL.  Each compression ended at a smaller volume than the previous 
compression(s)—ending at V = 15.2, 13.3, 11.5, and 6.0 µL.   
(B)  W42A/F47A molecules partially desorb before completely desorbing from a TO/W 
interface.  γ values during the expansions and compressions in (A) were converted to Π 
and plotted against area.  Expansions and compressions are labeled by color and number, 
starting at 1 for the first post-washout expansion and compression.  The compression 
isotherms were smoothed by using a spline interpolation of smoothing parameter 0.38.   
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The γ values during expansion and compression phases were converted to Π and 
plotted against surface area (Figures 6.8B, 6.9B,).  In Figure 6.8B (WT ApoC3/TO/W), 
the first three sets of (i.e., first six) expansions and compressions were reversible and the 
expansion isotherms aligned, as did the compression isotherms.  Hysteresis was observed 
between expansion and compression phases, due to a bend in the expansion isotherms.  
This bend is near A = 30 mm
2
, 2 mm
2
 above the area from which the drop was expanded.  
The bend in the fourth expansion isotherm is at 22.0 mm
2
, but it is 2 mm
2
 higher than the 
area at the start of the previous compression (Figure 6.8B).  This bend suggests that 
apoC3 molecules may expand to occupy larger surface area as it becomes available. 
 The compression П/A isotherms were smoothed by using a spline interpolation of 
smoothing parameter 0.38.  The first derivative was determined at steps of ΔA = 0.2 
mm
2.  Values of slope (dП/dA) were plotted as a function of area for the compression 
isotherms (Figure 6.8B).  The slope profile can show four phases depending on endpoint: 
1) Slope is a constant, negative value.  For the first three compressions, dП/dA ≈ -
0.6 (mN/m)/mm
2
 as area is compressed to A ≈ 33.0 mm2.  The first six expansion 
and compression isotherms overlay at A > 33.0 mm
2
 and the constant slope 
suggests that vacant binding sites created by expansion of the TO/W interface are 
being eliminated at a constant rate during the first phase of compression. 
2) Slope becomes more negative as П changes are larger for each subsequent 
decrease in area.  dП/dA reaches an absolute minimum (marked as (1) for the 
slope profiles of the second and third compression isotherms).  For each 
compression, this mininum occurs at areas equal to the area of the drop before the 
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previous expansion.  This suggests that—during the second phase of 
compression—all vacant binding sites are eliminated and the surface density of 
apoC3 increases until it is equivalent to the post-washout surface density of 
apoC3, relative to surface area.  Consistent with this, П values on the П/A 
isotherms are equal to ПWO at areas corresponding to these minima in dП/dA.   
3) As area continued to decrease, dΠ/dA increased as dΠ became less negative for 
each dA.  The minimum is a turning point (AP, ΠP), beyond which bound apoC3 
molecules at least partially desorb to relax the surface and reduce dΠ for each dA. 
4) The slope reached a constant value near dΠ/dA = 0 (mN/m)/mm2.  This point is 
the envelope point (AENV, ΠENV)—marked as (2) on the slope profile of the third 
compression—beyond which bound apoC3 molecules completely desorb from the 
surface.  Pressure changes were minimized (dΠ/dA ≈ 0 (mN/m)/ mm2) as area 
decreases further, indicating that apoC3 was desorbing into the bulk phase. 
 
Similar to data for apoC2 (Figure 5.5), a comparison of all of the compression 
isotherms in Figure 6.8B indicates that compression of the apoC3/TO/W interface is 
reversible between partial areas AP (equal to the area prior to the previous expansion) and 
retention areas AENV.  This result indicates that part of the lipid-bound apoC3 molecule 
desorbs above the partial pressure (ПP) prior to desorption of the entire molecule above 
the retention pressure (ПENV).   
The third compression (magenta) of the WT apoC3/TO/W interface in Figure 
6.8B ended at A < AENV.  This compression induced desorption of apoC3 molecules from 
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the surface, such that isotherms for the final expansion (navy) and compression (purple) 
isotherms exhibit notable hysteresis from the first six isotherms.  ПP and ПENV values are 
the same for all compression isotherms of the WT apoC3/TO/W interface to A ≤ AENV.  
ПP = 17.2±0.2 mN/m and was approximately equal to ПWO (Table 6.2).  ПENV = 20.4±0.3 
mN/m.  This experiment was repeated (n > 5) at different pre-washout concentrations of 
WT apoC3 and these values were the same.   
 Identical trends were observed in the П/A isotherms of W42A/F47A at a TO/W 
interface (Figure 6.9).  Hysteresis was observed between expansion and compression 
isotherms (Figure 6.9B).  This hysteresis is due to a bend in the expansion isotherms and 
this bend is ~2 mm
2
 above the area from which the drop was expanded (30.0, 29.0, 26.4, 
and 23.8 mm
2
 for the four expansion isotherms).  The hysteresis in W42A/F47A/TO/W 
isotherms was smaller than that in similar isotherms for WT apoC3 (Figure 6.9B); and 
there was no hysteresis between expansion versus compression isotherms for the 
quadruple mutants at a TO/W interface (data not shown).  These results indicate that the 
hysteresis in expansion versus compression isotherms correlates with the ability of 
protein to fold, insert into, and change conformation on changes in surface area.  For 
W42A/F47A at a TO/W interface, ПP = 15.7±0.3 mN/m—approximately equal to the 
ПWO of this interface (Table 6.2)—and ПENV = 18.1±0.3 mN/m.  This experiment was 
repeated (n > 5) at different pre-washout concentrations of W42A/F47A and these values 
were the same.   
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To compare the desorption behavior of the apoC3 variants from lipid surfaces, 
П/A isotherms from compressions to A < AENV at TO/W and POPC/TO/W interfaces—
and the slope of these isotherms—were plotted in Figures 6.10 and 6.11.  At a TO/W 
interface, envelope pressure (ПENV) followed the rank order: WT apoC3 > F47A/L50A = 
W42A/F47A > W42A/F47A/L50A > W42A/F47A/F64A/W65A = W54A/F61A/F64A/ 
W65A (Figure 6.10).  However, the compression isotherms were significantly different, 
as reflected in plots of dП/dA as a function of area for each peptide (Figure 6.10).   
The structure and presence of aromatic residues was essential for apoC3 to adopt 
multiple conformations on interfacial compression.  The four phases described above 
were observed in the slope profiles of the compression isotherms of WT, F47A/L50A, 
W42A/F47A, and W42A/F47A/L50A apoC3 at a TO/W interface (Figure 6.10).  AP and 
AENV are very similar for all four peptides. This result indicates that the peptides occupy 
similar surface areas on the TO drop after adsorption.  However, minimum dП/dA values 
are less negative for the double and triple mutants (dП/dA ≈ -1.2 (mN/m)/mm2) than for 
WT apoC3 (dП/dA ≈ -1.6 (mN/m)/mm2).  Together with with Пeq results (Figure 6.5), 
this result indicates that the mutants do not insert into the surface as well as WT apoC3, 
likely due to loss of secondary structure (Larsson et al., 2013).  
 No pronounced minima are present in the compression isotherms of the quadruple 
mutants at the TO/W interface (Figure 6.10).  Rather, slope is constant (dП/dA ≈ -0.6, -
0.45 (mN/m)/mm
2 
for W42A/F47A/F64A/W65A and W54A/F61A/F64A/W65A) from 
large areas to A ≈ 28.5 mm2 (W54A/F61A/F64A/W65A) or 27.0 mm2 (W42A/F47A/ 
F64A/W65A).  At smaller areas, dП/dA increases and approaches 0 (mN/m)/mm2.    
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Figure 6.10. At the TO/W interface, ПENV and the sensitivity of pressure responses 
to changes in area decrease with loss of helical content in apoC3.   
In separate experiments, all six apoC3 variants were added to the aqueous phase at 
2.0±0.5 µg/mL and adsorbed to a TO/W interface.  After a washout of 150 mL, the 
peptide/TO/W interface was gradually expanded and compressed at a rate of 1.2 µL/min, 
similar to protocol shown in Figures 6.8 and 6.9.  Compressions ended at areas smaller 
than the retention area (A ≤ AENV) to ensure desorption of peptide.  Shown here are П/A 
isotherms from the compression phase, and their slopes.  Slopes were derived as in 
Figures 6.8 and 6.9. 
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Figure 6.11.  At POPC/TO/W interfaces, ПENV and the sensitivity of pressure 
response to area changes decrease with loss of helical content in apoC3.   
In separate experiments, all six apoC3 variants were added to the aqueous phase at 
2.0±0.5 µg/mL and adsorbed to POPC/TO/W interfaces of four initial pressures (Пi).  
These Пi values corresponded to POPC surface concentrations of 34.3% (A), 40.0% (B), 
45.5% (C), and 50.5% (D).  After a washout of 150 mL, each peptide/POPC/TO/W 
interface was expanded and compressed at 1.2 µL/min.  Compressions ended at areas 
smaller than the retention area (A ≤ AENV) to ensure desorption of peptide.   Values of γ 
during the compression phase were converted to Π and plotted against area per POPC 
molecule (APM).  Shown in (A-D) are compression П/APM isotherms and their slopes.   
 216 
 
dП/dA of apoC3/TO/W interface approaches 0 (mN/m)/mm2 at a faster rate for 
W54A/F61A/F64A/W65A than W42A/F47A/F64A/W65A, but AENV is similar for both 
peptides—and is 2-3 mm2 smaller than AENV of the other apoC3 variants (Figure 6.10).  
Together with the absence of defined minima in dП/dA, this result indicates that near-
complete loss of structure in apoC3 abolishes protein response to increases in П on the 
lipoprotein surface and multi-step desorption of the protein from the surface. 
Addition of POPC to the TO/W interface—at various concentrations (ΓPOPC)—
increased retention pressures (ПENV) of each apoC3 variant (Figure 6.12), but did not alter 
desorption behavior of each variant (Figures 6.11) with a few notable differences.   
The presence of POPC at the interface increased the sensitivity of П response to 
changes in area.  The compression isotherms of structured apoC3 variants (WT apoC3, 
the double and triple mutants) exhibit four phases, similar to isotherms at a TO/W 
interface.  However, dП/dA slowly decreases during the first phase (i.e., is not constant) 
as POPC contributes to eliminating regions of TG exposed to the surface.  In addition, 
dП/dA approaches a non-zero, negative constant during the fourth phase of compression.  
As peptide desorbs from the interface, dП/dA ≠ 0 (mN/m)/mm2 since the surface density 
of PC lipid increases.  |dП/dA| during the fourth phase of compression increases for 
interfaces that contain more POPC (Figure 6.11).  The compression isotherms of the 
apoC3 variants W42A/F47A/F64A/W65A and W54A/F61A/F64A/W65A do not exhibit 
minima in slope (Figures 6.11), which further suggests that intact secondary structure is 
required for the ordered, two-step desorption of apoC3 from lipid surfaces. 
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A plot of ПENV—determined as described above at a TO/W interface—as a 
function of ΓPOPC shows this order at POPC/TO/W interfaces:  WT apoC3 = F47A/L50A 
> W42A/F47A > W42A/F47A/L50A ≥ W54A/F61A/F64A/W65A > W42A/F47A/F64A/ 
W65A (Figure 6.12).  At most POPC/TO/W interfaces, F47A/L50A desorption kinetics 
(Figures 6.11B, C) and ПENV (Figure 6.12) are similar to those of WT apoC3.  Together 
with the ПENV differences in the quadruple mutants at POPC/TO/W interfaces, this result 
indicates that W42 is central to the lipid binding of apoC3.  
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Figure 6.12.  Tryptophan 42 enhances apoC3 retention at lipid/water interfaces. 
Experiments similar to those in Figure 3.3 were conducted over a range of Πi values for 
all six apoC3 variants.  Πi values were converted to ΓPOPC, as described previously 
(Mitsche & Small, 2011).  γ values during the compression phase were converted to Π 
and plotted against the area per POPC molecule (APM).  Since the slope profiles of 
compression П/APM isotherms of apoC3 variants at POPC/TO/W interfaces (Figure 
6.11) matched those of compression П/A isotherms at TO/W interfaces (Figure 6.10), the 
retention pressures (ENV) at which apoC3 peptides began to completely desorb from 
POPC/TO/W interfaces were calculated as described in Figures 6.8 and 6.9.  ΠENV values 
were plotted as a function of ΓPOPC for each apoC3 variant.  X- and y-error bars are the 
standard deviation from n = 2-5 experiments. 
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6.2.3 The Washout to Equilibrium Pressure Relation is Independent of Protein Structure 
The post-washout pressure (ПWO) of each apoC3 variant was independent of pre-
washout, bulk phase peptide concentration and Пeq (Figure 6.6).  As discussed in Section 
5.2.4, members of our lab speculated that the independence of ПWO from Пeq for 
exchangeable, helical peptides signifies that at least one population of lipid-bound 
peptide is not in a concentration-dependent equilibrium with lipid-free peptide (Mitsche 
& Small, 2013).  This further suggests that two lipid-bound populations are in a surface 
pressure-dependent equilibrium with each other and may differ in conformation (Mitsche 
& Small, 2013).  This model is shown for apoC2 in Figure 5.11. 
In this model, lipid-bound peptide in the second, less-exchangeable population 
remain bound, while molecules in the first, more exchangeable population desorb during 
a washout as the concentration of lipid-free peptide approaches 0 µg/mL (Mitsche & 
Small, 2013).  A corollary of this model is that bound peptide in the less-exchangeable 
population occupy a larger area, insert deeper, or form more extensive interactions on the 
lipid surface than molecules in the more-exchangeable population. 
As shown in Figures 6.6 and 6.13, ПWO was independent of pre-washout, bulk 
phase peptide concentration (and Пeq) for all six apoC3 variants.  These results strongly 
indicate that the ПWO/Пeq relationship observed for exchangeable peptides is independent 
of the helical content of the peptides.  The multiple lipid-bound states of exchangeable 
peptides may be kinetically related but are not necessarily different structural 
conformations as in the model in Figure 5.11 and in (Mitsche & Small, 2013).  
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Figure 6.13. ПWO is independent of Пeq for every apoC3 variant, independent of 
helical content.  
The pressure profiles, П(t), of peptide/TO/W interfaces during washouts are plotted for 
the most structured peptide, WT apoC3 (A), and one of the least structured peptides, 
W42A/F47A/F64A/W65A (B).  П is plotted from high to low values on the y-axis.  In 
both (A, B), interfaces of various initial peptide surface concentrations (i.e., Пeq) are 
represented.  Washouts exchanged >148 mL of buffer and were conducted at various 
rates and durations, as listed in each panel.  The average post-washout pressures (ПWO) of 
WT and W42A/F47A/F64A/W65A apoC3 at the TO/W interface are listed in Table 6.3.  
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To probe differences in the washout-induced desorption of apoC3 variants, the 
pressure П(t) profiles of WT and W42A/F47A/F64A/W65A apoC3—i.e., the variants 
with the most and least amount of helical content—at the TO/W interface were plotted 
for washouts of various rates, durations, and amounts of buffer exchanged (Figure 6.13).  
ПWO was independent of each of these washout parameters for both WT (Figure 6.13A) 
and W42A/F47A/F64A/W65A (Figure 6.13B) apoC3 at the TO/W interface.     
 Washout П(t) profiles of larger amplitude (Пeq – ПWO) and lower noise were 
approximated by a single exponential decay and the parameters from these fits are shown 
in Table 6.3.  W42A/F47A/F64A/W65A apoC3 desorbed at a faster rate than WT apoC3, 
as shown by quicker times for П to reach ПWO (Figure 6.13) and a larger dissociation rate 
constant (kd) (Table 6.3).  The П(t) profiles of W42A/F47A/F64A/ W65A at a TO/W 
interface showed significantly more noise than those of WT apoC3 at a TO/W interface 
during washouts, such that exponential decay parameters were only determined for the 
П(t) profile of the largest amplitude (Figure 6.13B, cyan).  These results indicate that 
protein that has more helical content better inserts into the lipid surface—as indicated by 
differences in Пeq (Figure 6.5) and ПWO (Figure 6.6)—and therefore desorbs at slower 
rates.    
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Pre-Washout 
Concentration 
[μg/mL] 
Experimental Parameters Parameters from Exponential Fit 
Πeq 
[mN/m] 
ΠWO 
[mN/m] 
Πeq-Πwo 
[mN/m] 
ΠWO 
[mN/m] 
Πeq-Πwo 
[mN/m] 
kd 
[min
-1
] 
R
2
 
WT ApoC3 
0.73 18.8 17.8 1.0 N/A 
1.4 19.2 17.5 1.7  
2.1 19.7 17.4 2.3  
2.1 20.1 17.9 2.2  
2.5 20.3 17.1 3.2 17.2 3.25 0.083 0.99 
4.3 20.9 17.9 3.0 18.0 2.86 0.104 0.97 
7.1 22.0 17.8 4.2 18.0 3.97 0.138 0.99 
Averages  17.6±0.4    0.11±0.02 
W42A/F47A/F64A/W65A ApoC3 
0.59 14.7 12.2 2.5 N/A 
2.4 15.3 12.2 3.1  
2.4 15.6 12.2 3.4     
3.65 15.9 12.5 3.3  
10.1 18.0 12.6 5.4 12.5 5.70 0.317 0.94 
Averages  12.3±0.2     
Table 6.3.  Dissociation properties of WT and W42A/F47A/F64A/W65A apoC3 from 
TO/W interfaces during washout.   
Adsorption and washout data (Пeq, ПWO, Пeq-ПWO) are shown for adsorption of two 
apoC3 variants from a bulk phase of varied protein concentration to the TO/W interface.  
The data correspond to Figure 5.13, and are colored according to the figure.  The washout 
П(t) curves were approximated by a monoexponential decay function.  Experimental 
values of Пeq and ПWO are compared to those from the exponential fit, for washout data 
of low noise (high R
2) and large amplitude (i.e., Пeq-ПWO).   
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6.3 ApoC3 Lipid-Binding is Essential, but not Sufficient, for LPL Inhibition 
Previous studies showed that the C-terminus of apoC3 (residues 41-78) was 
responsible for mediating lipid-binding and inhibiting LPL, while the N-terminus of 
apoC3 plays a limited, secondary role in these functions (Lambert et al., 1996; Liu, 
Talmud, et al., 2000; Sparrow et al., 1977).   In this study, we probed the roles of select 
C-terminal residues and the helical content of apoC3 in lipid-binding to gain novel 
insight into the unknown mechanism by which apoC3 inhibits LPL. 
The loss in helical content of apoC3—modeled by double, triple, and quadruple 
point mutations—resulted in the impaired ability of apoC3 insert into lipid/water 
interfaces.  ApoC3 variants remodeled TO/W (Figure 6.5) and POPC/TO/W (Figure 6.7) 
interfaces by different ΔП, with a rank order of:  WT > F47A/L50A = W42A/F47A > 
W42A/F47A/L50A > W42A/F47A/F64A/W65A = W54A/F61A/F64A/W65A. 
Differences in ΔП were not due to differences in the amount of peptide at the 
interface. After adsorption of the apoC3 variants to these lipid/water interfaces, the 
peptides occupied similar surface areas, as shown by the inflection points occurring at 
similar areas in compression isotherms (Figures 6.10, 6.11).  Differences in ΔП were not 
attributable to differences in the surface density of peptide at the interface.  Peptide 
desorbs from the TO/W interface due to washout, but the post-washout pressures (ПWO) 
follow the same rank order as above for the apoC3 variants (Figure 6.6, Table 6.2).  
The loss of structure in apoC3 resulted in an impaired ability of apoC3 to undergo 
an ordered, two-step desorption from TO/W (Figures 6.8-6.10) and POPC/TO/W (Figure 
6.11) interfaces.  For each apoC3 variant at lipid/water interfaces, the interface could be 
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compressed to retention pressures (ПENV) that were 2-3 mN/m greater than ПWO before 
peptide irreversibly desorbed.  During this interval, peptide could partially desorb from—
and/or exhibit conformational rearrangement on—the interfaces as shown in Figures 6.8 
and 6.9.  These conformational changes were impaired by alanine substitutions and 
abolished in the quadruple point mutants (Figures 6.10, 6.11).  The rate (kd) of apoC3 
desorption from lipid surfaces increased with alanine substitutions (Figure 6.13, Table 
6.3).   
The loss of select aromatic residues impaired the ability of apoC3 to insert into 
and desorb from lipid surfaces to a greater extent than loss of secondary structure alone.  
At POPC/TO/W interfaces, F47A/L50A adopted similar conformational rearrangements 
as WT apoC3 (Figure 6.11) and desorbed at similar ПENV (Figure 6.12), despite having 
lower helical content (Figure 6.4).  These results indicate that F47—perhaps due to its 
location at the N-terminal end of the C-terminal helix—is not as critical as other 
hydrophobic residues for apoC3 insertion into and retention at more polar lipid surfaces.   
In similar studies with apoC1, the change in charge of R23P apoC1 resulted in an 
impaired ability of the peptide to undero conformational rearrangements at the POPC/ 
TO/W interface (Figure 4.7).  This correlated with decreased peptide insertion into the 
interface, as compared to WT apoC1 (Figure 4.3), but did not correlate with structural 
changes.  Peptides of similar helical content (G15P, M38P) behaved similarly to WT 
apoC1.  These data indicate that select residues or charge distribution, in addition to 
helical content, regulate insertion of helices in the apoCs into lipid surfaces.   
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In a previous study, K58E apoC3—a point mutation associated with 
hypotriglyceridemia in humans—showed drastically reduced lipid binding in Fat Western 
lipid protein overlay assays than other apoC3 variants (Qin et al., 2011).  K58E apoC3 
weakly bound phospholipids and did not bind other lipids.  In contrast, WT and K58R 
robustly bound to PE or PC phospholipids and sphingomyelin; and to a lesser extent 
cholesterol and diacylglycerol.  This suggests that the change in charge at the polar/apolar 
boundary of the C-terminal helix was responsible for disrupting protein:lipid interactions. 
From our data for apoC3 and R23P apoC1 variants, we speculate that K58E exhibits a 
reduced ability to insert into lipid/water interfaces due to a change in charge at the 
interface and/or disrupted helical content.  This likely explains the inability of K58E to 
form lumenal lipid droplets, which are essential to VLDL1 assembly (Qin et al., 2011).   
The loss of tryptophans in apoC3 significantly reduced ПENV (Figure 6.12) and 
impaired multi-step desorption (Figure 6.11).  Of these residues, W42 was most critical 
for lipid binding.  W42 is the most hydrophobic residue in the central helix and its loss 
results in 50-70% reduction in the transfer free energy of the helical apolar face (Table 
6.1).  W42A/F47A and W42A/F47A/L50A had significantly lower affinity than 
F47A/L50A and WT apoC3 for POPC/TO/W interfaces (Figures 6.10, 6.11).  Likewise, 
W42A/F47A/F64A/W65A had lower ПENV than W54A/F61A/F64A/W65A at POPC/TO/ 
W interfaces (Figure 6.12).  Since the C-terminal helices in the quadruple mutants have 
similar hydrophobicities (Table 6.1), these results suggest that W42 promotes folding of 
the central helix in apoC3, which is critical to adsorption and desorption at lipid surfaces.    
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At interfaces of higher initial pressure (Пi > 9 mN/m) and POPC surface 
concentration (ΓPOPC > 42%), W42A/F47A/L50A apoC3 remodeled the interface by 
similar ΔП as the quadruple mutants, resulting in similar exclusion pressures (Figure 6.7).  
These results indicate that aromatic residues closer to the central region of apoC3 (W42, 
W54, and F61) are more important for inducing proper protein folding and mediating 
lipid-binding than F64 and W65—residues at the end of the C-terminal helix.  Consistent 
with this, the elimination of these bulky, hydrophobic residues in F64A/W65A apoC3 
resulted in higher peptide helical content (74%) than in WT apoC3 (45%), in the presence 
of 2,2,2-trifluoroethanol (TFE) (Liu, Talmud, et al., 2000).   
Our results show a correlation between the affinity of apoC3 variants for VLDL-
like lipid surfaces and the ability of these peptides to inhibit LPL (Figure 6.3).  This 
provides further support that apoC3 can competitively inhibit LPL via high affinity 
binding to lipid substrate.  In the previous study (Larsson et al., 2013), the cluster of 
W42/F47/L50 was critical for LPL inhibition.  Mutants L27A/V35A (Figure 6.3A) and 
F64A/W65A (Liu, Talmud, et al., 2000) inhibited  LPL with similar potency as WT 
apoC3.  However, mutation of residue pairs L27/V35 or F64/W65 to alanines, in tandem 
with similar mutations in W42/F47, abolished the ability of apoC3 to inhibit LPL at any 
concentration (Figure 6.3A) which was associated with an increase in LPL binding to 
substrate at levels similar to control (Figure 6.3B).  These results indicate that loss of N- 
or C-terminal hydrophobic residues do not impair the ability of apoC3 to compete with 
LPL for lipid substrate, unless these mutations are compounded by mutation in W42.  
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In previous studies (Larsson et al., 2013; Liu, Talmud, et al., 2000), F64A/W65A 
and W54A/F61A/F64A/W65A apoC3 inhibited LPL activity on Intralipid with similar 
potency as WT apoC3 at all concentrations ≤ 4 µM.  This is shown for the quadruple 
point mutant in Figure 6.3A.  However, this inhibition cannot be due to a competition for 
lipid.  F64A/W65A bound PC lipid with significantly lower affinity than WT apoC3, as 
marked by larger peptide:DMPC particles (80Å versus 61Å in average radii) and slower 
DMPC clearance with more peptide free in solution at the end of the assay (Liu, Talmud, 
et al., 2000).  Likewise, W54A/F61A/F64A/W65A bound PC lipid and TG with 
significantly lower affinity than WT apoC3, as discussed above.   
These results indicate that the binding of apoC3 to lipid is not sufficient to inhibit 
LPL.  One hypothesis is that the inhibition of LPL by apoC3 is due to protein:protein 
interactions (Pownall & Massey, 1986).  However, no interactions between apoC3 and 
LPL have been shown.  Changes in the charge of the C-terminal helix in mutations 
(D66N, K51A) did not influence LPL inhibition by apoC3 (Larsson et al., 2013).  These 
results indicate that the C-terminal helix of apoC3—despite the enrichment of acidic 
residues at its polar face—does not interact with LPL through charge-charge interactions, 
nor does apoC3 repel LPL due to differences in protein charge.   
One possibility is that W42 and other hydrophobic residues in F64A/F65A and 
W54A/F61A/F64A/W65A apoC3 induce proper folding in most of the protein sequence 
on emulsion particles isolated from 10% or 20% Intralipid—and this is sufficient to 
prevent LPL from binding.  At large areas (A ≥ 36 mm2 at a TO/W interface) on 
compression isotherms, W54A/F61A/F64A/W65A induced greater pressure changes in 
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TO/W (Figure 6.10) and POPC/TO/W (Figure 6.11) interfaces than the other apoC3 
mutants.  These results suggest that at low pressures (П < 10 mN/m), this quadruple 
mutant may insert into lipid surfaces and prevent LPL from binding with similar potency 
as WT apoC3 (Figure 6.3A).  However, this is inconsistent with the slower adsorption 
kinetics (Figure 6.5A) and low degree of interfacial remodeling (Figures 6.5-6.7) of 
W54A/F61A/F64A/W65A relative to WT apoC3, which reflects the ability of the peptide 
to compete with LPL for lipid binding.  In summary, mutations in aromatic residues at 
the end of the C-terminal helix likely impair the lipid-binding, but not the LPL inhibition, 
of apoC3 in vivo (Larsson et al., 2013; Liu, Talmud, et al., 2000).  Mechanisms by which 
apoC3 inhibit LPL that are independent of substrate competition merit further study. 
From our results, we propose the following model for LPL regulation by apoC3.  
In normolipidemic individuals, plasma concentrations of apoC3 are 80-100 μg/mL (Jong, 
Hofker, et al., 1999; Wang et al., 1985).  At these concentrations, most (60%) of plasma 
apoC3 is localized to HDL (Fredenrich et al., 1997) and apoC3 has no inhibitory effect 
on LPL (Wang et al., 1981, 1985).   
In the hypertriglyceridemic state, the expression of apoC3 is up-regulated by 
glucose and/or loss of insulin sensitivity (Yao & Wang, 2012).  Plasma apoC3 levels 
increase to > 300 μg/mL (Cohn et al., 2004; Huff et al., 1988).  In addition, the 
percentage of total apoC3 on TG-rich lipoproteins increases from 20% to upwards of 
60% in hypertriglyceridemic patients (Fredenrich et al., 1997).  This enrichment of 
apoC3 on VLDL is likely to occur in the hepatocyte as apoC3 promotes VLDL1 
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maturation through fusion of TG-rich lipid droplets in the Golgi with nascent VLDL (Qin 
et al., 2011; Sundaram, Zhong, Bou Khalil, Links, et al., 2010).   
Our results indicate the apoC3 inserts tightly into the surface of VLDL (Figures 
6.5-6.7).  ApoC3 adopts multiple conformations as П increases (Figures 6.8-6.11), such 
that it is likely to remain bound to VLDL as the particle acquires other exchangeable 
apolipoproteins from plasma and local П increases.  ApoC3—enriched at the surface—
prevents LPL from binding to VLDL (Figure 6.3), hydrolyzing TG, and inducing changes 
in П required to displace apoC3 from the surface.  We showed that apoC2—the LPL 
cofactor—has a higher affinity for lipid surfaces than apoC3 (Chapter 5), such that apoC3 
is unlikely to inhibit LPL via displacement of apoC2 from VLDL.  ApoC3 on VLDL may 
prevent apoC2 binding to the surface, as apoC3 plasma levels are 6-fold higher than 
apoC2 levels in hypertriglyceridemic subjects (Cohn et al., 2004; Huff et al., 1988).   
In summary, this work characterized the behavior of six apoC3 variants at 
lipid/water interfaces mimicking the VLDL surface.  We determined the role of helical 
content and select aromatic residues on the binding of apoC3 to these interfaces.  We 
correlated these results with in vitro LPL activity assays with the same variants (Larsson 
et al., 2013) and proposed a model for  the pronounced inhibition of LPL by apoC3 in the 
hypertriglyceridemic state (Wang et al., 1985).   
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7. Chapter 7:  Conclusions from Structure-Function Studies of the ApoCs 
The major goal of this thesis was to determine the biophysical characteristics (i.e., 
adsorption, desorption, conformational rearrangement) of the apoCs at lipid surfaces that 
mimic the lipoprotein surface and correlate differences in lipid affinity with differences in 
protein structure.  We used apoC1 point mutants (Chapter 4), N- and C-terminal 
fragments of apoC2 (Chapter 5), and apoC3 point mutants to probe the role of secondary 
structure in, and protein regions responsible for high-affinity lipid-binding.  This chapter 
will highlight significant differences in the lipid affinities of the WT apoCs. 
 Two studies (Bolanos-Garcia et al., 2008; Krebs et al., 1983) used a Pockels-
Langmuir surface balance to probe the affinity of the human and rat apoCs for the 
air/water (A/W) and egg PC/A/W interfaces.  The apoCs have similar affinities for these 
interfaces, as compared to each other and across species.  The apoCs had similar 
exclusions pressures (ПEX), adsorption-induced pressure changes (ΔП), and saturation 
pressures (ПSAT) at A/W and PC/A/W interfaces.  At the A/W interface, ПSAT ≈ 24 and 23 
mN/m for rat apoC2 and apoC3, respectively (Krebs et al., 1983).  In comparison, the 
human apoCs saturated the A/W interface at surface concentrations of 1.5 mg/m
2
 and 
ПSAT of 23.5 (apoC1), 25.0 (apoC2), and 26.5 (apoC3) mN/m (Bolanos-Garcia et al., 
2008).  These studies did not characterize desorption of the apoCs from the interfaces.  In 
this chapter, we compare our results for the adsorption of the apoCs to lipid/water 
interfaces with these previous results.  We discuss our results for desorption of the apoCs 
from lipid surfaces and conclude with a discussion of the physiological implications.  
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7.1: The ApoCs Remodel Lipid/Water Interfaces by a Similar Extent 
In our studies, at the TO/W interface, ПSAT = 22.0±0.5 mN/m and the surface was 
saturated at similar aqueous phase concentrations (>7 µg/mL) for all three apoCs (Figure 
7.1A).  The ПSAT of apoC1 (~19.0 mN/m in Figure 7.1A) increased by ~2.5 mN/m to 
approach ПSAT of the other apoCs when apoC1 was added to the bulk phase from stock 
solution of 2.5 mg/mL protein in HFIP.  This result indicates that increasing amounts of 
HFIP may increase ΔП by acting at the interface or increasing the helical content of 
protein.  At apoC concentrations < 2 µg/mL, HFIP did not influence adsorption behavior 
as apoC1 (added from phosphate buffer) modified TO/W (Figure 7.1A) and POPC/TO/W 
(Figure 7.1B) interfaces by similar ΔП as apoC2 and apoC3 (added from HFIP).  The 
possible effects of HFIP on protein:lipid interactions are discussed in Appendix D.   HFIP 
did not influence multi-phase desorption behavior, ПP, ПENV, or ПWO of the apoCs.  
A saturation pressure of 22.0±0.5 mN/m for each apoC at the TO/W interface is 
1-2 mN/m lower than the average ПSAT of the apoCs at A/W and PC/A/W interfaces 
(Bolanos-Garcia et al., 2008; Krebs et al., 1983).  This small difference is likely due to 
differences in interfacial properties and differences intrinsic to the instruments used, 
which are discussed in Section 3.1.   
The apoCs modified POPC/TO/W interfaces to a similar extent, as marked by ΔП 
values (Figure 7.1B).  This resulted in similar exclusion pressures (ПEX) at POPC/ TO/W 
interfaces: ПEX = 32.3, 30.9, and 31.5 mN/m for apoC1, apoC2, and apoC3 (Figure 7.1B).  
Consistent with these results, ПEX = 31.3, 33.1, and 33.6 mN/m for rat isoforms of 
apoC3, glycosylated apoC3, and apoC2 at a PC/A/W interfaces (Krebs & Phillips, 1983).   
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Figure 7.1:  The apoCs bind to and modify lipid surfaces to a similar extent.  
(A) For each of the apoCs (apoC1, apoC2, apoC3), peptide was added to the aqueous 
phase (6 or 7 mL of 5 mM sodium phosphate buffer, pH 7.4) at various concentrations.  
ApoC1 was added from stock solution of 1.0 or 2.5 mg/mL protein in phosphate buffer.  
ApoC2 and apoC3 each were added from stock solutions of 2.5 or 5.0 mg/mL protein in 
HFIP.  Protein adsorption to a TO/W interface increased pressure by ΔП, which was 
plotted against bulk phase concentration.   
(B) The ability of each apoC to bind to and modify POPC/TO/W interfaces was 
determined at several POPC surface concentrations (ΓPOPC).  For POPC/TO/W interfaces 
of different initial pressures (Πi), which correspond to different ΓPOPC, the change in 
pressure (ΔΠ) from adsorption of each apoC peptide (added at 1.50±0.25 µg/mL, i.e. 
1.25x10
-7M, to the aqueous phase) was recorded.  ΔΠ values were plotted against Πi for 
each apoC.  Linear regression was applied to each data set and was significant (R
2
 ≥ 
0.95).  The x-intercept is the exclusion pressure (ΠEX).  
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Altogether, these ΔП, ПSAT, and ПEX results reflect similarity in the ability of all 
three apoCs to bind and insert into lipid surfaces, which could be due to the similar 
lengths, structures, and mean hydrophobicities of the apoCs.  
 
7.2: ApoC2 Desorbs from Lipid Surfaces at Higher Pressures than ApoC1, ApoC3 
In contrast to adsorption, desorption was distinct for each apoC at TO/W (Figure 
7.2) and POPC/TO/W (Figure 7.3) interfaces.  At the TO/W interface, П/A isotherms 
overlapped from A < 33 mm
2
 to A ≈ 30 mm2, П ≈ 18.2 mN/m (Figure 7.2).  This result 
indicates that the apoCs occupy similar surface areas after adsorption to the TO/W 
interface.  As area decreased from 30 mm
2
, apoC1 desorbed at a retention area of AENV = 
28.5±0.5 and pressure of ПENV = 18.5±0.5 mN/m (Figure 7.2).  For apoC2 and apoC3, П 
increased until each peptide desorbed at AENV = 27.5±0.5, ПENV = 20.4±0.3.  These 
results indicate that apoC2 and apoC3 are better able to insert into the TO/W interface 
and remain bound at higher pressures. 
 POPC enhanced the affinity of apoC2 for the lipid surface to a significantly 
greater extent than the other apoCs.  ApoC2 desorbed from POPC/TO/W interfaces at 
ПENV values that were 2 to 2.5 mN/m larger than those of apoC1 and apoC3 (Figures 7.3 
7.4).  In addition, apoC2 removed PC lipid on desorption with greater than two-fold 
efficacy of the other two apoCs (Chapter 5).  These results indicate that apoC2 has the 
greatest affinity for PC lipid, allowing it to remain bound up to higher retention pressures. 
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Figure 7.2.  ApoC1 desorbs from a TO/W interface at lower П than apoC2, apoC3.  
Pressure/Area (П/A) isotherms were plotted for each apoC adsorbed to the TO/W 
interface.   For each apoC, peptide was added to the bulk phase at 2.0±0.5 µg/mL and 
adsorbed to a TO/W interface.  After washout, the peptide/TO/W interface was expanded 
and then compressed at a rate of 1.2 µL/min.  Compressions ended at areas smaller than 
the retention area (A ≤ AENV) to ensure desorption of peptide. The experiment was 
repeated multiple times (n > 5) for each apoC.  Shown here are П/A isotherms that 
represent a typical compression phase of each apoC/TO/W interface.  First derivatives of 
the smoothed isotherms are shown at the bottom.  These data were highly reproducible, 
as shown in n ≥ 5 experiments for each apoC at a TO/W interface. 
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Figure 7.3.  ApoC1 and apoC3 desorb at smaller П than apoC2 on compression of 
POPC/TO/W interfaces.  
In separate experiments, all three of the apoCs were added to the bulk phase at 2.0±0.5 
µg/mL and adsorbed to POPC/TO/W interfaces of three initial pressures (Пi).  These Пi 
values corresponded to POPC surface concentrations (ΓPOPC) of 35.5% (A), 41.0% (B), 
and 46.2% (C).  After a 150-mL washout, each peptide/POPC/TO/W interface was 
expanded and compressed at 1.2 µL/min.  Compressions ended at areas below retention 
areas (A ≤ AENV) to ensure desorption of peptide.   Values of γ during compression were 
converted to Π and area values were converted to area per POPC molecule (APM).  
Shown in (A-C) are П/APM isotherms, and their slopes, from the compression phase. 
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Figure 7.4.  ApoC2 is retained at POPC/TO/W interfaces to higher pressures than 
the other apoCs.   
Retention pressures (ENV) for apoC2, apoC3, and apoC1 were plotted against the POPC 
surface concentration (POPC) of various interfaces (POPC = 0% for a TO/W interface).   
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In contrast to apoC2, apoC3 exhibited a binding preference for TG in lipid 
surfaces.  At all POPC/TO/W interfaces, apoC3 compression isotherms overlap with 
those of apoC2 at large areas (Figure 7.3).  As area decreases, slope does not change as 
rapidly for apoC3 as for apoC2 isotherms.  ApoC3 isotherms diverge from those of 
apoC2 and eventually overlap with those of apoC1 (Figure 7.3).  These results indicate 
that PC does not significantly enhance the affinity of apoC3 for lipid surfaces. 
The preference of apoC3 for the TO/W interface was also evident in washout 
behavior (see below).  Independent of protein surface concentration or washout rate, 
apoC3 desorbed from the TO/W interface with a rate constant of kd = 0.11 min
-1. 
 In 
contrast, apoC2 and apoC1 desorbed faster with kd ≈ 0.37 min
-1
.  This indicates that the 
preference of apoC3 for TG results in slower dissociation from more apolar surfaces.  In 
the C-terminal helix of apoC3, aromatic residues comprise 7 of the 9 residues in the 
apolar face, which results in a highly favorable free energy of transfer from water to lipid 
surfaces.  We speculate that these residues can insert into the TG core of VLDL and CM, 
keeping the protein bound at high pressures and retarding dissociation. 
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7.3: Physiological Implications from Differences in Lipid Affinities of the ApoCs 
These results have several novel physiological implications, as shown in Figure 
7.5.  ApoC2 has the highest lipid affinity (Figure 7.5A), such that apoC1 and apoC3—at 
normolipidemic levels in plasma—do not inhibit LPL via displacement of apoC2 from 
the surface of TG-rich lipoproteins.  Rather, the plasma concentrations of the apoCs must 
determine their ability to displace each other from the surface of TG-rich lipoproteins.   
In a typical individual, the apoCs have no inhibitory effect on LPL in 
normolipidemic subjects (Wang et al., 1981, 1985).  The higher affinity of apoC2 for PC 
may allow it to remain bound near the site of LPL activity as surface pressure increases 
during TG hydrolysis.  In hypertriglyceridemic patients, plasma apoC3 levels can 
increase to > 300 μg/mL and apoC2 levels increase to 50-60 μg/mL (Cohn et al., 2004; 
Huff et al., 1988).  The percentage of total apoC3 on TG-rich lipoproteins increases from 
20% to 50% in normo- versus hyper-triglyceridemic patients (Fredenrich et al., 1997).  At 
these 5- to 6-fold higher concentrations, apoC3 likely out-competes apoC2 or LPL for 
binding at the surface of VLDLs or chylomicrons  (Figure 7.5B).  LPL inhibitory activity 
of the lipoprotein of plasma from hypertriglyceridemic subjects strongly correlated with 
elevated levels of apoC3 (Wang et al., 1985).   
ApoC3 has the highest affinity of the apoCs for the TO/W interface, but its lipid 
affinity is enhanced the least by PC lipid.  This provides a basis for the role of apoC3 in 
promoting VLDL synthesis (Yao & Wang, 2012), described in Section 2.4.3.  Our results 
indicate that apoC3 is ideally suited to bind TG in order to form lumenal lipid droplets 
(LLDs).  It was previously shown that the C-terminal helix of apoC3 promotes formation  
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Figure 7.5.  Regulation of VLDL and chylomicron metabolism by the apoCs.   
(A)  ApoC2 has the highest lipid affinity, allowing it to interact with LPL and tolerate 
changes in surface pressure induced by enzyme activity.  The apoCs bind to nascent 
VLDL and chylomicrons in plasma.  ApoC3 preferentially binds to TG-rich regions.  Due 
to similar sizes and structures, the apoCs remodel lipid surfaces to a similar extent.  As 
LPL hydrolyzes TG in the particle core, particle size decreases while surface pressure 
increases.  Each apoC exhibits multiple conformations, such that one of its helices may 
desorb from lipoprotein surfaces as pressure increases.  For apoC2, the C-terminal helix 
likely desorbs to interact with LPL and promote its activity.  The C-terminal helices of 
apoC1 and apoC3 anchor each protein to lipid surfaces, while the N-terminal helices 
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desorb.  As surface pressure continues to increase, apoC1 and apoC3 desorb at lower 
retention pressures than apoC2.  The enhanced affinity of apoC2 for PC lipid allows it to 
be retained up to higher pressures.  Desorption of apoC2:PC complexes likely triggers the 
inactivation of LPL and release of the enzyme from remnant particles.   
(B)  In the hypertriglyceridemic state, apoC3 competes with apoC2 and/or LPL for lipid 
binding to inhibit LPL.  The expression of apoC3 is significantly upregulated in the 
hypertriglyceridemic, insulin-resistant state.  As a result, the levels of apoC3 are 
increased by >5-fold in plasma and by >7-fold on VLDL and chylomicrons (see text).  
The higher plasma levels of apoC3, likely allow the protein to compete with apoC2 
and/or LPL for binding to the lipoprotein surface via mass-effect.  In addition, higher 
levels of apoC3 on TG-rich lipoproteins may prevent LPL from accessing substrate.    
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of LLDs in post-ER compartments, while the N-terminal helix of apoC3 promotes fusion 
of these LLDs with VLDL precursor (Qin et al., 2011).  We showed that tryptophans in 
the C-terminal half mediate adsorption and desorption of apoC3 to lipid surfaces, which 
is likely essential for the formation of LLDs.   
We also identified the lipid-anchoring regions in the other apoCs.  As shown with 
peptide fragments (Section 5.2.3), the N-terminal helix of apoC2 mediates adsorption and 
desorption from lipid surfaces.  As shown by a comparison of ПENV at POPC/TO/W 
interfaces for M38P and G15P—apoC1 mutants with similar secondary structure—the C-
terminal helix of apoC1 mediates desorption from lipid surfaces (Section 4.3.2).  These 
helices represent the region of highest hydrophobicity in each apoC, which likely 
determines its higher lipid affinity. 
 We showed that apoC1 (Section 4.3.2), apoC2 (Section 5.2.2), and apoC3 
(Section 6.2.2) exhibit at least two conformations at lipid surfaces, such that as pressure 
increases helices can desorb from the interface.  Loss of structure by point mutants in 
apoC1 and apoC3 abolish this conformational flexibility; and it was not present in the N- 
and C-terminal fragments of apoC2 (Section 5.2.3).  These results demonstrate that the 
intact, bi-helical structure of each apoC is essential for mediating adsorption, desorption, 
and conformational rearrangement at lipid surfaces (Figure 7.5A).  
These results have several novel physiological implications.  The ability of the C-
terminal helix of apoC2 to desorb from the lipid surface as pressure increases likely 
facilitates its ability to interact with LPL and promote activity above the enzyme’s critical 
pressure, as discussed in Section 5.3.  In the hypertriglyceridemic state,VLDL is secreted 
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rich in apoC3 (Yao & Wang, 2012).  The C-terminus of apoC3 likely anchors it to the 
VLDL surface, even as pressure increases due to adsorption of apolipoproteins and the 
conformation of the N-terminus changes.  As a result, apoC3 prevents LPL access to TG 
substrate and inhibits the enzyme (Larsson et al., 2013).  A two-helix arrangement, in 
which one helix binds lipid with higher affinity, is the critical structural motif for 
promoting ABCA1-mediated cholesterol efflux in the apoCs (Smith, Segrest, & 
Davidson, 2013).  We speculate that the ability of at least one helix in each apoC to 
desorb from lipid surfaces is essential to facilitate lipid movement in cholesterol efflux. 
7.4 Future Directions 
Several future directions are warranted by these studies.  Our studies of apoC2 
and apoC3 point mutants indicate that loss of select hydrophobic residues and/ore helical 
structure impairs lipid binding properties.  Similar tensiometry studies with apoC2 point 
mutants K19T, W26R, or E38K and apoC3 point mutants A23T, Q38K, or K58E, which 
alter the plasma lipid profile in human carriers, would provide a direct correlation from 
decreased lipid affinity to loss of in vivo function.   Tensiometry studies of inactive and 
active isoforms of LPL—in the presence and absence of each apoC—would test models 
of LPL regulation supported by the current work.  These studies could adopt protocols 
used in tensiometry studies of pancreatic lipase and colipase at an oil/water interface 
(Labourdenne et al., 1997; Labourdenne, Brass, Ivanova, Cagna, & Verger, 1997).  
Finally, the fluorescence of probes attached to proteins could be monitored at the drop 
surface.  Each apoC could be labeled at various regions with environment sensitive (i.e. 
lipid-bound or detached) probes to determine its ability to adopt multiple conformations. 
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A. Appendix A: Regulation of ApoC Gene Expression 
Regulation of ApoC1 and ApoC2 Gene Expression 
The expression of genes in the apoE/C1/C2/C4 cluster is regulated by two 
homologous hepatic control regions (HCR-1 and HCR-2), of 350 bp each (Figure A.1) 
(Zannis et al., 2001a; Zannis, Kan, Kritis, Zanni, & Kardassis, 2001b).  Experiments with 
transgenic mice showed that either region will drive expression of all four apolipoprotein 
genes, but HCR-1 had a dominant effect on expression of apoE and apoC1, while HCR-2 
had a dominant effect on expression of apoC2 and apoC4 (Zannis et al., 2001a, 2001b).  
However, HCR-1 promoted apoC2 expression, via the apoC2 promoter region, in human 
hepatocytes (Hep2G) (Vorgia, Zannis, & Kardassis, 1998).  Co-transfection experiments 
showed that HCR-1 enhanced the strength of the apoC2 promoter in HepG2 cells by 2.5-
fold, but had no effect in intestinal (CaCo) 2 cells nor in fibroblasts (COS-1) in the 
absence of hepatocyte nuclear factor (HNF)-4.   
The 545-nucleotide long intergenic sequence between the apoC4 and apoC2 genes 
is the proximal promoter for apoC2 and contains five regulatory elements designated A-E 
(Vorgia et al., 1998).  Element B contains a hormone response element (HRE) that is 
recognized by HNF-4 and element C contains an HRE with different spacing that is 
recognized by apoA1 regulatory protein (ARP)-1 and v-erbA-related (EAR)-2 (Figure 
A.1) (Zannis et al., 2001a).  These factors positively regulate transcription.   
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Figure A.1. Schematic representation of the apoE/C1/C4/C2 gene cluster.  
The different regions required for tissue-specific expression of genes in the cluster are 
shown. ApoCI’ indicates the position of the apoC1 pseudogene.  The regulatory elements 
and factors of the hepatic control region (HCR)-1, 2, the multienhancer (ME)-2, and the 
human apoC2 promoter regions that regulate gene transcription in vivo are shown. ME-1 
is not shown, but is ~4 kb upstream of the apoC1 gene.  Figure adapted from (Zannis et 
al., 2001a). 
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Transactivation of the apoC2 promoter involves synergistic interactions of HNF-4 
bound to distal HCR-1 sites and HNF-4 or other factors bound to elements B and C. 
HNF-4 trans-activated the apoC2 promoter/HCR-1 cluster in COS-1 cells 33-fold versus 
9-fold trans-activation achieved with the apoC2 promoter alone (Vorgia et al., 1998). 
HCR-1-mediated transcriptional enhancement of the apoC2 promoter was reduced 
from 11- to 2.5-fold by deletion or point mutations of the HRE in element C and 
abolished by elimination of the HREs in elements B and C.  The HCR-1/apoC2 promoter 
cluster is induced by bile acids and retinoids (Kardassis et al., 2003).  Chenodeoxycholic 
acid (CDCA) and retinoic acid increased steady-state apoC2 mRNA levels in HepG2 
cells through interaction with the farnesoid X receptor α (FXRα)/retinoid X receptor α 
(RXRα) heterodimer.  This heterodimer interacts with a novel inverted repeat (IR-1) 
present in HCR-1.  Transactivation of the HCR-1/promoter cluster by CDCA was 
abolished by mutations in either the IR-1 repeat or in the HREs of the apoC2 promoter. 
Two homologous multienhancer regions (ME-1 and ME-2), each 620 bp long,  
buttress the apoC1 gene (Figure A.1).  These regions were shown to regulate apoE 
expression in macrophages,  adipocytes, the brain, and skin (Zannis et al., 2001).  
Functional response elements for RXR and LXR have been identified in the HCRs and 
MEs (Laffitte et al., 2001). RXR and LXR are nuclear orphan receptors that form 
heterodimers, have specific oxysterols as ligands, and interact with LXR response 
elements (LXREs) to up-regulate the expression of ABC transporters (ABCA1, ABCG1) 
and other proteins in response to the lipid loading of macrophages.  The RXR/LXR 
heterodimer, in response to oxysterol ligands, induced a 2-14-fold increase in expression 
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of all genes in the apoE/apoC1/apoC2/apoC4 cluster in murine and human macrophages 
(Mak et al., 2002).  The induction of all four mRNAs was attenuated in macrophages 
derived from LXRα/β-null mice.  Vector constructs of ME-1 or ME-2 upstream of the 
apoC2 promoter were transfected in HepG2 hepatocytes and, in response to LXR/RXR 
ligands, promoted expression of apoC2 (Mak et al., 2002).  In sum, activated LXR 
promotes apoE, apoC1, and apoC2 expression in macrophages to promote lipid efflux. 
Expression of apoC2 is negatively regulated by PPAR-α.  Peroxisome-
proliferator-activated receptors (PPARs) are members of the nuclear receptor superfamily 
of ligand-activated transcription factors that mediate storage and catabolism of fatty acids 
(Kliewer, Xu, Lambert, & Willson, 2001). Fibrates activate PPAR-α, resulting in 
increased lipoprotein lipolysis, reduction of hepatic TG production, increased uptake of 
LDL, and increased HDL production (Kei et al., 2012).  Fenofibrate treatment in rats 
inhibited hepatic, but not intestinal, apoC2 gene expression in a dose- and time-dependent 
manner (Weinberg et al., 2002).  Similarly, fenofibrate administration in humans results 
in significant reductions in plasma apoC2 (Malmendier et al., 1989).  Fenobric acid, the 
active metabolite of fenofibrate, also reduced apoC2 mRNA levels in human and rat 
hepatocytes (Weinberg et al., 2002). 
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Regulation of ApoC3 Gene Expression 
The expression of apoC3 is significantly up-regulated in insulin-resistant, hyper-
triglyceridemic states.  Cell-culture studies showed that the apoC3 promoter has four 
proximal (from B-E) and six (J, I, I4, H, G, F) distal regulatory elements and is associated 
with several regulatory factors (Figure A.2), as reviewed in (Zannis, Kan, et al., 2001a).   
HNF-4 and the ubiquitous factor SP1 drive expression of the human apoC3 gene (Zannis 
et al., 2001a).  Elements I, H, and F in the distal promoter have three binding sites for 
SP1 (Figure A.2).  Mutations in all three sites abolished transcription of apoC3 promoter 
constructs in all tissues in transgenic mice (Zannis et al., 2001a).  HNF-4 is essential for 
apoC3 expression in hepatocytes.  Element B in the proximal promoter contains an HRE 
from nucleotides -92 to -67 that strongly binds HNF-4 (Figure A.2) (Talianidis et al., 
1995).  Element I4 in the distal promoter contains an HRE (-732/-712) that binds HNF-4 
(Figure A.2).  In transgenic mice, mutations or deletions in elements B, I4 or B + I4 
reduced or abolished apoC3 expression in liver and intestine (Zannis et al., 2001a).   
Glucose enhances apoC3 expression via the transcription factors HNF-4 and 
carbohydrate response element binding protein (ChREBP).  Glucose increased secreted 
apoC3 and apoC3 mRNA levels in primary rat and immortalized human hepatocytes in a 
dose-dependent manner (Caron et al., 2011).  A carbohydrate response element (ChRE) 
was identified in the apoC3 proximal promoter that overlaps with the binding site of 
HNF-4 (Caron et al., 2011).  Mutation of the ChRE abolished glucose sensitivity of 
apoC3 expression vectors in rat and human hepatoctyes.  Silencing HNF-4 or ChRE 
genes with siRNA attenuated glucose induction of the apoC3 genes by >50% in IHH.  
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Figure A.2. Schematic representations of the apoA1/apoC3/apoA4 gene cluster.  
(a)  The locations of several hormone response elements (HRE)—marked B-J—in the 
gene cluster are highlighted.   
(b) The regulatory factors that bind to the response elements are shown.  In a set of 
experiments, the apoC3 promoter construct was linked to a chloramphenicol acetyl-
transferase (CAT) reporter and transfected into HepG2 or CaCo-2 cells.  CAT activity 
was measured and set as 100% activity.  Arrows in (b) indicate the sites of mutation in 
the construct and numbers represent the activity of the mutated constructs in HepG2 and 
CaCo-2 cells.  Figure adapted from (Zannis et al., 2001a). 
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The human apoC3 promoter region contains an insulin response element (IRE) 
from -490 to -449 bp (Chen et al., 1994; Li et al., 1995).  Transcription of the apoC3 gene 
is reduced by insulin (Chen, et al., 1994; Li et al., 1995).  In one study, insulin-deficient, 
diabetic mice had elevated blood glucose and TG, and a ≤1.5-fold increase in hepatic 
apoC3 mRNA, as compared to WT mice (Chen et al., 1994).  Insulin treatment 
normalized the glucose and TG levels in diabetic mice, and diminished hepatic apoC3 
mRNA levels by ~59%.  The nuclear run-on technique showed that these changes in 
mRNA levels were the results of changes in transcriptional activity of the apoC3 gene.   
In another study, (Li et al., 1995), the loss of insulin regulation in a variant form 
of the human apoC3 promoter was mapped to polymorphic sites -482 and -455 in the 
IRE.  Two DNA polymorphisms, C→T at nt -482 and T→C at nt -455, were identified in 
the apoC3 promoter in a subject with severe hypertriglyceridemia (Dammerman et al., 
1993).  Insulin decreased the transcriptional activity of the WT promoter in HepG2 cells, 
but had no effects on promoters with one or both of these mutations (Li et al., 1995).  
The nuclear transcription factor forkehead box O1 (FoxO1) mediates insulin 
action on apoC3 expression (Caron et al., 2011).  In co-transfection experiments in 
Hep2G cells, Foxo1 stimulated hepatic apoC3 expression, marked by luciferase activity, 
only when the apoC3 promoter region contained the IRE.  Electrophoretic mobility shift 
assays (EMSA) and chromatin immunoprecipitation (ChIP) showed that Foxo1 binding 
to to the IRE of the apoC3 promoter was impaired on mutations in the IRE.   
These results were supported by studies in FoxO1 transgenic mice (Caron et al., 
2011) and suggest this model: insulin inhibits apoC3 expression through the IRS/PI3K/ 
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AKT/FoxO1 pathway, but in insulin-resistant or deficient states apoC3 expression is 
unrestrained, which enhances VLDL production and promotes hypertriglyceridemia.   
Figure A.3 shows a model of the signaling mechanisms in insulin-resistant states that 
elevate apoC3 expression and promote VLDL assembly.  
Transcription of the apoC3 gene is also negatively regulated by nuclear receptor 
proteins, including PPARα and FXR.  Administration of different fibrates to rats 
decreased liver apoC3 mRNA levels up to 90% in a dose- and time-dependent manner, 
with no change in intestinal apoC3 mRNA (Staels et al., 1995).  The decrease in liver 
apoC3 mRNA was rapid (<1 day) and reversible, as liver apoC3 mRNA was restored to 
control levels <1 week after treatment termination.  Fibrate treatment also decreased 
apoC3 mRNA and secreted apoC3 levels in HepG2 cells transiently transfected with 
plasmids containing the human apoC3 promoter. 
PPAR-mediated suppression of apoC3 transcription results from transcriptional 
suppression of HNF-4 and displacement of HNF-4 from the apoC3 promoter region 
(Hertz et al., 1995).  Treatment of rats with amphipathic carboxylates decreased liver 
mRNA and plasma protein levels of HNF-4 levels.  Run-on transcription assays with 
pooled liver nuclei from treated rats showed that the decrease in HNF-4 mRNA was due 
to transcriptional suppression.   Co-transfection experiments in HepG2 and HeLa cells 
showed that apoC3 promoter expression decreased up to 10-fold on expression of PPARα 
at a 2:1 or 1:1 (wt/wt) ratio to HNF-4.  Mobility shift assays using a 
32
P-labeled apoC3 
promoter element showed that PPARα binds from nt -87 to -66 in element B and 
eliminates binding of HNF-4.  These results indicate that PPARα, in response to fibrates   
 253 
 
 
Figure A.3.  Model for regulation of apoC3 expression and VLDL1 production.   
(a) Under normal hepatic signaling conditions, insulin signaling suppresses hepatic 
VLDL production.  Insulin promotes intracellular degradation of newly synthesized 
apoB, through the PI3K pathway, and suppresses expression of microsomal MTP and 
apoC3, through the FoxO1 pathway.  Insulin suppresses lipolysis, which decreases fatty 
acid influx into the liver.  VLDL that is produced is VLDL2. 
(b) Under dysregulated hepatic insulin signaling, insulin cannot render apoB susceptible 
to intracellular degradation, nor can it negatively regulate MTP and apoC3 suppression.  
De novo lipogenesis (DNL) is not suppressed and fatty acid influx increases.  In addition, 
glucose stimulates apoC3 expression, through HNF-4.  Increased levels of MTP, TG, and 
apoC3 create an optimal condition for VLDL1 assembly and secretion.  Catabolism of 
VLDL1 to LDL is inhibited by apoC3.  Figure adopted from (Yao & Wang, 2012). 
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or amphipathic carboxylates, suppresses HNF-4 transcription and displaces HNF-4 from 
the promoter region of the apoC3 gene to suppress apoC3 expression. 
A similar study  (Claudel et al., 2003) showed that treatment of mice with the 
farnesoid X receptor (FXR) agonist taurocholic acid strongly decreased plasma TG 
levels, which was associated with reduced apoC3 plasma and liver mRNA levels.  
Incubation of human primary hepatocytes and HepG2 cells with bile acids or a synthetic 
FXR agonist resulted in a dose-dependent decrease in apoC3 expression. An FXR 
response element (FXRE) was identified in the I4 regulatory element.  Hep2G cells were 
transfected with WT or FXRE-mutant apoC3 promoter-driven luciferase reporter 
plasmids in the presence and absence of FXR and RXR vectors.  The mutant promoter 
induced luciferase activity that was enhanced via bile-acid stimulation and did not 
decrease on transfection with FXR/RXR.  ChIP experiments showed that, on activation 
by bile acids, the FXR/RXR heterodimer binds to the FXRE site and replaces HNF-4 in 
the I4 regulatory region.  These results indicate that FXR suppresses apoC3 expression 
via competition with HNF-4 for binding to the apoC3 promoter.  Bile acids suppressed 
the liver expression of apoC3 in HNF-4-deficient mice (Claudel et al., 2003), which 
indicates that FXR/RXR also inhibits apoC3 gene expression by active mechanisms.   
Other nuclear orphan receptors, including PPARγ (Nagashima et al., 2005), Rev-
erbα (Coste & Rodríguez, 2002), and retinoic acid-related orphan receptor (ROR)-α1 
(Raspé et al., 2001) positively (RORα1) or negatively (PPARγ, Rev-erbα) regulated 
apoC3 expression in humans, HepG2 cells, mice, and other systems.  RORα1 and Rev-
erbα compete for the same element in the proximal promoter (Coste & Rodríguez, 2002).  
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B. Appendix B:  Apolipoprotein C2 and Amyloid Fibrils 
 Lipid-free apoC2 self-assembles at concentrations >0.1 mg/mL in vitro into 
homogeneous fibrils with increased levels of β-structure and hallmarks of amyloid, such 
as red-green birefringence in the presence of Congo Red under cross-polarized light, 
increased fluorescence in the presence of thioflavin T, and a fibrous structure when 
examined by EM (Hatters et al., 2000; Hatters, Minton, et al., 2002; Hatters, Wilson, et 
al., 2002).  At physiological ionic strength and pH, apoC2 aggregates into somewhat 
soluble, “twisted-ribbon” fibrils (Figure B.1).   
ApoC2 fibrils formed in vitro were investigated by structural techniques such as 
fibre diffraction, scanning transmission electron microscopy (STEM), fluorescence 
resonance energy transfer (FRET), analytical ultracentrifugation (AUC), and 
hydrogen/deuterium exchange NMR.  Results suggested a “letter-G-like” β-strand-loop-
β-strand model for each apoC2 unit in the amyloid fibril (Figure B.2) (Teoh, Pham, et al., 
2011).  A classical cross-β diffraction pattern with reflections at 4.67 Å and 9.46 Å—
which indicate the spacing between β-strands and between β-sheets—was observed in x-
ray fibre diffraction experiments (Teoh, Pham, et al., 2011).  This supports a simple 
cross-β-structure composed of two parallel β-sheets.   
Mass per length results from examination of apoC2 fibrils by STEM indicate that 
apoC2 fibrils contain one apoC2 molecule per 4.7 Å rise in the long axis of the fibril 
(Teoh, Pham, et al., 2011).  Cross-linking results using single-cysteine substitution 
mutants revealed disulfide bonds in apoC2 dimers and higher order species (Teoh, Pham, 
et al., 2011).  The proximity required for these bonds is consistent with a parallel model   
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Figure B.1. Transmission electron micrographs of fibrils formed by apoC2.   
(A, B) Fibrils were formed by incubation of apoC2 at 0.3 mg/mL in 100 mM sodium 
phosphate, pH 7.4, for 2 days. ApoC2 was stained with potassium phosphotungstate (A) 
or uranyl formate (B). ApoC2 fibrils have flat, ribbon-like morphology and a semiregular 
helical structure is more apparent when stained with potassium phosphotungstate.  (C) A 
collection of closed-loop structures obtained under a range of staining conditions.  Scale 
bar is 100 nm.  Figure adopted from (Hatters et al., 2000). 
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Figure B.2. Letter G-like structural model for apoC2 monomers in amyloid fibrils.   
(A) Structural model for apoC2 amyloid fibrils, constructed with 8 apoC2 monomers 
using the program CYANA.  Four monomers are shown in different colors.  There are 
two β-strands (encompassing residues 20-36 and 58-74) in parallel register between 
monomers.  Residues D69 and W26 are internalized and oriented towards each other.   
(B) Molecular Dynamics (MD) simulations of full-length tetramers show little change in 
overall structure from 0 to 85 ns.  (C) The percentage of time that each residue spends in 
β-strand conformation over the final 50 ns of MD simulations.  Three of the four prolines 
in apoC2 are in the first 12 residues and the fourth is at position 43, such that these 
regions are unlikely to form β-strands. Figure adopted from (Teoh, Pham, et al., 2011). 
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for apoC2 fibrils.  Hydrogen/deuterium exchange data showed that N- and C-terminal 
regions from residues 20-36 and 58-74 of apoC2 in amyloid fibrils have slower amide 
proton exchange rates than monomeric apoC2 (Wilson et al., 2007), which indicates that 
these regions form the β-strands in each monomer.  Altogether, these results indicate that 
apoC2 can aggregate into fibrils of parallel β-sheets, with regions 20-36 and 58-74 
forming β-strands in each monomer (Figure B.2) 
No apoC2 amyloid fibrils have been observed in vivo.  ApoA1, apoA2, and 
apoA4 amyloid fibrils are associated with hepatic, systemic, and renal amyloid diseases 
(Hatters & Howlett, 2002; Hatters et al., 2000; Medeiros et al., 2004).  The accumulation 
of apoA1, A2, and C2 in amyloid deposits of atherosclerotic lesions may contribute to the 
progression of cardiovascular diseases (Medeiros et al., 2004; Mucchiano, Häggqvist, 
Sletten, & Westermark, 2001; Mucchiano, Jonasson, Häggqvist, Einarsson, & 
Westermark, 2001).  ApoC2 deposits initiated macrophage inflammatory responses 
including reactive oxygen species production and tumor necrosis factor alpha expression 
in vitro (Medeiros et al., 2004).   
The propensity of apoC2 to aggregate into fibrils stems from its low 
conformational stability in the absence of lipid (Hatters & Howlett, 2002).  In vitro assays 
showed that short-chain (x = 3-5 carbons), saturated phospholipids (DiCxPC) at sub-
micellar concentrations, oxidized cholesterol metabolites (abundant in atherosclerotic 
plaques), and several low-hydrophobicity lipids at sub-micellar concentrations accelerate 
apoC2 amyloid formation (Griffin et al., 2008; Ryan, Griffin, Teoh, Ooi, & Howlett, 
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2011; Stewart et al., 2007).  These lipids induce a tetrameric apoC2 that nucleates fibril 
aggregation, as shown by AUC.  
Shear flow induces an irreversible change in apoC2 secondary structure to 
promote amyloid formation (Teoh, Bekard, et al., 2011).  Since intravascular fluids are 
continuously subjected to mechanical shear forces caused by the pulsatile nature of blood 
flow, this result suggests that disruption in blood flow near atherosclerotic plaques 
promotes apoC2 aggregation into fibrils.  Altogether, these results indicate that 
accumulation of lipid metabolites in atherosclerotic plaques—along with disrupted blood 
flow caused by the plaques—may promote the formation of amyloid fibrils by apoC2 in 
vivo.  
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C. Appendix C:  The Roles of the Apolipoprotein Cs in HDL Metabolism 
ApoC1 promotes HDL synthesis and maturation by promoting ATP-binding cassette 
transporter 1 (ABCA1)-mediated cholesterol efflux and activating lecithin cholesterol 
acyltransferase (LCAT).  However, apoC1 inhibits HDL catabolism via inhibition of 
hepatic lipase (HL), cholesterol ester transfer protein (CETP), and HDL lipid uptake by 
scavenger receptor class B type 1 (SR-B1).  ApoC2 and apoC3 perform some of these 
functions (ABCA1-mediated cholesterol efflux, inhibition of HL activity and SR-B1-
mediated uptake of HDL) with similar or reduced potency, but do not promote HDL 
maturation in vivo.  Inhibition of CETP and activation of LCAT are unique to apoC1.  
Evidence for these functions is discussed in this appendix.   
 
The ApoCs Promote ABCA1-Mediated Cholesterol Efflux In Vitro 
The apoCs promote cholesterol and phospholipid efflux through the human ATP-
binding cassette transporter ABCA1 in vitro (Remaley et al., 2001; Smith et al., 2013).  
Cholesterol and phospholipid efflux increased ~3-fold on addition of lipid-poor apoC1, 
C2, or C3 to HeLa cells that expressed ABCA1-GFP (Remaley et al., 2001); or on 
addition of apoC1 to macrophages that expressed cAMP-inducible ABCA1 (Smith et al., 
2013).  Increased specific binding of apolipoproteins to HeLa cells expressing ABCA1 
was only observed for apoA1 and apoA2 (Remaley et al., 2001).  This indicates that the 
apoCs likely promote ABCA1 activity through protein-lipid interactions.   
A recent study probed the secondary structure required for ABCA1 activation 
(Smith et al., 2013).  This study tested the ability of full length apoC1 and apoA2, helical 
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fragments of each protein, and constructs of each protein to clear DMPC liposomes and 
efflux radio-labeled cholesterol from macrophages.  The minimum structural element 
required to promote cholesterol efflux was a set of 11-mer and 22-mer amphipathic α-
helices.  One helix must have a higher lipid affinity than the other—the fast-binding C-
terminal helices of apoC1 and apoA2 cleared DMPC at a much faster rate and to a greater 
extent than the other helices in each protein and must be incorporated in any construct 
that activated ABCA1.  This fast-acting helix must be linked to a slower-acting helix:  the 
individual helices of apoC1, even when added together, were unable to promote 
cholesterol efflux from macrophages.   
These results indicate that a two-helix peptide, with one helix of higher lipid 
affinity, is essential for mediating ABCA1-mediated cholesterol efflux.  In addition, 
acidic residues at the polar face of helices were not required—single (E33K, E40K, 
E44K, E51K) or double charge mutants of apoC1 cleared DMPC and promoted 
cholesterol efflux to the same extent as WT apoC1.  This further indicates the cholesterol 
efflux is not mediated by protein-protein, but rather protein-lipid interactions, such that 
mutations at the polar face of helices are tolerated. 
 
ApoC1 Promotes Cholesterol Ester Formation by LCAT In Vitro 
ApoC1, but not apoC2 nor apoC3, activates lecithin cholesterol acyltransferase 
(LCAT) in vitro.  ApoC1 activates LCAT with 10-45% of the effectiveness of apoA1, 
depending on the lipid substrate (Jonas et al., 1984; Soutar et al., 1975; Soutar, Sigler, 
Smith, Gotto, & Sparrow, 1978; Steyrer & Kostner, 1988).  These assays analyzed the 
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formation of cholesterol ester (CE) by LCAT in the presence of increasing concentrations 
of apolipoproteins.  ApoC2, apoC3 and apoA2 did not enhance LCAT activity (Soutar et 
al., 1975) while apoE enhanced LCAT activity by ≤ 18% (Rye, Bright, Psaltis, & Barter, 
2006; Zorich, Jonas, & Pownall, 1985).  Compared to apoA1, the lower plasma 
concentration and activation potency of apoC1 indicate that LCAT activation by apoC1 
in vivo is secondary to activation by apoA1.   
Similar in vitro LCAT activation assays have been conducted with apoC1 
fragments to locate the region of apoC1 responsible for LCAT activation.  Residues 1-38 
and 39-57 of apoC1 were unable to activate LCAT (Soutar et al., 1975), which suggests 
that coordination of the N- and C-terminal helices is required for LCAT activation.  In 
vitro assays with mixed DMPC:cholesterol vesicles as substrate showed that fragments 
representing residues 32-57, 24-57, and 17-57 of apoC1 could activate LCAT with 50%, 
60%, and 100% of the effectiveness of WT apoC1 (Soutar et al., 1978).  These results 
indicate that the majority of apoC1 structure is required to promote LCAT activity.   
 
The ApoCs Inhibit the Catabolism of HDL by Hepatic Lipase 
The apoCs may prevent HDL catabolism through inhibition of hepatic lipase 
(HL).  In vitro assays showed that all three apoCs inhibit HL, which hydrolyzes TG and 
CE in IDL and HDL.  These assays used radiolabeled triolein, emulsified with 5% gum 
arabic, as a substrate and added HL to media with or without the apoCs, which were 
purified from VLDL (Kinnunen & Ehnolm, 1976).  Increasing concentrations of apoC in 
the media inhibited HL-mediated hydrolysis of TG in a sigmoidal fashion.  ApoC3 
 263 
 
exhibited slightly higher inhibition potency than the other apoCs, but at concentrations 
equivalent to plasma levels (6-10 mg/dL), each apoC inhibited HL by 90-100%.   
A study of apoC1 transgenic, apoE-null mice  apoC1 inhibits HL in vivo (Conde-
Knape, Bensadoun, Sobel, Cohn, & Shachter, 2002).  These mice had hyperlipidemia in 
fasting and non-fasting states—IDL and VLDL cholesterol levels were double and TG 
levels were elevated 3- to 14-fold in apoC1 transgenic, apoE-null mice, as compared to 
apoE null mice.  HDL was enriched in apoC1 and depleted of apoA2.  HDL was isolated 
from these mice and used in similar in vitro activity assays as described above.  HL 
activity was significantly reduced, likely due to the increased concentration of HDL-
apoC1.  These results indicate that apoC1 inhibits HL, perhaps by competing for lipid-
binding or preventing association of the enzyme with the HDL surface. 
 
ApoC1 is a Potent Inhibitor of CETP In Vitro and in Mice 
HDL apolipoproteins are linked to the inhibition of cholesterol ester transfer 
protein (CETP), which transfers TG to HDL from VLDL, IDL, or LDL in exchange for 
CE (Hewing & Fisher, 2012).  The rate of CE exchange increases as the ratio of LDL to 
HDL increases, but decreases significantly at higher HDL/LDL cholesterol ratios (P J 
Barter & Jones, 1980; Ihm, Quinn, Busch, Chataing, & Harmony, 1982).  To identify the 
HDL apolipoprotein(s) responsible for inhibition of CETP, HDL was isolated and 
delipidated before HDL apolipoproteins were separated into 30 fractions (Gautier et al., 
2000).  These fractions were incubated with mixtures of LDL, radiolabeled CE, HDL, 
and CETP.  The only apolipoprotein that inhibited CETP at nearly the same level as 
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control was apoC1.  All others had <25% inhibitory potency.  These results indicate that 
apoC1 is the HDL-protein responsible for inhibition of CETP.   
The effect of apoC1 on CETP was further explored in mice.  Transgenic mice that 
expressed human CETP (mice do not express CETP) on an apoC1-deficient background 
(HuCETPTg/apoC1-KO mice) had much higher CETP activity than transgenic mice on a 
WT background (Gautier et al., 2002).  HuCETPTg/apoC1-KO mice showed a 6-fold 
increase in VLDL-cholesterol ester levels that was associated with a 50% decrease in CE 
content and the CE:TG ratio on HDL and a reduction in mean HDL particle diameter, as 
compared to WT mice.  HuCETPTg mice showed intermediate changes in these 
parameters, as compared to HuCETPTg/apoC1-KO and WT mice.  These results indicate 
that introduction of CETP to mice promotes exchange of cholesterol ester between HDL 
and VLDL subfractions; and this reaction is enhanced in the absence of apoC1. 
Inhibition of CETP is mediated by the positive charge of apoC1 at physiological 
pH.  In vitro cholesterol transfer assays showed that CETP inhibition was decreased as 
HDL concentration increases but unchanged as CETP concentration increases (Dumont et 
al., 2005).  This indicates that apoC1 inhibits CETP through its ability to modify the HDL 
substrate, rather than through a specific blockade of the CETP molecule.  ApoC1 was 
introduced to these assays, in non-acetylated and acetylated forms.  Acetylation of the 
lysines on apoC1 significantly reduced the ability of apoC1 to inhibit CETP in a dose-
dependent manner, despite no change in the ability of acetylated apoC1 to associate with 
HDL.  These results indicate that elevated HDL-apoC1 shifts HDL from an optimal 
electronegativity of -11.6 mV to a lower electronegativity, which decreases the 
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association of CETP with HDL and CE transfer rate (Desrumaux et al., 1998; Masson, 
Athias, & Lagrost, 1996).   
The C-terminal helix of apoC1, especially if extended to K52, is rich in lysines 
and is responsible for inhibition of CETP.  In the assays described above, a peptide 
representing residues 34-54 of apoC1 inhibited CETP to a similar extent as WT apoC1 at 
various doses, while residues 4-25 did not inhibit CETP (Dumont et al., 2005).  
Altogether, these results indicate that apoC1, at elevated levels on HDL, alter the charge 
state of HDL and impairs interaction with CETP.  ApoC2 and apoC3, which are acidic at 
physiological pH, are likely unable to alter HDL electronegativity and inhibit CETP. 
    
The ApoCs Inhibit Uptake of HDL Lipids 
The apoCs inhibit the SR-B1 mediated uptake of HDL lipids.  In one study 
(Huard et al., 2005), HepG2 cells that expressed apoC2 or apoC3 at reduced levels due to 
antisense strategies showed a 70-160% increase in their capacity to take up HDL-CE, as 
compared to control cells.  Conversely, incubation of HepG2 cells with radiolabeled 
HDL-3 and purified apoC2 or apoC3 resulted in a dose-dependent decrease in uptake of 
HDL-CE (Huard et al., 2005).  These results indicate that apoC2 and apoC3 can inhibit 
the uptake of HDL lipids (here, cholesterol ester) by the SR-B1 on hepatocytes.  
In another study, hepatocytes were isolated from WT mice and incubated in vitro 
with HDL containing a radiolabeled, non-hydrolyzable analogue of cholesterol ether in 
the presence or absence of apoC1, apoC3, or oxidized LDL (de Haan et al., 2008).  The 
inhibitors, at a concentration of 20 µg/mL (apoCs) or 100 µg/mL (oxLDL), reduced SR-
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B1-mediated uptake of HDL-cholester ether by 53% (apoC1), 37% (apoC3), and 57% 
(oxLDL).  The results were similar for apoC1 and oxLDL (apoC3 was not tested) in 
assays using hepatocytes isolated from LRP
-/-
LDLR
-/-
VLDLR
-/-
 mice.  Consistent with 
this, apoC1
+/-
 and apoC1
-/- 
mice showed a dose-dependent decrease in plasma levels of 
HDL-cholesterol, while adenovirus-mediated expression of apoC1 in mice showed a 
dose-dependent increase in plasma levels of HDL-cholesterol compared to WT mice (de 
Haan et al., 2008).  Altogether, these results (de Haan et al., 2008; Huard et al., 2005) 
indicate that apoC1 is a more potent inhibitor of HDL binding to and lipid uptake by SR-
B1 than apoC3 or apoC2.   
The mechanism of HDL uptake inhibition is unknown.  As all three apoCs inhibit 
HDL uptake, the positive charge of apoC1 or negative charge of apoC3 is not essential 
for this effect.  The apoCs may inhibit binding of HDL to SR-B1 by modifying HDL 
particles to reduce binding to SR-B1 or stabilizing HDL to impair access to CE (de Haan 
et al., 2008).    
To probe the ability of apoC3 to promote HDL synthesis and the role of HDL in 
hypertriglyceridemia, human apoC3 was expressed, using a recombinant adenovirus, in 
apoE
-/-
/apoA1
-/-
 and ABCA1
-/-
 (Kypreos, 2008).  A moderate dose of apoC3 adenovirus, 
which keeps TG levels in WT mice within the normolipidemic range (≤150 mg/dL), was 
used for experiments with apoE
-/-
/apoA1
-/-
 and ABCA1
-/-
 mice.  Infected apoE
-/-
/apoA1
-/-
 
mice exhibited a marked increase in HDL levels but only modest increases in plasma 
cholesterol and TG, as compared to apoE
-/-
/apoA1
-/-
 mice. This indicates that excess 
apoC3 promotes the de novo biogenesis of HDL in the absence of apoE and apoA1.   
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In contrast, infected ABCA1
-/-
 mice failed to form HDL particles and developed 
hypertriglyceridemia by 3 days post-infection.  Hypertriglyceridemia correlated with the 
accumulation of human apoC3 on VLDL.  This phenotype was reversible on treatment 
with an LPL adenovirus.   These results suggest that apoC3—even at typical or slightly 
elevated levels—promotes ABCA1-mediated cholesterol efflux and HDL synthesis.  This 
prevents accumulation of apoC3 on the surface of TG-rich lipoproteins.  In states of 
elevated apoC3 levels or impaired HDL synthesis, apoC3 accumulates on TG-rich 
lipoproteins, which results in impaired lipolysis and clearance, and hypertriglyceridemia 
(Figure C.1). 
In summary, apoC1 promotes HDL synthesis and maturation by promoting 
ABCA1-mediated cholesterol efflux and activating LCAT, but inhibits HDL catabolism 
via inhibition of HL, CETP, and SR-B1-mediated uptake.  ApoC2 and apoC3 perform 
some of these functions (ABCA1-mediated cholesterol efflux, inhibition of HL activity 
and SR-B1-mediated uptake of HDL) with similar or reduced potency, but do not 
promote HDL maturation in vivo.  Inhibition of CETP and activation of LCAT is unique 
to apoC1, likely due to its basic charge and the arrangement of its N-terminal helix. 
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Figure C.1.  The roles of apoC3 and ABCA1 in the biogenesis of apoC3-containing 
HDL and the development of hypertriglyceridemia.   
ApoC3 is primarily synthesized in the liver and secreted in the form of lipid-poor apoC3 
into circulation.  In the presence of ABCA1 (+ABCA1 branch of the diagram), apoC3 
promotes cholesterol efflux via ABCA1 and formation of apoC3-containing HDL 
particles.  Activation of this pathway causes a ‘sequestration’ of apoC3, such that the 
amount of apoC3 available for association with TG-rich lipoproteins (i.e., VLDL and 
chylomicrons) is limited.  As a result, in normolipidemic subjects the LPL-mediated 
lipolysis of chylomicron- and VLDL-TG is uninhibited, as is clearance (or further 
catabolism) of VLDL- and chylomicron remnants.  In the absence of ABCA1 (-ABCA1 
branch in the diagram), little HDL is formed and a vast majority of lipid-poor apoC3 and 
possibly other exchangeable apolipoproteins) accumulates in TG-rich lipoproteins.  This 
results in impaired lipoprotein lipolysis, clearance from the circulation, and 
hypertriglyceridemia.  Figure adopted from (Kypreos, 2008). 
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D. Appendix D: ApoCs Show Similar Washout Behavior at a TO/W Interface 
For apoC2 and apoC3 at a TO/W interface, the post-washout pressure (ПWO) was 
a constant, independent of Пeq.  This suggested that there are at least two lipid-bound 
populations of peptide that are in a pressure-dependent equilibrium with each other.  One 
lipid-bound population was in a concentration-dependent equilibrium with lipid-free 
peptide, while the other lipid-bound population was not.  This model is discussed for 
apoC2 in Section 5.2.4, but was shown not to depend on peptide structure for apoC3 
variants in Section 6.2.3.   
To see if this model was true for apoC1, washout data at a TO/W interface was 
plotted in Figure D.1A for washouts of various rates.  For most of our experiments with 
apoC1, the protein was dissolved in phosphate buffer and this model was not true. ПWO 
varied with Пeq and washout rate, while the difference Пeq - ПWO = 2.2±0.2 mN/m (Table 
D.1).  However, the range in Пeq values was 2.0 mN/m, as compared to ranges of 3.2 and 
4.1 mN/m for apoC3 and apoC2.  When apoC1 was pre-dissolved in HFIP, similar to the 
stock solutions of the other apoCs, apoC1 adsorbed to higher Пeq, extending the range in 
Пeq values to 3.4 mN/m (Figure D.1B, Table D.1).  Пeq - ПWO values increased while ПWO 
was constant (17.0±0.2 mN/m); similar to the behavior observed for the other apoCs. 
One explanation for this behavior is that HFIP—at higher bulk phase 
concentrations—is incorporated into the TO/W interface and alters surface tension.  Пeq 
is altered by HFIP, but all HFIP is removed by washout such that ПWO is unchanged.  If 
this was true, the tension of the TO/W interface should be increasingly altered by greater 
concentrations of HFIP.  Rather, the TO/W interface reaches a saturation pressure with   
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Figure D.1.  A similar amount of apoC1 desorbs from the TO/W interface during 
washout, independent of Пeq.   
The pressure profiles, П(t), were plotted for apoC1/TO/W interfaces.  In (A, B), 
interfaces of various initial peptide surface concentrations (i.e., Пeq) are represented.  
Washouts exchanged >149.6 mL of buffer and were conducted at the rates and durations 
listed in each panel.  (A) The change in pressure (Пeq-ПWO) from washouts did not differ 
with Пeq and washout rate.  (B) HFIP enhances apoC1 binding to the TO/W interface.  
ApoC1 was added to the bulk phase from stock solutions of 2.5 mg/mL apoC1 in either 5 
mM phosphate buffer or HFIP.  ApoC1 saturated the TO/W interface at П = 19.6 mN/m, 
but HFIP increased ПSAT to 21.5 mN/m.  Washout П(t) profiles were plotted for 
apoC1/TO/W interfaces at Пeq below these pressures.   
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Washout 
Rate 
[mL/min] 
Experimental Parameters Parameters from Exponential Fit 
Πeq 
[mN/m] 
ΠWO 
[mN/m] 
Πeq-Πwo 
[mN/m] 
ΠWO 
[mN/m] 
Πeq-Πwo 
[mN/m] 
kd 
[min
-1
] 
R
2
 
ApoC1 from PB Stock Solution 
4.18 18.6 16.5 2.1 N/A 
6.26 18.0 15.9 2.1  
6.26 18.4 16.2 2.2  
6.26 18.6 16.5 2.1  
6.26 19.3 16.7 2.6  
8.35 17.6 16.1 1.5  
8.35 17.8 15.8 2.0  
8.35 18.3 16.5 1.8  
8.35 18.5 16.3 2.2  
8.35 18.9 16.3 2.6  
8.35 19.3 16.8 2.5 17.1 2.3 0.258 0.84 
8.35 19.6 17.0 2.6 17.3 2.5 0.265 0.85 
12.53 18.2 16.5 1.7 N/A 
Averages   2.2±0.2    
ApoC1 from HFIP Stock Solution 
8.35 19.0 17.0 2.0 N/A 
8.35 20.0 16.9 3.1 17.1 2.91 0.366 0.83 
8.35 21.0 17.2 3.8 17.4 3.67 0.433 0.83 
Averages  17.0±0.2     
Table D.1.  Dissociation properties of apoC1 from TO/W interfaces during washout.   
Adsorption and washout data are shown for adsorption of apoC1 from a bulk phase of 
varied protein concentration to the TO/W interface.  Data from Figure 7.6A are italicized 
and colored according to the figure.  П(t) curves were approximated by a 
monoexponential decay function, for data of low noise and large amplitude. 
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increasing concentrations of apoC2 or apoC3 and, therefore, HFIP.  In addition, the bulk 
phase concentration of protein at which the interface was saturated was 7.5±0.5 µg/mL 
for all three apoCs, independent of the presence of HFIP (Figure 7.1A). 
An alternative explanation is that HFIP induces helical content in the apoCs 
similar to the effects of tetrafluorethylene (TFE) on apoC helical content (Liu, Talmud, et 
al., 2000).  Consistent with this, HFIP increased the helical content of the lipid-free 
apoC3 variants used in this study by 20±5% from completely disordered peptides 
(Larsson et al., 2013), as shown by far-UV CD.  If the enhanced structure in apoCs 
incubated with HFIP persists, this could result in a greater ability of protein to bind to and 
modify lipid surfaces.  The increase in structure may allow each helical protein to insert 
more deeply into the lipid surface or, as proposed in (Mitsche & Small, 2013), to exhibit 
a second, lipid-bound population that is independent of the bulk phase concentration of 
protein.  As a result, post-washout pressure (ПWO) is independent of Пeq.   
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